USRE34606E - Modified enzymes and methods for making same - Google Patents

Modified enzymes and methods for making same Download PDF

Info

Publication number
USRE34606E
USRE34606E US07/556,918 US55691890A USRE34606E US RE34606 E USRE34606 E US RE34606E US 55691890 A US55691890 A US 55691890A US RE34606 E USRE34606 E US RE34606E
Authority
US
United States
Prior art keywords
subtilisin
iaddend
iadd
substituted
position equivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/556,918
Inventor
David A. Estell
James A. Wells
Richard R. Bott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Inc filed Critical Genencor Inc
Priority to US07/556,918 priority Critical patent/USRE34606E/en
Application granted granted Critical
Publication of USRE34606E publication Critical patent/USRE34606E/en
Assigned to GENENCOR INTERNATIONAL, INC. reassignment GENENCOR INTERNATIONAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENENCOR, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07Bacillus

Definitions

  • This invention relates to the production and manipulation of proteins using recombinant techniques in suitable hosts. More specifically, the invention relates to the production of procaryotic proteases such as subtilsin and neutral protease using recombinant microbial host cells, to the synthesis of heterologous proteins by microbial hosts, and to the directed mutagenesis of enzymes in order to modify the characteristics thereof.
  • procaryotic proteases such as subtilsin and neutral protease
  • Bacillus species produce two major extracellular proteases, a neural protease (a metalloprotease inhibited by EDTA) and an alkaline protease (or subtilsin, a serine endoprotease). Both generally are produced in greatest quantity after the exponential growth phase, when the culture enters stationary phase and begins the process of sporulation.
  • a neural protease a metalloprotease inhibited by EDTA
  • an alkaline protease or subtilsin, a serine endoprotease
  • subtilisin has found considerable utility in industrial and commercial applications (see U.S. Pat. No. 3,623,957 and J. Millet, 1970, "J. Appl. Bact.” 33:207).
  • subtilisins and other proteases are commonly used in detergents to enable removal of protein-based stains. They also are used in food processing to accommodate the proteinaceous substances present in the food preparations to their desired impact on the composition.
  • proteases which are excreted by Bacillus. For one thing, since at least two such proteases exist, screening for the loss of only one is difficult. Additionally, the large number of pleiotropic mutations affecting both sporulation and protease production make the isolation of true protease mutations difficult.
  • Temperature sensitive mutants of the neutral protease gene have been obtained by conventional mutagenic techniques, and were used to map the position of the regulatory and structural gene in the Bacillus subtilis chromosome (H. Uehara et al., 1979, "J. Bact.” 139:583-590). Additionally, a presumed nonsense mutation of the alkaline protease gene has been reported (C. Roitsch et al., 1983, "J. Bact.” 155:145-152).
  • Bacillus temperature sensitive mutants have been isolated that produce inactive serine protease or greatly reduced levels of serine protease. These mutants, however, are asporogenous and show a reversion frequency to the wild-type of about from 10 -7 to 10 -8 (F. Priest, Id. p. 719). These mutants are unsatisfactory for the recombinant production of heterologous proteins because asporogenous mutants tend to lyse during earlier stages of their growth cycle in minimal medium than do sporogenic mutants, thereby prematurely releasing cellular contents (including intracellular proteases) into the culture supernatant. The possibility of reversion also is undesirable since wild-type revertants will contaminate the culture supernatant with excreted proteases.
  • Bacillus sp. have been proposed for the expression of heterologous proteins, but the presence of excreted proteases and the potential resulting hydrolysis of the desired product has retarded the commercial acceptance of Bacillus as a host for the expression of heterologous proteins.
  • Bacillus megaterium mutants have been disclosed that are capable of sporulation and which do not express a sporulation-associated protease during growth phases.
  • the assay employed did not exclude the presence of other proteases, and the protease in question is expressed during the sporulation phase (C. Loshon et al., 1982, "J. Bact.” 150:303--311). This, of course, is the point at which heterologous protein would have accumulated in the culture and be vulnerable.
  • Bacillus strain that is substantially free of extracellular neutral and alkaline protease during all phases of its growth cycle and which exhibits substantially normal sporulation characteristics.
  • Enzymes having characteristics which vary from available stock are required.
  • enzymes having enhanced oxidation stability will be useful in extending the shelf life and bleach compatibility of proteases used in laundry products.
  • reduced oxidation stability would be useful in industrial processes that require the rapid and efficient quenching of enzymatic activity.
  • Modifying the pH-activity profiles of an enzyme would be useful in making the enzymes more efficient in a wide variety of processes, e.g. broadening the pH-activity profile of a protease would produce an enzyme more suitable for both alkaline and neutral laundry products. Narrowing the profile, particularly when combined with tailored substrate specificity, would make enzymes in a mixture more compatible, as will be further described herein.
  • procaryotic carbonyl hydrolases (principally proteases but including lipases) will facilitate preparation of a variety of different hydrolases, particularly those having other modified properties such as Km, Kcat, Km/Kcat ratio and substrate specificity. These enzymes can then be tailored for the particular substrate which is anticipated to be present, for example in the preparation of peptides or for hydrolytic processes such as laundry uses.
  • a method for producing procaryotic carbonyl hydrolase such as subtilisin and neutral protease in recombinant host cells is described in which expression vectors containing sequences which encode desired subtilisin or neutral protease, including the pro, pre, or prepro forms of these enzymes, are used to transform hosts, the host cultured and desired enzymes recovered.
  • the coding sequence may correspond exactly to one found in nature, or may contain modifications which confer desirable properties on the protein that is produced, as is further described below.
  • the novel strains then are transformed with at least one DNA moiety encoding a polypeptide not otherwise expressed in the host strain, the transformed strains cultured and the polypeptide recovered from the culture.
  • the DNA moiety is a directed mutant of a host Bacillus gene, although it may be DNA encoding a eucaryotic (yeast or mammalian) protein.
  • the novel strains also serve as hosts for protein expressed from a bacterial gene derived from sources other than the host genome, or for vectors expressing these heterologous genes, or homologous genes from the host genome. In the latter event enzymes such as amylase are obtained free of neutral protease or subtilisin. In addition, it is now possible to obtain neutral protease in culture which is free of enzymatically active subtilisin, and vice-versa.
  • step (d) synthesizing a plurality of oligonucleotides, the 5' and 3' ends of which each contain sequences capable of annealing to the restriction enzyme sites introduced in step (c) and which, when ligated to the moiety, are expressed as substitutions, deletions and/or insertions of at least one amino acid in or into said precursor protein;
  • step (e) digesting the moiety of step (c) with restriction enzymes capable of cleaving the unique sites;
  • step (f) ligating each of the oligonucleotides of step (d) into the digested moiety of step (e) whereby a plurality of mutant DNA moieties are obtained.
  • a mutation is introduced into isolated DNA encoding a procaryotic carbonyl hydrolase which, upon expression of the DNA, results in the substitution, deletion or insertion of at least one amino acid at a predetermined site in the hydrolase.
  • This method is useful in creating mutants of wild type proteins (where the "precursor” protein is the wild type) or reverting mutants to the wild type (where the "precursor” is the mutant.
  • Mutant enzymes are recovered which exhibit oxidative stability and/or pH-activity profiles which differ from the precursor enzymes.
  • Procaryotic carbonyl hydrolases having varied Km, Kcat, Kcat/Km ratio and substrate specificity also are provided herein.
  • mutant enzymes obtained by the methods herein are combined in known fashion with surfactants or detergents to produce novel compositions useful in the laundry or other cleaning arts.
  • FIG. 1 shows the sequence of a functional B. amyloliquefaciens subtilisin gene.
  • FIG. 1A the entire functional sequence for B. amyloliquefaciens, including the promoter and ribosome binding site, are present on a 1.5 kb fragment of the B. amyloliquefaciens genome.
  • FIG. 1B shows the nucleotide sequence of the coding strand, correlated with the amino acid sequence of the protein. Promoter (p) ribosome binding site (rbs) and termination (term) regions of the DNA sequence are also shown.
  • FIG. 2 shows the results of replica nitrocellulose filters of purified positive clones probed with Pool 1 (Panel A) and Pool 2 (Panel B) respectively.
  • FIG. 3 shows the restriction analysis of the subtilisin expression plasmid (pS4).
  • pBS42 vector sequences (4.5 kb) are shown in solid while the insert sequence (4.4 kb) is shown dashed.
  • FIG. 4 shows the results of SDS-PAGE preformed on supernatants from cultures transformed with pBS42 and pS4.
  • FIG. 5 shows the construction of the shuttle vector pBS42.
  • FIG. 6 shows a restriction map for a sequence including the B. subtilis subtilisin gene.
  • FIG. 7 is the sequence of a functional B. subtilis subtilisin gene.
  • FIG. 8 demonstrates a construction method for obtaining a deletion mutant of a B. subtilis subtilisin gene.
  • FIG. 9 discloses the restriction map for a B. subtilis neutral protease gene.
  • FIG. 10 is a nucleotide sequence for a B. subtilis neutral protease gene.
  • FIG. 11 demonstrates the construction of a vector containing a B. subtilis neutral protease gene.
  • FIGS. 12, 13 and 16 disclose embodiments of the mutagenesis technique provided herein.
  • FIG. 14 shows the enhanced oxidation stability of a subtilisin mutant.
  • FIG. 15 demonstrates a change in the pH-activity profile of a subtilisin mutant when compared to the wild type enzyme.
  • FIG. 17 is a reproduction in pertinent-part of Table C. .Iaddend.
  • Procaryotic carbonyl hydrolases are enzymes which hydrolyze compounds containing ##STR1## bonds in which X is oxygen or nitrogen. They principally include hydrolases, e.g. lipases and peptide hydrolases, e.g. subtilisins or metalloproteases.
  • Peptide hydrolases include ⁇ -aminoacylpeptide hydrolase, peptidylamino-acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallocarboxypeptidase, thiol proteinase, carboxlproteinase and metalloprotinease. Serine, metallo, thiol and acid proteases are included, as well as endo and exo-proteases.
  • Subtilisins are serine proteinases which generally act to cleave internal peptide bonds of protein or peptides.
  • Metalloproteases are exo- or endoproteases which require a metal ion cofactor for activity.
  • enzymes and their genes may be obtained from many procaryotic organisms. Suitable examples include gram negative organisms such as E. coli or pseudomonas and gram positive bacteria such as micrococcus or bacillus.
  • the genes encoding the carbonyl hydrolase may be obtained in accord with the general method herein. As will be seen from the examples, this comprises synthesizing labelled probes having putative sequences encoding regions of the hydrolase of interest, preparing genomic libraries from organisims expressing the hydrolase, and screening the libraries for the gene of hybridization to the probes. Positively hybridizing clones ar mapped and sequenced.
  • the cloned genes are ligated into an expression vector (which also may be the cloning vector) with requisite regions for replication in the host, the plasmid transfected into a host for enzyme synthesis and the recombina host cells cultured under conditions favoring enzyme synthesis, usually selection pressure such as is supplied by the presence of an antibiotic, the resistance to which is encoded by the vector. Culture under these conditions results in enzyme yields multifold greater than the wild type enzyme synthesis of the parent organism, even if it is the parent organism that is transformed.
  • an expression vector which also may be the cloning vector
  • “Expression vector” refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host.
  • control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation.
  • the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself.
  • "plasmid” and “vector” are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
  • Recombinant host cells refers to cells which have been transformed or transfected with vectors constructed using recombinant DNA techniques. As relevant to the present invention, recombinant host cells are those which produce procaryotic carbonyl nydrolases in its various forms by virtue of having been transformed with expression vectors encoding these proteins. The recombinant host cells may or may not have produced a form of carbonyl hydrolase prior to transformation.
  • operably linked when describing the relationship between two DNA regions simply means that they are functionally related to each other.
  • a presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence.
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence;
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
  • proteolytic enzyme refers to a hydrolase which contains additional N-terminal amino acid resides which render the enzyme inactive but, when removed, yield an enzyme. Many proteolytic enzymes are found in nature as translational proenzyme products and, in the absence of post-translational products, are expressed in this fashion.
  • Presequence refers to a signal sequence of amino acids bound to the N-terminal portion of the hydrolase which may participate in the secretion of the hydrolase. Presequences also may be modified in the same fashion as is described here, including the introduction of predetermined mutations.
  • the subject protein When bound to a nydrolase, the subject protein becomes a "prehydrolase". Accordingly, relevant prehydrolase for the purposes herein are presubtilisin and preprosubtilisin. Prehydrolases are produced by deleting the "pro” sequence (or at least that portion of the pro sequence that maintains the enzyme in its inactive state) from a prepro coding region, and then expressing the prehydrolase. In this way the organism excretes the active rather than proenzyme.
  • the cloned carbonyl hydrolase is used to transform a host cell in order to express the hydrolase. This will be of interest where the hydrolase has commercial use in its unmodified form, as for example subtilisin in laundry products as noted above.
  • the hydrolase gene is ligated into a high copy. number plasmid.
  • This plasmid replicates in hosts in the sense that it contains the well-known elements necessary for plasmid replication: a promoter operably linked to the gene in question (which may be supplied as the gene's own homologous promotor if it is recognized, i.e., transcribed, by the host), a transcription termination and polyadenylation region (necessary for stability of the mRNA transcribed by the host from the hydrolase gene) which is exogenous or is supplied by the endogenous terminator region of the hydrolase gene and, desirably, a selection gene such as an antibiotic resistance gene that enables continuous cultural maintenance of plasmid-infected host cells by growth in antibiotic-containing media.
  • a promoter operably linked to the gene in question which may be supplied as the gene's own homologous promotor if it is recognized, i.e., transcribed, by the host
  • a transcription termination and polyadenylation region (necessary for stability of the mRNA transcribed by the
  • High copy number plasmids also contain an origin of replication for the host, thereby enabling large numbers of plasmids to be generated in the cytoplasm without chromosonal limitations.
  • a precursor enzyme is the enzyme prior to its modification as described in this application. Usually the precursor is the enzyme as expressed by the organism which donated the DNA modified in accord herewith.
  • the term "precursor" is to be understood as not implying that the product enzyme was the result of manipulation of the precursor enzyme per se.
  • the gene may be detected from a recombination positive (rec + ) organism containing a homologous gene. This is accomplished by recombination of an in vitro deletion mutation of the cloned gene with the genome of the organism. Many strains of organisms such as E.coli and Bacillus are known to be capable of recombination. All that is needed is for regions of the residual DNA from the deletion mutant to recombine with homologous regions of the candidate host.
  • the deletion may be within the coding region (leaving enzymatically inactive polypeptides) or include the entire coding region as long as homologous flanking regions (such as promoters or termination regions) exist in the host.
  • Acceptability of the host for recombination deletion mutants is simply determined by screening for the deletion of the transformed phenotype. This is most readily accomplished in the case of carbonyl hydrolase by assaying host cultures for loss of the ability to cleave a chromogenic substrate otherwise hydrolyzed by the hydrolase.
  • Transformed hosts contained the protease deletion mutants are useful for synthesis of products which are incompatible with proteolytic enzymes. These hosts by definition are incapable of excreting the deleted proteases described herein, yet are substantially normally sporulating. Also the other growth characteristics of the transformants are substantially like the parental organism. Such organisms are useful in that it is expected they will exhibit comparatively less inactivation of heterologous proteins than the parents, and these hosts do have growth characteristics superior to known protease-deficient organisms. However, the deletion of neutral protease and subtilisin as described in this application does not remove all of the proteolytic activity of Bacillus.
  • intracellular proteases which are not ordinarily excreted extracellularly "leak” or diffuse from the cells during late phases of the culture. These intracellular proteases may or may not be subtilisin or neutral protease as those enzymes are defined herein. Accordingly, the novel Bacillus strains herein are incapable of excreting the subtilisin and/or neutral protease enzymes which ordinarfly are excreted extracellularly in the parent strains. "Incapable" means not revertible to the wild type.
  • Reversion is a finite probability that exists with the heretofore known protease-deficient, naturally occurring strains since there is no assurance that the phenotype of such strains is not a function of a readily revertible mutation, e.g. a point mutation. This is to be contrasted with the extremely large deletions provided herein.
  • the deletion mutant-transformed host cells herein are free of genes encoding enzymatically active neutral protease or subtilisin, which genes are defined by those being substantially homologous with the genes set forth in FIGS. 1, 7 or 10.
  • "Homologous" genes contain coding regions capable of hybridizing under high stringency conditions with the genes shown in FIGS. 1, 7 or 10.
  • the microbial strains containing carbonyl hydrolase deletion mutants are useful in two principal processes. In one embodiment they are advantageous in the fermentative production of products ordinarily expressed by a host that are desirably uncontaminated with the protein encoded by the deletion gene.
  • An example is fermentative synthesis of amylase, where contaminant proteases interfere in many industrial uses for amylase.
  • the novel strains herein relieve the art from part of the burden of purifying such products free of contaminating carbonyl hydrolases.
  • subtilisin and neutral protease deletion-mutant strains are useful in the synthesis of protein which is not otherwise encoded by the strain. These proteins will fall within one of two classes.
  • the first class consists of proteins encoded by genes exhibiting no substantial pretransformation homology with those of the host. These may be proteins from other procaryotes but ordinarily are eucaryotic proteins from yeast or higher eucaryotic organisms, particularly mammals.
  • the novel strains herein serve as useful hosts for expressible vectors containing genes encoding such proteins because the probability for proteolytic degradation of the expressed, non-homologous proteins is reduced.
  • the second group consists of mutant host genes exhibiting substantial pretransformation homology with those of the host. These include mutations of procaryotic carbonyl hydrolases such as subtilisin and neutral protease, as well as microbial (rennin, for example rennin from the genus Mucor). These mutants are selected in order to improve the characteristics of the precursor enzyme for industrial uses.
  • procaryotic carbonyl hydrolases such as subtilisin and neutral protease
  • rennin for example rennin from the genus Mucor
  • a novel method is provided to facilitate the construction and identification of such mutants.
  • the gene encoding the hydrolase is obtained and sequenced in whole or in part. Then the sequence is scanned for a point at which it is desired to make a mutation (deletion, insertion or substitution) of one or more amino acids in the expressed enzyme. The sequences flanking this point are evaluated for the presence of restriction sites for replacing a short segment of the gene with an oligonucleotide pool which when expressed will encode various mutants. Since unique restriction sites are generally not present at locations within a convenient distance from the selected point (from 10 to 15 nucleotides), such sites are generated by substituting nucleotides in the gene in such a fashion that neither the reading frame nor the amino acids encoded are changed in the final construction.
  • flanking region which does not contain a site.
  • Mutation of the gene in order to change its sequence to conform to the desired sequence is accomplished by M13 primer extension in accord with generally known methods.
  • the gene Once the gene is cloned, it is digested with the unique restriction enzymes and a plurality. of end termini-complementary oligonucleotide cassettes are ligated into the unique sites.
  • the mutagenesis is enormously simplified by this method because all of the oligonucleotides can be synthesized so as to have the same restriction sites, and no synthetic linkers are necessary to create the restriction sites.
  • a suitable DNA sequence computer search program simplifies the task of finding potential 5' and 3' unique flanking sites.
  • a primary. constraint is that any mutation introduced in creation of the restriction site must be silent to the final constructed amino acid coding sequence.
  • a candidate restriction site 5' to the target codon a sequence must exist in the gene which contains at least all the nucleotides but for one in the recognition sequence 5' to the cut of the candidate enzyme.
  • the blunt cutting enzyme SmaI (CCC/GGG) would be a 5' candidate if a nearby 5' sequence contained NCC, CNC, or CCN.
  • N needed to be altered to C this alteration must leave the amino acid coding sequence intact.
  • a cassette having termini ranging from a blunt end up to a four base-overhang will function without difficulty.
  • this hypothetical EcoRV site would have significantly shortened the oligonucleotide cassette employed (9 and 13 base pairs) thus allowing greater purity and lower pool bias problems. Flanking sites should obviously be chosen which cannot themselves ligate so that ligation of the oligonucleotide cassette can be assured in a single orientation.
  • the mutation per se need not be predetermined.
  • an oligonucleotide cassette or fragment is randomly mutagenized with nitrosoguanidine or other mutagen and then in turn ligated into the hydrolase gene at a predetermined location.
  • mutant carbonyl hydrolases expressed upon transformation of the suitable hosts are screened for enzymes exhibiting desired characteristics, e.g. substrate specificity, oxidation stability, pH-activity profiles and the like.
  • a change in substrate specificity is defined as a difference between the Kcat/Km ratio of the precursor enzyme and that of the mutant.
  • the Kcat/Km ratio is a measure of catalytic efficiency. Procaryotic carbonyl hydrolases with increased or diminished Kcat/Km ratios are described in the examples.
  • the objective will be to secure a mutant having a greater (numerically larger) Kcat/Km ratio for a given substrate, thereby enabling the use of the enzyme to more efficiently act on a target substrate.
  • An increase in Kcat/Kcm ratio for one substrate may be is accompanied by a reduction in Kcat/Km ratio for another substrate. This is a shift in substrate specificity, and mutants exhibiting such shifts have utility where the precursors are undesirable, e.g. to prevent undesired hydrolysis of a particular substrate in an admixture of substrates.
  • Kcat and Km are measured in accord with known procedures, or as described in Example 18.
  • Oxidation stability is a further objective which is accomplished by mutants described in the examples.
  • the stability may be enhanced or diminished as is desired for various uses.
  • Enhanced stability is effected by deleting one or more methionine, tryptophan, cysteine or lysine residues and, optionally, substituting another amino acid residue not one of methionine, tryptophan, cysteine or lysine.
  • the opposite substitutions result in diminished oxidation stability.
  • the substituted residue is preferably alanyl, but neutral residues also are suitable.
  • a pH-activity profile is a plot of pH against enzyme activity and may be constructed as illustrated in Example 19 or by methods known in the art. It may be desired to obtain mutants with broader profiles, i.e., those having greater activity at certain pH than the precursor, but no significantly greater activity at any pH, or mutants with sharper profiles, i.e. those having enhanced activity when compared to the precursor at a given pH, and lesser activity elsewhere.
  • mutants preferably are made within the active site of the enzymes as these mutations are most likely to influence activity. However, mutants at other sites important for enzyme stability or conformation are useful.
  • mutations at tyrosine-1, aspartate+32, asparagine+155, tyrosine+104, methionine+222, glycine+166, histidine+64, glycine+169, phenylalanine+189, serine+33, serine+221, tyrosine+217, glutamate+156 and/or alanine+152 produce mutants having changes in the characteristics described above or in the processing of the enzyme.
  • amino acid position numbers are those assigned to B. amyloliquefaciens subtilisin as seen from FIG. 7. It should be understood that a deletion or insertion in the N-terminal direction from a given position will shift the relative amino acid positions so that a residue will not occupy its original or wild type numerical position. Also, allelic differences and the variation among various procaryotic species will result in positions shifts, so that position 169 in such subtilisins will not be occupied by glycine. In such cases the new positions for glycine will be considered equivalent to and embraced within the designation glycine+169. The new position for glycine+169 is readily identified by scanning the subtilisin in question for a region homologous to glycine+169 in FIG. 7.
  • amino acid residues may be mutated.
  • the enzymes herein may be obtained as salts. It is clear that the ionization state of a protein will be dependent on the pH of the surrounding medium, if it is in solution, or of the solution from which it is prepared, if it is in solid form. Acidic proteins are commonly prepared as, for example, the ammonium, sodium, or potassium salts; basic proteins as the chlorides, sulfates, or phosphates. Accordingly, the present application includes both electrically neutral and salt forms of the designated carbonyl hydrolases, and the term carbonyl hydrolase refers to the organic structural backbone regardless of ionization state.
  • the mutants are particularly useful in the food processing and cleaning arts.
  • the carbonyl hydrolases including mutants, are produced by fermentation as described herein and recovered by suitable techniques. See for example K. Anstrup, 1974, Industrial Aspects of Biochemistry, ed. B. Spencer pp. 23-46. They are formulated with detergents or other surfactants in accord with methods known per se for use in industrial processes, especially laundry. In the latter case the enzymes are combined with detergents, builders, bleach and/or fluorescent whitening agents as is known in the art for proteolytic enzymes.
  • Suitable detergents include linear alkyl benzene sulfonates, alkyl ethoxylated sulfate, sulfated linear alcohol or ethoxylated linear alcohol.
  • compositions may be formulated in granular or liquid form. See for example U.S. Pat. Nos. 3,623,957; 4,404,128; 4,381,247; 4,404,115; 4,318,818; 4,261,868; 4,242,219; 4,142,999; 4,111,855; 4,011,169; 4,090,973; 3,985,686; 3,790,482; 3,749,671; 3,560,392; 3,558,498; and 3,557,002.
  • Plasmids are designated by a small p preceeded and/or followed by capital letters and/or numbers.
  • the starting plasmids herein are commercially available, are available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures.
  • Klenow treatment refers to the process of filling a recessed 3' end of double stranded DNA with deoxyribonucleotides complementary to the nucleotides making up the protruding 5' end of the DNA strand. This process is usually used to fill in a recessed end resulting from a restriction enzyme cleavage of DNA. This creates a blunt or flush end, as may. be required for further ligations.
  • Treatment with Klenow is accomplished by reacting (generally for 15 minutes at 15° C.) the appropriate complementary deoxyribonucleotides with the DNA to be filled in under the catalytic activity (usually 10 units) of the Klenow fragment of E. coli DNA polymerase I ("Klenow"). Klenow and the other reagent needed are commercially available. The procedure has been published extensively. See for example T. Maniatis et al., 1982, Molecular Cloning, pp. 107-108.
  • “Digestion” of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction enzymes, and the sites for which each is specific is called a restriction site. "Partial” digestion refers to incomplete digestion by a restriction enzyme, i.e., conditions are chosen that result in cleavage of some but not all of the sites for a given restriction endonuclease in a DNA substrate.
  • the various restriction enzymes. used herein are commercially available and their reaction conditions, cofactors and other requirements as established by the enzyme suppliers were used. Restriction enzymes commonly are designated by.
  • Recovery or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on 6 percent polyacrylamide gel electrophoresis, identification of the fragment of interest by molecular weight (using DNA fragments of known molecular weight as markers), removal of the gel section containing the desired fragment, and separation of the gel from DNA.
  • This procedure is known generally. For example, see R. Lawn et al., 1981, “Nucleic Acids Res.” 9:6103-6114, and D. Goeddel et al., (1980) "Nucleic Acids Res.” 8:4057.
  • Southern Analysis is a method by which the presence of DNA sequences in a digest or DNA-containing composition is confirmed by hybridization to a known, labelled oligonucleotide or DNA fragment.
  • Southern analysis shall means separation of digests on 1 percent agarose and depurination as described by G. Wahl et al., 1979, "Proc. Nat. Acad. Sci. U.S.A.” 76:3683-3687, transfer to nitrocellulose by the method of E. Southern, 1975, "J. Mol. Biol.” 98:503-517, and hybridization as described by T. Maniatis et al., 1978, "Cell” 15:687-701.
  • Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or chromosomal integrant.
  • the method used herein for transformation of E. coli is the CaCl 2 method of Mandel et al., 1970, "J. Mol. Biol.” 53:154, and for Bacillus, the method of Anagnostopoulos et al., 1961, “J. Bact.” 81:791-746.
  • Ligase DNA ligase
  • Preparation of DNA from transformants means isolating plasmid DNA from microbial culture. Unless otherwise stated, the alkaline/SDS method of Maniatis et al., Id. p. 90, was used.
  • Oligonucleotides are short length single or double stranded polydeoxynucleotides which were chemically synthesized by the method of Crea et al., 1980, "Nucleic Acids Res.” 8:2331-2348 (except that mesitylene nitrotriazole was used as a condensing agent) and then purified on polyacrylamide gels.
  • the known amino acid sequence of the extracellular B. amyloliquefaciens permits the construction of a suitable probe mixture.
  • the sequence of the mature subtilisin is included (along with the additional information contributed by the present work) in FIG. 1. All codon ambiguity for the sequence of amino acids at position 117 through 121 is covered by a pool of eight oligonucleotides of the sequence ##STR2##
  • Chromosomal DNA isolated from B. amyloliquefaciens was partially digested by Sau 3A, and the fragments size selected and ligated into the BamH1 site of dephosphorylated pBS42.
  • pBS42 is shuttle vector containing origins of replication effective both in E. coli and Bacillus. It is prepared as described in Example 4).
  • the Sau3A fragment containing vectors were transformed into E. coli K12 strain 294 (ATCC No. 31446) according to the method of M. Mandel, et al., 1970, "J. Mol. Bio.” 53:154 using 80-400 nanograms of library DNA per 250 ⁇ L of competent cells.
  • Cells from the transformation mixture were plated at a density of 1-5 ⁇ 10 3 transformants per 15 Omm plate containing LB medium+12.5 ⁇ g/ml chloramphenicol, and grown overnight at 37° C. until visible colonies appeared.
  • the plates were then replica plated onto BA85 nitrocellulose filters overlayed on LB/chloramphenicol plates. The replica plates were grown 10-12 hours at 37° C. and the filters transferred to fresh plates containing LB and 150 ⁇ g/ml spectinomycin to amplify the plasmid pool.
  • Bacillus subtilis I-168 (Catalog No. 1-A1, Bacillus Genetic Stock Center) was transformed with pS4 and and a single chloramphenicol resistant transformant then grown in minimal medium. After 24 hours, the culture was centrifuged and both the supernatant (10-200 ⁇ l) and pellet assayed for proteolytic activity by measuring the change in absorbance per minute at 412 nm using 1 ml of the chromogenic substrate succinyl-L-ala-ala-pro-phe-p-nitroanilide (0.2 ⁇ M) in 0.1M sodium phosphate (pH 8.0) at 25° C.
  • succinyl-L-ala-ala-pro-phe-p-nitroanilide 0.2 ⁇ M
  • 0.1M sodium phosphate pH 8.0
  • subtilis I-168 culture transformed with pBS42 used as a control showed less than 1/200 of the activity shown by the pS4 transformed culture. Greater than 95 percent of the protease activity of the pS4 culture was present in the supernatant, and was completely inhibited by treatment with phenylmethylsulfonyl fluoride (PMSF) but not by EDTA.
  • PMSF phenylmethylsulfonyl fluoride
  • Lane 2 which is the supernatant from pBS42 transformed B. subtilis, does not give the 31,000 MW band associated with subtilisin which is exhibited by Lane 1 from pS4 transformed hosts.
  • the approximately 31,000 MW band result from subtilisin is characteristic of the slower mobility shown by the known M.W. 27,500 subtilisin preparations in general.
  • pBS42 is formed by three-way ligation of fragments derived from pUB11, pC194, and pBR322 (see FIG. 5).
  • the fragment from pUB110 is the approximately 2600 base pair fragment between the HpaII site at 1900 and the BamH1 site at 4500 and contains an origin of replication operable in Bacillus: T. Grycztan, et al., 1978 "J. Bacteriol.”, 134: 318 (1978); A. Jalanko, et al., 1981 "Gene", 14: 325.
  • the BamHI site was tested with Klenow.
  • the pBR322 portion is the 1100 base pair fragment between the PvuII site at 2067 and the Sau3A site at 3223 which contains the E. coli origin of replication: F. Bolivar, et al., 1977 "Gene", 2: 95;-J Sutcliffe, 1978, Cold Spring Harbor Symposium 43: I, 77.
  • the pC194 fragment is the 1200 base pair fragment between the HpaII site at 973 and the Sau3A site at 2006 which contains the gene for chloramphenicol resistance expressible in both E. coli and B subtilis; S. Ehrlich, "Proc. Natl. Acad. Sci. (USA)", 74:1680; S. Horynuchi et al., 1982, "J. Bacteriol.” 150: 815.
  • pBS42 thus contains origins of replication operable both in E. coli and in Bacillus and an expressible gene for chloramphenicol resistance.
  • B. subtilis 1168 chromosomal DNA was digested with EcoRI and the fragments resolved on gel electrophoresis.
  • a single 6 kb fragment hybridized to a [ ⁇ - 32 P] CTP nick translation - labeled fragment obtained from the C-terminus of the subtilisin structural gene in pS4, described above.
  • the 6 kb fragment was electroluted and ligated into pBS42 which had been digested and EcoRI and treated with bacterial alkaline phosphatase.
  • E. coli ATCC 31446 was transformed with the ligation mixture and transformants selected by growth on LB agar containing 12.5 ⁇ g chloramphenicol/ml. Plasmid DNA was prepared from a pooled suspension of 5,000 transformed colonies.
  • This DNA was transformed into B. subtilis BG84, a protease deficient strain, the preparation of which is described in Example 8 below. Colonies which produced protease were screened by. plating on LB agar plus 1.5 percent w/w Carnation powdered nonfat skim milk and 5 ⁇ g chloramphenicol/ml (hereafter termed skim milk selection plates) and observing for zones of clearance evidencing proteolytic activity.
  • Plasmid DNA was prepared from protease producing colonies, digested with EcoRI, and examined by Southern analysis for the presence of the 6 kb EcoRI insert by hybridization to the 32 P-labelled C-terminus fragment of the subtilisin structural gene from B. amyloliquefaciens. A positive clone was identified and the plasmid was designated pS168.1.
  • B. subtilis BG84 transformed with pS168.1 excreted serine protease at a level 5-fold over that produced in B. subtilis 1168.
  • FIG. 6 A restriction map of the 6.5 kb EcoRI insert is shown in FIG. 6.
  • the subtilisin gene was localized to within the 2.5 kb KpnI-EcoRI fragment by subcloning various restriction enzyme digests and testing for expression of subtilisin in B. subtilis BG84.
  • Southern analysis with the labelled fragment from the C-terminus of the B. amyloliquefaciens subtilisin gene as a probe localized the C-terminus of the B. subtilis gene to within or part of the 631 by HincII fragment B in the center of this subclone (see FIG. 6).
  • the tandem HincII fragments B, C, and D and HincII-EcoRI fragment E FIG. 6.
  • a two step ligation shown in FIG. 8, was required to construct a plasmid carrying a defective gene which would integrate into the Bacillus chromosome.
  • pS168.1 which contained the 6.5 kb insert originally recovered from the B. subtilis genomic library as described in Example 5 above, was digested with EcoRI, the reaction products treated with Klenow, the DNA digested with HincII, and the 800 bp EcoRI-HincII fragment E (see FIG. 6) that contains, in part, the 5' end of the B. subtilis subtilisin gene, was recovered. This fragment was ligated into pJH101(pJH101is available from J. Hoch (Scripps) and is described by F. A.
  • pIDV1 contained fragment E in the orientation shown in FIG. 8.
  • pS168.1 was digested with HincII and the 700 bp HincII fragment B, which contains the 3' end of the subtilisin gene, was recovered.
  • pIDV1 was digested at its unique HincII site and fragment B ligated to the linearized plasmid, transformed in E.
  • plasmid pIDV1.4 contained fragment B in the correct orientation with respect to fragment E.
  • This plasmid pIDV1.4 shown in FIG. 8, is a deletion derivative of the subtilisin gene containing portions of the 5' and 3' flanking sequences as well.
  • B. subtilis BG77 a partial protease-deficient mutant (Prt +/- ) prepared in Example 8 below was transformed with pIDV1.4. Two classes of chloramphenicol resistant (Cm r ) transformants were obtained. Seventy-five percent showed the same level of proteases as BG77 (Prt +/- ) and 25 percent were almost completely protease deficient (Prt - ) as observed by relative zones of clearing on plates containing LB agar plus skim milk.
  • the Cm r Prt - transformants could not be due to a single crossover integration of the plasmid at the homologous regions for fragment E or B because, in such a case, the gene would be uninterrupted and the phenotype would be Prt +/- .
  • the protease deficient phenotype was not observed.
  • the Cm r phenotype of Cm r Prt - pIDV1.4 transformants was unstable in that Cm s Prt- derivatives could be isolated from Cm r Prt.sup.
  • BG2018 a BGSC strain carrying two auxotrophic mutations flanking the subtilisin gene
  • the derivative organism was designated BG2019.
  • the labelled pool containing sequences conforming closest to a unique sequence in a B. subtilis genome was selected by digesting B. subtilis (1A72, Bacillus Genetic Stock Center) DNA with various restriction enzymes, separating the digests on an electrophoresis gel, and hybridizing each of the four probe pools to each of the blotted digests under increasingly stringent conditions until a single band was seen to nybridize.
  • Increasingly stringent conditions are those which tend to disfavor hybridization, e.g., increases in formamide concentration, decreases in salt concentration and increases in temperature. At 37° C.
  • a lambda library of B. subtilis strain BGSC 1-A72 was prepared in conventional fashion by partial digestion of the Bacillus genomic DNA by Sau3A, separated of the partial digest by molecular weight on an electrophoresis gel, elution of 15-20 kb fragments (R. Lawn et al., 1981, "Nucleic Acids Res.” 9:6103-6114), and ligation of the fragments to BamHI digested charon 30 phage using a Packagene kit from Promega Biotec.
  • E. coli DP50supF was used as the host for the phage library, although any known host for Charon lambda phage is satisfactory.
  • the E. coli was plated with the library phage and cultured, after which plaques were assayed for the presence of the neutral protease gene by transfer to nitrocellulose and screening with probe pool 4 (Benton and Davis, 1977, "Science” 196:180-182). Positive plaques were purified through two rounds of single plaque purification, and two plaques were chosen for further study, designated ⁇ NPRG1 and ⁇ NPRG2.
  • DNA was prepared from each phage by restriction enzyme hydrolysis and separation on electrophoresis gels. The separated fragments were blotted and hybridized to labelled pool 4 oligonucleotides. This disclosed that ⁇ NPRG1 contained a 2400 bp HindIII hybridizing fragment, but no 4300 EcoRI fragment, while ⁇ NPRG2 contained a 4300 bp EcoRI fragment, but no 2400 by HindIII fragment
  • the 2400 bp ⁇ NPRG1 fragment was subcloned into the HindIII site of pJH101by the following method.
  • ⁇ NPRG1 was digested by HindIII, the digest fractionated by electrophoresis and the 2400 by fragment recovered from the gel.
  • the fragment was ligated to alkaline phosphatase-treated HindIII digested pJH101and the ligation mixture used to transform E. coli ATCC 31446 by the calcium chloride shock method of V. Herschfield et al., 1974, "Proc. Nat. Acad. Sci. (U.S.A.)" 79:3455-3459).
  • Transformants were identified by selecting colonies capable of growth on plates containing LB medium plus 12.5 ⁇ g chloramphenicol/ml.
  • Transformants colonies yielded several plasmids.
  • the orientation of the 2400 bp fragment in each plasmid was determined by conventional restriction analysis (orientation is the sense reading or transcriptional direction of the gene fragment in relation to the reading direction of the expression vector into which it is ligated.)
  • Two plasmids with opposite orientations were obtained and designated pNPRsubH6 and pNPRsubH1.
  • the 4300 bp EcoRI fragment of ⁇ NPRG2 was subcloned into pBR325 by the method described above for the 2400 bp fragment except that ⁇ NPRG2 was digested with EcoRI and the plasmid was alkaline phosphatase-treated, EcoRI-digested pBR325.
  • pBR325 is described by. F. Bolivar, 1978, "Gene” 4:121-136.
  • Two plasmids were identified in which the 4300 bp insert was present in different orientations. These two plasmids were designated pNPRsubRI and pNPRsubRIb.
  • the pNPRsubH1 insert was sequentially digested with different restriction endonucleases and blot hybridized with labelled pool 4 in order to prepare a restriction map of the insert (for general procedures of restriction mapping see T. Maniatis et al., Id., p. 377).
  • a 430 bp RsaI fragment was the smallest fragment that hybridized to probe pool 4.
  • the RsaI fragment was ligated into the SmaI site of M13 mp8 (J. Messing et al., 1982, "Gene” 19:269-276 and J. Messing in Methods in Enzymology, 1983, R.
  • the sequences of the various fragments from restriction enzyme digests were compared and an open reading frame spanning a codon sequence translatable into the amino and carboxyl termini of the protease (P. Levy et al., Id.) was determined.
  • An open reading frame is a DNA sequence commencing at a known point which in reading frame (every three nucleotides) does not contain any internal termination codons.
  • the open reading frame extended past the amino terminus to the end of the 2400 by HindIII fragment.
  • the 1300 bp BgIII - HindIII fragment was prepared from pNPRsubRIb (which contained the 4300 bp EcoRI fragment of ⁇ NPRG2) and cloned in M13 mp8.
  • the sequence of this fragment which contained the portion of the neutral protease leader region not encoded by the 2400 by fragment of pNPRsubH1, was determined for 400 nucleotides upstream from the HindIII site.
  • the entire nucleotide sequence as determined for this neutral protease gene, including the putative secretory leader and prepro sequence, are shown in FIG. 10.
  • the numbers above the line refer to amino acid positions.
  • the underlined nucleotides in FIG. 10 are believed to constitute the ribosome binding (Shine-Dalgarno) site, while the overlined nucleotides constitute a potential hairpin structure presumed to be a terminator.
  • the first 27-28 of the deduced amino acids are believed to be the signal for the neutral protease, with a cleavage point at ala-27 or ala-28.
  • the "pro" sequence of a proenzyme structure extends to the amino-terminal amino acid (ala-222) of the mature, active enzyme.
  • a high copy plasmid carrying the entire neutral protease gene was constructed by (FIG. 11) ligating the BG1II fragment of pNPRsubR1, which contains 1900 bp (FIG. 9), with the PvuII - HindIII fragment of pNPRsubH1, which contains 1400 bp.
  • pBS42 (from Example 4 was digested with BamHI and treated with bacterial alkaline phosphatase to prevent plasmid recircularization.
  • pNPRsubR1 was digested to Bg1II, the 1900 bp fragment was isolated from gel electrophoresis and ligated to the open BamHI sites of pBS42. The ligated plasmid was used to transform E.
  • coli ATCC 31446 by the calcium chloride shock method (V. Hershfield et al., Id.), and transformed cells selected by growth on plates containing LB medium with 12.5 ⁇ g/ml chloramphenicol.
  • a plasmid having the Bg1 II fragment in the orientation shown in FIG. 11 was isolated from the transformants and designated pNPRsubB1.
  • pNPRsubB1 was digested (linearized) with EcoRI, repaired to flush ends by Kienow treatment and then digested with HindIII. The larger fragment from the HindIII digestion (containing the sequence coding for the amino terminal and upstream regions) was recovered.
  • the carboxyl terminal region of the gene was supplied by a fragment from pNPRsubH1, obtained by digestion of pNPRsubH1 with PvuII and HindIII and recovery of the 1400 bp fragment.
  • the flush end PvuII and the HindIII site of the 1400 bp fragment was ligated, respectively, to the blunted EcoRI and the HindIII site of pNPRsubB1, as shown in FIG. 11.
  • This construct was used to transform B. subtilis strain BG84 which otherwise excreted no proteolytic activity by the assays described below. Transformants were selected on plates containing LB medium plus 1.5 percent carnation powdered nonfat milk and 5 ⁇ g/ml chloramphenicol. Plasmids from colonies that cleared a large halo were analyzed. Plasmid pNPR10, incorporating the structural gene and flanking regions of the neutral protease gene, was determined by restriction analysis to have the structure shown in FIG. 11.
  • B. subtilis strain BG84 was produced by N-methyl-N'-nitro-N-nitrosoguanidine (NTG) mutagenesis of B. subtilis I168 according to the general technique of Adelberg et al., 1965, "Biochem. Biophys. Res. Commun.” 18:788-795.
  • Mutagenized strain I168 was plated on skim milk plates (without antibiotic). Colonies producing a smaller halo were picked for further analysis. Each colony was characterized for protease production on skim milk plates and amylase production on starch plates.
  • the protease deficiency mutation was designated prt-77.
  • the prt-77 allele was moved to a spoOA background by congression as described below to produce strain BG84, a sporulation deficient strain.
  • BG84 was completely devoid of protease activity on skim milk plates and does not produce detectable levels of either subtilisin or neutral protease when assayed by measuring the change in absorbance at 412 nm per minute upon incubation with 0.2 ⁇ m/ml succinyl (-L-ala-L-ala-L-pro-L-phe) p-nitroanilide (Vega) in 0.1M sodium phosphate, pH 8, at 25° C. BG84 was deposited in the ATCC as deposit number 39382 on July 21, 1983. Samples for subtilisin assay were taken from late logarithmic growth phase supernatants of cultures grown in modified Schaeffer's medium (T. Leighton et al., 1971, "J. Biol. Chem.” 246:3189-3195).
  • BG84 transformed with pNPR10 was inoculated into minimal medial supplemented with 0.1 percent casein hydrolysate and 10 ⁇ g chloramphenicol and cultured for 16 hours.
  • 0.1 ml of culture supernatant was removed and added to a suspension of 1.4 mg/ml Azocoll proteolytic substrate (Sigma) in 10 mM Tris-HCl, 100 mM NaCl pH 6.8 and incubating with agitation. Undigested substrate was removed by centrifugation and the optical density read at 505 nm. Background values of an Azocoll substrate suspension were subtracted.
  • the amount of protease excreted by a standard protease-expressing strain, BG16 was used to establish an arbitrary level of 100.
  • the two RsaI bonded regions in the 2400 bp insert of pNPRsubH1, totalling 527 bp, can be deleted in order to produce an incomplete structural gene.
  • the translational products of this gene are enzymatically inactive.
  • a plasmid having this deletion was constructed as follows. pJH101 was cleaved by digestion with HindIII and treated with bacterial alkaline phosphatase. The fragments of the neutral protease gene to be incorporated into linearized pJH101 were obtained by digesting pNPRsubH1 with HindIII and RsaI, and recovering the 1200 bp HindIII-RsaI and 680 bp RsaI-HindIII fragments by gel electrophoresis.
  • Plasmid pNPRsubh1 ⁇ was transformed into B. subtilis strain BG2019 (the subtilisin deleted mutant from Example 6) and chromosomal integrants were selected on skim milk plates. Two types of Cm r transformants were noted, those with parental levels of proteolysis surrounding the colony, and those with almost no zone of proteolysis. Those lacking a zone of proteolysis were picked, restreaked to purify individual colonies, and their protease deficient character on skim milk plates confirmed. One of the Cm r , proteolysis deficient colonies was chosen for further studies (designated BG22034).
  • Cm s revertants of BG2034 were isolated by overnight growth in LB media containing no Cm, plating for individual colonies, and replica plating on media with and without Cm. Three Cm s revertants were isolated, two of which were protease proficient, one of which was protease deficient (designated BG2036). Hybridization analysis of BG2036 confirmed that the plasmid had been lost from this strain, probably by recombination, leaving only the deletion fragments of subtilisin and neutral protease.
  • proteases The growth, sporulation and expression of proteases was examined in strains lacking a functional gene for either the neutral or alkaline protease or both.
  • the expression of proteases was examined by a zone of clearing surrounding a colony on a skim milk plate and by measurement of the protease levels in liquid culture supernatants (Table B).
  • Strain BG2054 considered equivalent to BG2036 (Example 11) in that it carried the foregoing deletions in both genes, showed no detectable protease activity in this assay and no detectable halo on milk plates.
  • the deletion of either or both of the protease genes had no apparent effect on either growth or sporulation.
  • Strains carrying these deletions had normal growth rates on both minimal glucose and LB media.
  • the strains sporulated at frequencies comparable to the parent strain BG16. Examination of morphology of these strains showed no apparent differences from strains without such deletions.
  • pS4-5 a derivative of pS4 made according to Wells et al., "Nucleic Acids Res.”, 1983, 11:7911-7924 was digested with EcoRI and BamHI, and the 1.5 kb EcoRIBamHI fragment recovered. This fragment was ligated into replicative form M-13 mp9 which had been digested with EcoRI and BamHI (Sanger et al., 1980, "J. Mol. Biol.” 143 161-178. Messing et al, 1981, “Nucleic Acids Research", 9, 304-321. Messing, J. and Vieira, J. (1982) Gene 19, 269-276).
  • M-13 mp9 phage ligations designated M-13 mp9 SUBT, were used to transform E. coli strain JM101 and single stranded phage DNA was prepared from a two mL overnight culture.
  • An oligonucleotide primer was synthesized having the sequence 5'-GTACAACGGTACCTCACGCACGCTGCAGGAGCGGCTGC-3'.
  • This primer conforms to the sequence of the subtilis gene fragment encoding amino acids 216-232 except that the 10 bp of codons for amino acids 222-225were deleted, and the codons for amino acids 220, 227 and 228 were mutated to introduce a KpnI site 5' to the met-222 codon and a PstI site 3' to the met ⁇ 222 codon. See FIG. 12. Substituted nucleotides are denoted by asterisks, the underlined codons in line 2 represent the new restriction sites and the scored sequence in line 4 represents the inserted oligonucleotides.
  • the primer (about 15 ⁇ M) was labelled with [ 32 p] by incubation with [ ⁇ 32 p]-ATP (10 ⁇ L in 20 ⁇ L reaction)(Amersham 5000 Ci/mmol, 10218) and T 4 polynucleotide kinase (10 units) followed by non-radioactive ATP (100 ⁇ M) to allow complete phosphorylation of the mutagenesis primer.
  • the kinase was inactivated by heating the phosphorylation mixture at 68° C. for 15 min.
  • the primer was hybridized to M-13 mp9 SUBT as modified from Norris et al., 1983, "Nucleic Acids Res.” 11, 5103-5112 by combining 5 ⁇ L of the labelled mutagenesis primer ( ⁇ 3 ⁇ M), ⁇ 1 ⁇ g M-13 mp9 SUBT template, 1 ⁇ L of 1 ⁇ M M-13 sequencing primer (17-mer), and 2.5 ⁇ L of buffer (0.3M Tris pH 8, 40 mM MgCl 2 , 12 mM EDTA, 10 mM DTT, 0.5 mg/ml BSA). The mixture was heated to 68° C. for 10 minutes and cooled 10 minutes at room temperature.
  • the remainder of the digested reaction mixture was diluted to 200 ⁇ L with 10 mM Tris, pH 8, containing 1 mM EDTA, extracted once with a 1:1 (v:v), phenol/chloroform mixture, then once with chloroform, and the aqueous phase recovered.
  • 15 ⁇ L of 5M ammonium acetate (pH 8) was added along with two volumes of ethanol to precipitate the DNA from the aqueous phase.
  • the DNA was pelleted by centrifugation for five minutes in a microfuge and the supernatant was discarded. 300 ⁇ L of 70 percent ethanol was added to wash the DNA pellet, the wash was discarded and the pellet lyophilized.
  • pBS42 from example 4 above was digested with BamH1 and EcoRI and purified on an acrylamide gel to recover the vector.
  • 0.5 ⁇ g of the digested vector, 50 ⁇ M ATP and 6 units ligase were dissolved in 20 ⁇ l of ligation buffer. The ligation went overnight at 14° C.
  • the DNA was transformed into E. coli 294 rec + and the transformants grown in 4 ml of LB medium containing 12.5 ⁇ g/ml chloramphenicol. Plasmid DNA was prepared from this culture and digested with KpnI, EcoRI and BamHI. Analysis of the restriction fragments showed 30-50 percent of the molecules contained the expected KpnI site programmed by the mutagenesis primer.
  • the plasmid population not including the KpnI site resulted from M-13 replication before bacterial repair of the mutagenesis site, thus producing a heterogenous population of KpnI + and KnpI - plasmids in some of the transformants.
  • the DNA was transformed a second time into E. coli to clone plasmids containing the new KpnI site. DNA was prepared from 16 such transformants and six were found to contain the expected KpnI site.
  • Preparative amounts of DNA were made from one of these six transformants (designated p ⁇ 222) and restriction analysis confirmed the presence and location of the expected KpnI and PstI sites.
  • 40 ⁇ g of p ⁇ 222 were digested in 300 ⁇ L of KpnI buffer plus 30 ⁇ L KpnI (300 units) for 1.5 h at 37° C.
  • the DNA was precipitated with ethanol, washed with 70 percent ethanol, and lyophilized.
  • the DNA pellet was taken up in 200 ⁇ L HindIII buffer and digested with 20 ⁇ L (500 units) PstI for 1.5 h at 37° C.
  • the aqueous phase was extracted with phenol/CHCl 3 and the DNA precipitated with ethanol.
  • the DNA was dissolved in water and purified by polyacrylamide gel electrophoresis. Following electroelution of the vector band (120 v for 2 h at 0° C. in 0.1 times TBE (Maniatis et al., Id.)) the DNA was purified by phenol/CHCl 3 extraction, ethanol precipitation and ethanol washing.
  • the rest of the transformants ( ⁇ 200-400 transformants) were cultured in 4 ml of LB medium plus 12.5 ⁇ g chloramphenicol/ml. DNA was prepared from each transformation pool (A-D). This DNA was digested with KnpI, ⁇ 0.1 ⁇ g was used to retransform E coli rec + and the mixture was plated to isolate individual colonies from each pool. Ligation of the cassettes into the gene and bacterial repair upon transformation destroyed the KnpI and PstI sites. Thus, only p ⁇ 222 was cut when the transformant DNA was digested with KpnI. The cut plasmid would not transform E. coli. Individual transformants were grown in culture and DNA was prepared from 24 to 26 transformants per pool for direct plasmid sequencing. A synthetic oligonucleotide primer having the sequence 5'-GAGCTTGATGTCATGGC-3' was used to prime the dideoxy sequencing reaction. The mutants which were obtained are described in Table C below.
  • Two codon+222 mutants (i.e., gln and ile) were not found after the screening described.
  • a single 25 mer oligonucleotide was synthesized for each mutant corresponding to the top oligonucleotide strand in FIG. 12.
  • Each was phosphorylated and annealed to the bottom strand of its respective nonphosphorylated oligonucleotide pool (i.e., pool A for gln and pool D for ile). This was ligated into KnpI and PstI digested p ⁇ 222 and processed as described for the original oligonucleotide pools.
  • the frequency of appearance for single mutants obtained in this way was 2/8 and 0/7 for gln and ile, respectively.
  • the top strand was phosphorylated and annealed to its unphosphorylated complementary pool.
  • the heterophosphorylated cassette was ligated into cut p ⁇ 222 and processed as before.
  • the frequency of appearance of gln and ile mutants was now 7/7 and 7/7, respectively.
  • a biased heteroduplex repair observed for the completely unphosphorylated cassette may result from the fact that position 222 is closer to the 5' end of the upper strand than it is to the 5' end of the lower strand (see FIG. 12). Because a gap exists at the unphosphorylated 5' ends and the mismatch bubble in the double stranded DNA is at position 222, excision repair of the top strand gap would more readily maintain a circularly hybridized duplex capable of replication. Consistent with this hypothesis is the fact that the top strand could be completely retained by selective 5' phosphorylation. In this case only the bottom strand contained a 5' gap which could promote excision repair. This method is useful in directing biased incorporation of synthetic oligonucleotide strands when employing mutagenic oligonucleotide cassettes.
  • Examples 13-14 The procedure of Examples 13-14 was followed in substantial detail, except that the mutagenesis primer differed (the 37 mer shown in FIG. 13 was used), the two restriction enzymes were SacI and XmaIII rather than PstI and KpnI and the resulting constructions differed, as shown in FIG. 13.
  • Bacillus strains excreting mutant subtilisins at position 166 were obtained as described below in Example 16.
  • the mutant subtilisins exhibiting substitutions of ala, asp, gln, phe, his, lys, asn, arg, and val for the wild-type residue were recovered.
  • B. subtilis strain BG2036 obtained by the method of Example 11 was transformed by the plasmids of Examples 14, 15 or 20 and by pS4-5 as a control. Transformants were plated or cultured in shaker flasks for 16 to 48 h at 37° C. in LB media plus 12.5 ⁇ g/ml chloramphenicol. Mutant enzymatically active subtilisin was recovered by dialyzing cell broth against 0.01M sodium phosphate buffer, pH 6.2. The dialyzed broth was then titrated to pH 6.2 with 1N HCl and loaded on a 2.5 ⁇ 2 cm column of CM cellulose (CM-52 Whatman).
  • subtilisins Except mutants at position +222, were eluted with the same buffer made 0.08N in NaCl.
  • the mutant subtilisins at position +222 were each eluted with 0.1M sodium phosphate, pH 7.0.
  • the purified mutant and wild type enzymes were then used in studies of oxidation stability, Km, Kcat, Kcat/Km ratio, pH optimum, and changes in substrate specificity.
  • Subtilisins having cysteine and alanine substituted at the 222 position for wild-type methionine were assayed for resistance to oxidation by incubating with various concentrations of sodium nypochloride (Clorox Bleach).
  • BVGRpN benzoyl-L-Valyl-Glycyl-L-Arginyl-p-nitroanilide
  • sAAPFpN succinyl-L-Alanyl-L-Alanyl-L-Prolyl-L-Phenylalanyl-p-nitro-anilide
  • the Kcat/Km ratio for each of the mutants varied from that of the wild-type enzyme. As a measure of catalytic efficiency, these ratios demonstrate that enzymes having much higher activity against a given substrate can be readily designed and selected by screening in accordance with the invention herein. For example, A166 exhibits over 2 times the activity of the wild type on sAAPFpN.
  • the pH profile of the Cys+222 mutant obtained in Example 16 was compared to that of the wild type enzyme. 10 ⁇ l of 60 mg/ml sAAPFpN in DMSO, 10 ⁇ l of Cys+222 (0.18 mg/ml) or wild type (0.5 mg/ml) and 980 ⁇ l of buffer (for measurements at pH 6.6, 7.0 and 7.6, 0.1M NaPO 4 buffer; at pH 8.2, 8.6 and 9.2, 0.1M tris buffer; and at pH 9.6 and 10.0, 0.1M glycine buffer), after which the initial rate of change in absorbance at 410 nm per minute was measured at each pH and the data plotted in FIG. 15.
  • the Cys+222 mutant exhibits a sharper pH optimum than the wild type enzyme.
  • Examples 13-14 The procedure of Examples 13-14 was followed in substantial detail, except that the mutagenesis primer differed (the primer shown in FIG. 16 was used), the two restriction enzymes were KpnI and EcoRV rather than PstI and KpnI and the resulting constructions differed, as shown in FIG. 16.
  • Bacillus strains excreting mutant subtilisins at position 169 were obtained as described below in Example 16.
  • the mutant subtilisins exhibiting substitutions of ala and ser for the wild-type residue were recovered and assayed for changes in kinetic features.
  • the assay employed SAAPFpN at pH 8.6 in the same fashion as set forth in Example 18. The results were as follows:
  • Position 166 mutants from Examples 15 and 16 were assayed for alteration of specific activity on a naturally occurring protein substrate. Because these mutant proteases could display altered specificity as well as altered specific activity, the substrate should contain sufficient different cleavage sites i.e., acidic, basic, neutral, and hydrophobic, so as not to bias the assay toward a protease with one type of specificity. The substrate should also contain no derivitized residues that result in the masking of certain cleavage sites. The widely used substrates such as hemoglobin, azocollogen, azocasein, dimetnyl casein, etc., were rejected on this basis. Bovine casein, ⁇ and ⁇ 2 chains, was chosen as a suitable substrate.
  • a 1 percent casein (w/v) solution was prepared in a 100 mM Tris buffer, pH 8.0, 10 mM EDTA.
  • the assay protocol is as follows:
  • test enzyme 10-200 ⁇ g.
  • This assay mixture was mixed and allowed to incubate at room temperature for 20 minutes. The reaction was terminated upon the addition of 100 ⁇ l 100 percent trichloroacetic acid, followed by. incubation for 15 minutes at room temperature. The precipitated protein was pelleted by centrifugation and the optical density of the supernatant was determined spectrophotometrically at 280 nm. The optical density is a reflection of the amount of unprecipitated, i.e., hydrolyzed, casein in the reaction mixture. The amount of casein hydrolysed by each mutant protease was compared to a series of standards containing various amounts of the wild type protease, and the activity is expressed as a percentage of the corresponding wild type activity. Enzyme activities were converted to specific activity by dividing the casein hydrolysis activity by the 280 nm absorbance of the enzyme solution used in the assay.

Abstract

A cloned subtilsin gene has been modified at specific sites to cause amino acid substitutions at certain spots in the enzyme. The modified enzyme, preferably produced by Bacillus, is useful in combination with detergents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
Cross-reference is made to .[.application Ser. No. 509,419 filed June 24, 1983, and its continuation-in-part Ser. No. 614,616. Cross reference is made to application Ser. No. 614,617, application Ser. No. 614,615, and application Ser. No. 614,491, all of which are filed concurrently herewith..]. .Iadd.the following related applications, all of which were filed on May 29, 1984 concurrently with U.S. Application Ser. No. 06/614,612 now issued as U.S. Pat. No. 4,760,025, and subject to reissue application Ser. No. 556,918 filed Jul. 20, 1990: (a) U.S. application Ser. No. 06/614,615 (abandoned), in favor of U.S. application Ser. No. 07/488,433 (pending) filed Feb. 29, 1990; U.S. application Ser. No. 07/511,972 (abn) filed Apr. 17, 1990; U.S. application Ser. No. 07/334,081 (abn) filed Apr. 4, 1989; U.S. application Ser. No. 07/041,885 (abn) filed Apr. 23, 1987; (b) U.S. application Ser. No. 06/614,616 (abandoned), in favor of U.S. application Ser. No. 352,326 (abn) filed May 15, 1989; and (c) U.S. application Ser. No. 06/614,491 (abandoned), in favor of U.S. application Ser. No. 07/539,283 (abn) filed Jun. 14, 1990, and the continuation thereof U.S. application Ser. No. 07/760,833 filed Sep. 16, 1991 (pending). .Iaddend.
BACKGROUND
This invention relates to the production and manipulation of proteins using recombinant techniques in suitable hosts. More specifically, the invention relates to the production of procaryotic proteases such as subtilsin and neutral protease using recombinant microbial host cells, to the synthesis of heterologous proteins by microbial hosts, and to the directed mutagenesis of enzymes in order to modify the characteristics thereof.
Various bacteria are known to secrete proteases at some stage in their life cycles. Bacillus species produce two major extracellular proteases, a neural protease (a metalloprotease inhibited by EDTA) and an alkaline protease (or subtilsin, a serine endoprotease). Both generally are produced in greatest quantity after the exponential growth phase, when the culture enters stationary phase and begins the process of sporulation. The physiological role of these two proteases is not clear. They have been postulated to play a role in sporulation (J. Hoch, 1976, Adv. Genet." 18:69-98; P. Piggot et al., 1976, "Bact. Rev." 40:908-962; and F. Priest, 1977, "Bact. Rev." 41:711-753), to be involved in the regulation of cell wall turnover (L. Jolliffe et al., 1980, "J. Bact." 141:1199-1208), and to be scavenger enzymes (Priest, Id.). The regulation of expression of the protease genes is complex. They appear to be coordinately regulated in concert with sporulation, since mutants blocked in the early stages of sporulation exhibit reduced levels of both the alkaline and neutral protease. Additionally, a number of pleiotropic mutations exist which affect the level of expression of proteases and other secreted gene products, such as amylase and levansucrase (Priest, Id.).
Subtilisin has found considerable utility in industrial and commercial applications (see U.S. Pat. No. 3,623,957 and J. Millet, 1970, "J. Appl. Bact." 33:207). For example, subtilisins and other proteases are commonly used in detergents to enable removal of protein-based stains. They also are used in food processing to accommodate the proteinaceous substances present in the food preparations to their desired impact on the composition.
Classical mutagenesis of bacteria with agents such as radiation or chemicals has produced a plethora of mutant strains exhibiting different properties with respect to the growth phase at which protease excretion occurs as well as the timing and activity levels of excreted protease. These strains, however, do not approach the ultimate potential of the organisms because the mutagenic process is essentially random, with tedious selection and screening required to identify organisms which even approach the desired characteristics. Further, these mutants are capable of reversion to the parent or wild-type strain. In such event the desirable property is lost. The probability of reversion is unknown when dealing with random mutagenesis since the type and site of mutation is unknown or poorly characterized. This introduces considerable uncertainty into the industrial process which is based on the enzyme-synthesizing bacterium. Finally, classical mutagenesis frequently couples a desirable phenotype, e.g. low protease levels, with an undesirable character such as excessive premature cell lysis.
Special problems exist with respect to the proteases which are excreted by Bacillus. For one thing, since at least two such proteases exist, screening for the loss of only one is difficult. Additionally, the large number of pleiotropic mutations affecting both sporulation and protease production make the isolation of true protease mutations difficult.
Temperature sensitive mutants of the neutral protease gene have been obtained by conventional mutagenic techniques, and were used to map the position of the regulatory and structural gene in the Bacillus subtilis chromosome (H. Uehara et al., 1979, "J. Bact." 139:583-590). Additionally, a presumed nonsense mutation of the alkaline protease gene has been reported (C. Roitsch et al., 1983, "J. Bact." 155:145-152).
Bacillus temperature sensitive mutants have been isolated that produce inactive serine protease or greatly reduced levels of serine protease. These mutants, however, are asporogenous and show a reversion frequency to the wild-type of about from 10-7 to 10-8 (F. Priest, Id. p. 719). These mutants are unsatisfactory for the recombinant production of heterologous proteins because asporogenous mutants tend to lyse during earlier stages of their growth cycle in minimal medium than do sporogenic mutants, thereby prematurely releasing cellular contents (including intracellular proteases) into the culture supernatant. The possibility of reversion also is undesirable since wild-type revertants will contaminate the culture supernatant with excreted proteases.
Bacillus sp. have been proposed for the expression of heterologous proteins, but the presence of excreted proteases and the potential resulting hydrolysis of the desired product has retarded the commercial acceptance of Bacillus as a host for the expression of heterologous proteins. Bacillus megaterium mutants have been disclosed that are capable of sporulation and which do not express a sporulation-associated protease during growth phases. However, the assay employed did not exclude the presence of other proteases, and the protease in question is expressed during the sporulation phase (C. Loshon et al., 1982, "J. Bact." 150:303--311). This, of course, is the point at which heterologous protein would have accumulated in the culture and be vulnerable. It is an objective herein to construct a Bacillus strain that is substantially free of extracellular neutral and alkaline protease during all phases of its growth cycle and which exhibits substantially normal sporulation characteristics. A need exists for non-revertible, otherwise normal protease deficient organisms that can then be transformed with high copy number plasmids for the expression of heterologous or homologous proteins.
Enzymes having characteristics which vary from available stock are required. In particular, enzymes having enhanced oxidation stability will be useful in extending the shelf life and bleach compatibility of proteases used in laundry products. Similarly, reduced oxidation stability would be useful in industrial processes that require the rapid and efficient quenching of enzymatic activity.
Modifying the pH-activity profiles of an enzyme would be useful in making the enzymes more efficient in a wide variety of processes, e.g. broadening the pH-activity profile of a protease would produce an enzyme more suitable for both alkaline and neutral laundry products. Narrowing the profile, particularly when combined with tailored substrate specificity, would make enzymes in a mixture more compatible, as will be further described herein.
Mutations of procaryotic carbonyl hydrolases (principally proteases but including lipases) will facilitate preparation of a variety of different hydrolases, particularly those having other modified properties such as Km, Kcat, Km/Kcat ratio and substrate specificity. These enzymes can then be tailored for the particular substrate which is anticipated to be present, for example in the preparation of peptides or for hydrolytic processes such as laundry uses.
Chemical modification of enzymes is known. For example, see I. Svendsen, 1976, "Carlsberg Res. Commun." 41 (5):237-291. These methods, however, suffer from the disadvantages of being dependent upon the presence of convenient amino acid residues, are frequently nonspecific in that they modify all accessible residues with common side chains, and are not capable of reaching inaccessible amino acid residues without further processing, e.g. denaturation, that is generally not completely reversible in reinstituting activity. To the extent that such methods have the objective of replacing one amino acid residue side chain for another side chain or equivalent functionality, then mutagenesis promises to supplant such methods.
Predetermined, site-directed mutagenesis of tRNA synthetase in which a cys residue is converted to serine has been reported (G. Winter et al., 1982, "Nature" 299:758-758; A. Wilkinson et al., 1984, "Nature" 307:187-188). This method is not practical for large scale mutagenesis. It is an object herein to provide a convenient and rapid method for mutating DNA by saturation mutagenesis.
SUMMARY
A method for producing procaryotic carbonyl hydrolase such as subtilisin and neutral protease in recombinant host cells is described in which expression vectors containing sequences which encode desired subtilisin or neutral protease, including the pro, pre, or prepro forms of these enzymes, are used to transform hosts, the host cultured and desired enzymes recovered. The coding sequence may correspond exactly to one found in nature, or may contain modifications which confer desirable properties on the protein that is produced, as is further described below.
The novel strains then are transformed with at least one DNA moiety encoding a polypeptide not otherwise expressed in the host strain, the transformed strains cultured and the polypeptide recovered from the culture. Ordinarily, the DNA moiety is a directed mutant of a host Bacillus gene, although it may be DNA encoding a eucaryotic (yeast or mammalian) protein. The novel strains also serve as hosts for protein expressed from a bacterial gene derived from sources other than the host genome, or for vectors expressing these heterologous genes, or homologous genes from the host genome. In the latter event enzymes such as amylase are obtained free of neutral protease or subtilisin. In addition, it is now possible to obtain neutral protease in culture which is free of enzymatically active subtilisin, and vice-versa.
One may, by splicing the cloned genes for procaryotic carbonyl hydrolase into a high copy number plasmid, synthesize the enzymes in enhanced yield compared to the parental organisms. Also disclosed are modified forms of such hydrolases, including the pro and prepro zymogen forms of the enzymes, the pre forms, and directed mutations thereof.
A convenient method is provided for saturation mutagenesis, thereby enabling the rapid and efficient generation of a plurality of mutations at any one site within the coding region of a protein, comprising:
(a) obtaining a DNA moiety encoding at least a portion of said precursor protein;
(b) identifying a region within the moiety;
(c) substituting nucleotides for those already existing within the region in order to create at least one restriction enzyme site unique to the moiety, whereby unique restriction sites 5' and 3' to the identified region are made available such that neither alters the amino acids coded for by the region as expressed;
(d) synthesizing a plurality of oligonucleotides, the 5' and 3' ends of which each contain sequences capable of annealing to the restriction enzyme sites introduced in step (c) and which, when ligated to the moiety, are expressed as substitutions, deletions and/or insertions of at least one amino acid in or into said precursor protein;
(e) digesting the moiety of step (c) with restriction enzymes capable of cleaving the unique sites; and
(f) ligating each of the oligonucleotides of step (d) into the digested moiety of step (e) whereby a plurality of mutant DNA moieties are obtained.
By the foregoing method or others known in the art, a mutation is introduced into isolated DNA encoding a procaryotic carbonyl hydrolase which, upon expression of the DNA, results in the substitution, deletion or insertion of at least one amino acid at a predetermined site in the hydrolase. This method is useful in creating mutants of wild type proteins (where the "precursor" protein is the wild type) or reverting mutants to the wild type (where the "precursor" is the mutant.
Mutant enzymes are recovered which exhibit oxidative stability and/or pH-activity profiles which differ from the precursor enzymes. Procaryotic carbonyl hydrolases having varied Km, Kcat, Kcat/Km ratio and substrate specificity also are provided herein.
The mutant enzymes obtained by the methods herein are combined in known fashion with surfactants or detergents to produce novel compositions useful in the laundry or other cleaning arts.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the sequence of a functional B. amyloliquefaciens subtilisin gene.
In FIG. 1A, the entire functional sequence for B. amyloliquefaciens, including the promoter and ribosome binding site, are present on a 1.5 kb fragment of the B. amyloliquefaciens genome.
FIG. 1B shows the nucleotide sequence of the coding strand, correlated with the amino acid sequence of the protein. Promoter (p) ribosome binding site (rbs) and termination (term) regions of the DNA sequence are also shown.
FIG. 2 shows the results of replica nitrocellulose filters of purified positive clones probed with Pool 1 (Panel A) and Pool 2 (Panel B) respectively.
FIG. 3 shows the restriction analysis of the subtilisin expression plasmid (pS4). pBS42 vector sequences (4.5 kb) are shown in solid while the insert sequence (4.4 kb) is shown dashed.
FIG. 4 shows the results of SDS-PAGE preformed on supernatants from cultures transformed with pBS42 and pS4.
FIG. 5 shows the construction of the shuttle vector pBS42.
FIG. 6 shows a restriction map for a sequence including the B. subtilis subtilisin gene.
FIG. 7 is the sequence of a functional B. subtilis subtilisin gene.
FIG. 8 demonstrates a construction method for obtaining a deletion mutant of a B. subtilis subtilisin gene.
FIG. 9 discloses the restriction map for a B. subtilis neutral protease gene.
FIG. 10 is a nucleotide sequence for a B. subtilis neutral protease gene.
FIG. 11 demonstrates the construction of a vector containing a B. subtilis neutral protease gene.
FIGS. 12, 13 and 16 disclose embodiments of the mutagenesis technique provided herein.
FIG. 14 shows the enhanced oxidation stability of a subtilisin mutant.
FIG. 15 demonstrates a change in the pH-activity profile of a subtilisin mutant when compared to the wild type enzyme.
.Iadd.FIG. 17 is a reproduction in pertinent-part of Table C. .Iaddend.
DETAILED DESCRIPTION
Procaryotic carbonyl hydrolases are enzymes which hydrolyze compounds containing ##STR1## bonds in which X is oxygen or nitrogen. They principally include hydrolases, e.g. lipases and peptide hydrolases, e.g. subtilisins or metalloproteases. Peptide hydrolases include α-aminoacylpeptide hydrolase, peptidylamino-acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallocarboxypeptidase, thiol proteinase, carboxlproteinase and metalloprotinease. Serine, metallo, thiol and acid proteases are included, as well as endo and exo-proteases.
Subtilisins are serine proteinases which generally act to cleave internal peptide bonds of protein or peptides. Metalloproteases are exo- or endoproteases which require a metal ion cofactor for activity.
A number of naturally occurring mutants of subtilisin or neutral protease exist, and all may be employed with equal effect herein as sources for starting genetic material.
These enzymes and their genes may be obtained from many procaryotic organisms. Suitable examples include gram negative organisms such as E. coli or pseudomonas and gram positive bacteria such as micrococcus or bacillus.
The genes encoding the carbonyl hydrolase may be obtained in accord with the general method herein. As will be seen from the examples, this comprises synthesizing labelled probes having putative sequences encoding regions of the hydrolase of interest, preparing genomic libraries from organisims expressing the hydrolase, and screening the libraries for the gene of hybridization to the probes. Positively hybridizing clones ar mapped and sequenced. The cloned genes are ligated into an expression vector (which also may be the cloning vector) with requisite regions for replication in the host, the plasmid transfected into a host for enzyme synthesis and the recombina host cells cultured under conditions favoring enzyme synthesis, usually selection pressure such as is supplied by the presence of an antibiotic, the resistance to which is encoded by the vector. Culture under these conditions results in enzyme yields multifold greater than the wild type enzyme synthesis of the parent organism, even if it is the parent organism that is transformed.
"Expression vector" refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid" and "vector" are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
"Recombinant host cells" refers to cells which have been transformed or transfected with vectors constructed using recombinant DNA techniques. As relevant to the present invention, recombinant host cells are those which produce procaryotic carbonyl nydrolases in its various forms by virtue of having been transformed with expression vectors encoding these proteins. The recombinant host cells may or may not have produced a form of carbonyl hydrolase prior to transformation.
"Operably linked" when describing the relationship between two DNA regions simply means that they are functionally related to each other. For example, a presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence. A promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
"Prohydrolase" refers to a hydrolase which contains additional N-terminal amino acid resides which render the enzyme inactive but, when removed, yield an enzyme. Many proteolytic enzymes are found in nature as translational proenzyme products and, in the absence of post-translational products, are expressed in this fashion.
"Presequence" refers to a signal sequence of amino acids bound to the N-terminal portion of the hydrolase which may participate in the secretion of the hydrolase. Presequences also may be modified in the same fashion as is described here, including the introduction of predetermined mutations. When bound to a nydrolase, the subject protein becomes a "prehydrolase". Accordingly, relevant prehydrolase for the purposes herein are presubtilisin and preprosubtilisin. Prehydrolases are produced by deleting the "pro" sequence (or at least that portion of the pro sequence that maintains the enzyme in its inactive state) from a prepro coding region, and then expressing the prehydrolase. In this way the organism excretes the active rather than proenzyme.
The cloned carbonyl hydrolase is used to transform a host cell in order to express the hydrolase. This will be of interest where the hydrolase has commercial use in its unmodified form, as for example subtilisin in laundry products as noted above. In the preferred embodiment the hydrolase gene is ligated into a high copy. number plasmid. This plasmid replicates in hosts in the sense that it contains the well-known elements necessary for plasmid replication: a promoter operably linked to the gene in question (which may be supplied as the gene's own homologous promotor if it is recognized, i.e., transcribed, by the host), a transcription termination and polyadenylation region (necessary for stability of the mRNA transcribed by the host from the hydrolase gene) which is exogenous or is supplied by the endogenous terminator region of the hydrolase gene and, desirably, a selection gene such as an antibiotic resistance gene that enables continuous cultural maintenance of plasmid-infected host cells by growth in antibiotic-containing media. High copy number plasmids also contain an origin of replication for the host, thereby enabling large numbers of plasmids to be generated in the cytoplasm without chromosonal limitations. However, it is within the scope herein to integrate multiple copies of the hydrolase gene into host genome. This is facilitated by bacterial strains which are particularly susceptible to homologous recombination. The resulting host cells are termed recombinant host cells.
Once the carbonyl hydrolase gene has been cloned, a number of modifications are undertaken to enhance the use of the gene beyond synthesis of the wild type or precursor enzyme. A precursor enzyme is the enzyme prior to its modification as described in this application. Usually the precursor is the enzyme as expressed by the organism which donated the DNA modified in accord herewith. The term "precursor" is to be understood as not implying that the product enzyme was the result of manipulation of the precursor enzyme per se.
In the first of these modifications, the gene may be detected from a recombination positive (rec+) organism containing a homologous gene. This is accomplished by recombination of an in vitro deletion mutation of the cloned gene with the genome of the organism. Many strains of organisms such as E.coli and Bacillus are known to be capable of recombination. All that is needed is for regions of the residual DNA from the deletion mutant to recombine with homologous regions of the candidate host. The deletion may be within the coding region (leaving enzymatically inactive polypeptides) or include the entire coding region as long as homologous flanking regions (such as promoters or termination regions) exist in the host. Acceptability of the host for recombination deletion mutants is simply determined by screening for the deletion of the transformed phenotype. This is most readily accomplished in the case of carbonyl hydrolase by assaying host cultures for loss of the ability to cleave a chromogenic substrate otherwise hydrolyzed by the hydrolase.
Transformed hosts contained the protease deletion mutants are useful for synthesis of products which are incompatible with proteolytic enzymes. These hosts by definition are incapable of excreting the deleted proteases described herein, yet are substantially normally sporulating. Also the other growth characteristics of the transformants are substantially like the parental organism. Such organisms are useful in that it is expected they will exhibit comparatively less inactivation of heterologous proteins than the parents, and these hosts do have growth characteristics superior to known protease-deficient organisms. However, the deletion of neutral protease and subtilisin as described in this application does not remove all of the proteolytic activity of Bacillus. It is believed that intracellular proteases which are not ordinarily excreted extracellularly "leak" or diffuse from the cells during late phases of the culture. These intracellular proteases may or may not be subtilisin or neutral protease as those enzymes are defined herein. Accordingly, the novel Bacillus strains herein are incapable of excreting the subtilisin and/or neutral protease enzymes which ordinarfly are excreted extracellularly in the parent strains. "Incapable" means not revertible to the wild type. Reversion is a finite probability that exists with the heretofore known protease-deficient, naturally occurring strains since there is no assurance that the phenotype of such strains is not a function of a readily revertible mutation, e.g. a point mutation. This is to be contrasted with the extremely large deletions provided herein.
The deletion mutant-transformed host cells herein are free of genes encoding enzymatically active neutral protease or subtilisin, which genes are defined by those being substantially homologous with the genes set forth in FIGS. 1, 7 or 10. "Homologous" genes contain coding regions capable of hybridizing under high stringency conditions with the genes shown in FIGS. 1, 7 or 10.
The microbial strains containing carbonyl hydrolase deletion mutants are useful in two principal processes. In one embodiment they are advantageous in the fermentative production of products ordinarily expressed by a host that are desirably uncontaminated with the protein encoded by the deletion gene. An example is fermentative synthesis of amylase, where contaminant proteases interfere in many industrial uses for amylase. The novel strains herein relieve the art from part of the burden of purifying such products free of contaminating carbonyl hydrolases.
In a second principal embodiment, subtilisin and neutral protease deletion-mutant strains are useful in the synthesis of protein which is not otherwise encoded by the strain. These proteins will fall within one of two classes. The first class consists of proteins encoded by genes exhibiting no substantial pretransformation homology with those of the host. These may be proteins from other procaryotes but ordinarily are eucaryotic proteins from yeast or higher eucaryotic organisms, particularly mammals. The novel strains herein serve as useful hosts for expressible vectors containing genes encoding such proteins because the probability for proteolytic degradation of the expressed, non-homologous proteins is reduced.
The second group consists of mutant host genes exhibiting substantial pretransformation homology with those of the host. These include mutations of procaryotic carbonyl hydrolases such as subtilisin and neutral protease, as well as microbial (rennin, for example rennin from the genus Mucor). These mutants are selected in order to improve the characteristics of the precursor enzyme for industrial uses.
A novel method is provided to facilitate the construction and identification of such mutants. First, the gene encoding the hydrolase is obtained and sequenced in whole or in part. Then the sequence is scanned for a point at which it is desired to make a mutation (deletion, insertion or substitution) of one or more amino acids in the expressed enzyme. The sequences flanking this point are evaluated for the presence of restriction sites for replacing a short segment of the gene with an oligonucleotide pool which when expressed will encode various mutants. Since unique restriction sites are generally not present at locations within a convenient distance from the selected point (from 10 to 15 nucleotides), such sites are generated by substituting nucleotides in the gene in such a fashion that neither the reading frame nor the amino acids encoded are changed in the final construction. The task of locating suitable flanking regions and evaluating the needed changes to arrive at two unique restriction site sequences is made routine by the redundancy of the genetic code, a restriction enzyme map of the gene and the large number of different restriction enzymes. Note that if a fortuitous flanking unique restriction site is available, the above method need be used only in connection with the flanking region which does not contain a site.
Mutation of the gene in order to change its sequence to conform to the desired sequence is accomplished by M13 primer extension in accord with generally known methods. Once the gene is cloned, it is digested with the unique restriction enzymes and a plurality. of end termini-complementary oligonucleotide cassettes are ligated into the unique sites. The mutagenesis is enormously simplified by this method because all of the oligonucleotides can be synthesized so as to have the same restriction sites, and no synthetic linkers are necessary to create the restriction sites.
The number of commercially available restriction enzymes having sites not present in the gene of interest is generally large. A suitable DNA sequence computer search program simplifies the task of finding potential 5' and 3' unique flanking sites. A primary. constraint is that any mutation introduced in creation of the restriction site must be silent to the final constructed amino acid coding sequence. For a candidate restriction site 5' to the target codon a sequence must exist in the gene which contains at least all the nucleotides but for one in the recognition sequence 5' to the cut of the candidate enzyme. For example, the blunt cutting enzyme SmaI (CCC/GGG) would be a 5' candidate if a nearby 5' sequence contained NCC, CNC, or CCN. Furthermore, if N needed to be altered to C this alteration must leave the amino acid coding sequence intact. In cases where a permanent silent mutation is necessary to introduce a restriction site one may want to avoid the introduction of a rarely used codon. A similar situation for SmaI would apply for 3' flanking sites except the sequence NGG, GNG, or GGN must exist. The criteria for locating candidate enzymes is most relaxed for blunt cutting enzymes and most stringent for 4 base overhang enzymes. In general many candidate sites are available. For the codon-222 target described herein a BalI site (TGG/CCA) could have been engineered in one base pair 5' from the KpnI site. A 3'EcoRV site (GAT/ATC) could have been employed 11 base pairs 5' to the PstI site. A cassette having termini ranging from a blunt end up to a four base-overhang will function without difficulty. In retrospect, this hypothetical EcoRV site would have significantly shortened the oligonucleotide cassette employed (9 and 13 base pairs) thus allowing greater purity and lower pool bias problems. Flanking sites should obviously be chosen which cannot themselves ligate so that ligation of the oligonucleotide cassette can be assured in a single orientation.
The mutation per se need not be predetermined. For example, an oligonucleotide cassette or fragment is randomly mutagenized with nitrosoguanidine or other mutagen and then in turn ligated into the hydrolase gene at a predetermined location.
The mutant carbonyl hydrolases expressed upon transformation of the suitable hosts are screened for enzymes exhibiting desired characteristics, e.g. substrate specificity, oxidation stability, pH-activity profiles and the like.
A change in substrate specificity is defined as a difference between the Kcat/Km ratio of the precursor enzyme and that of the mutant. The Kcat/Km ratio is a measure of catalytic efficiency. Procaryotic carbonyl hydrolases with increased or diminished Kcat/Km ratios are described in the examples. Generally, the objective will be to secure a mutant having a greater (numerically larger) Kcat/Km ratio for a given substrate, thereby enabling the use of the enzyme to more efficiently act on a target substrate. An increase in Kcat/Kcm ratio for one substrate may be is accompanied by a reduction in Kcat/Km ratio for another substrate. This is a shift in substrate specificity, and mutants exhibiting such shifts have utility where the precursors are undesirable, e.g. to prevent undesired hydrolysis of a particular substrate in an admixture of substrates.
Kcat and Km are measured in accord with known procedures, or as described in Example 18.
Oxidation stability is a further objective which is accomplished by mutants described in the examples. The stability may be enhanced or diminished as is desired for various uses. Enhanced stability is effected by deleting one or more methionine, tryptophan, cysteine or lysine residues and, optionally, substituting another amino acid residue not one of methionine, tryptophan, cysteine or lysine. The opposite substitutions result in diminished oxidation stability. The substituted residue is preferably alanyl, but neutral residues also are suitable.
Mutants are provided which exhibit modified pH-activity profiles. A pH-activity profile is a plot of pH against enzyme activity and may be constructed as illustrated in Example 19 or by methods known in the art. It may be desired to obtain mutants with broader profiles, i.e., those having greater activity at certain pH than the precursor, but no significantly greater activity at any pH, or mutants with sharper profiles, i.e. those having enhanced activity when compared to the precursor at a given pH, and lesser activity elsewhere.
The foregoing mutants preferably are made within the active site of the enzymes as these mutations are most likely to influence activity. However, mutants at other sites important for enzyme stability or conformation are useful. In the case of Bacillus subtilisin or its pre, prepro and pro forms, mutations at tyrosine-1, aspartate+32, asparagine+155, tyrosine+104, methionine+222, glycine+166, histidine+64, glycine+169, phenylalanine+189, serine+33, serine+221, tyrosine+217, glutamate+156 and/or alanine+152 produce mutants having changes in the characteristics described above or in the processing of the enzyme. Note that these amino acid position numbers are those assigned to B. amyloliquefaciens subtilisin as seen from FIG. 7. It should be understood that a deletion or insertion in the N-terminal direction from a given position will shift the relative amino acid positions so that a residue will not occupy its original or wild type numerical position. Also, allelic differences and the variation among various procaryotic species will result in positions shifts, so that position 169 in such subtilisins will not be occupied by glycine. In such cases the new positions for glycine will be considered equivalent to and embraced within the designation glycine+169. The new position for glycine+169 is readily identified by scanning the subtilisin in question for a region homologous to glycine+169 in FIG. 7.
One or more, ordinarily up to about 10, amino acid residues may be mutated. However, there is no limit to the number of mutations that are to be made aside from commercial practicality.
The enzymes herein may be obtained as salts. It is clear that the ionization state of a protein will be dependent on the pH of the surrounding medium, if it is in solution, or of the solution from which it is prepared, if it is in solid form. Acidic proteins are commonly prepared as, for example, the ammonium, sodium, or potassium salts; basic proteins as the chlorides, sulfates, or phosphates. Accordingly, the present application includes both electrically neutral and salt forms of the designated carbonyl hydrolases, and the term carbonyl hydrolase refers to the organic structural backbone regardless of ionization state.
The mutants are particularly useful in the food processing and cleaning arts. The carbonyl hydrolases, including mutants, are produced by fermentation as described herein and recovered by suitable techniques. See for example K. Anstrup, 1974, Industrial Aspects of Biochemistry, ed. B. Spencer pp. 23-46. They are formulated with detergents or other surfactants in accord with methods known per se for use in industrial processes, especially laundry. In the latter case the enzymes are combined with detergents, builders, bleach and/or fluorescent whitening agents as is known in the art for proteolytic enzymes. Suitable detergents include linear alkyl benzene sulfonates, alkyl ethoxylated sulfate, sulfated linear alcohol or ethoxylated linear alcohol. The compositions may be formulated in granular or liquid form. See for example U.S. Pat. Nos. 3,623,957; 4,404,128; 4,381,247; 4,404,115; 4,318,818; 4,261,868; 4,242,219; 4,142,999; 4,111,855; 4,011,169; 4,090,973; 3,985,686; 3,790,482; 3,749,671; 3,560,392; 3,558,498; and 3,557,002.
The following disclosure is intended to serve as a representation of embodiments herein, and should not be construed as limiting the scope of this application.
Glossary of Experimental Manipulations
In order to simplify the Examples certain frequently occurring methods will be referenced by shorthand phrases.
Plasmids are designated by a small p preceeded and/or followed by capital letters and/or numbers. The starting plasmids herein are commercially available, are available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures.
"Klenow treatment" refers to the process of filling a recessed 3' end of double stranded DNA with deoxyribonucleotides complementary to the nucleotides making up the protruding 5' end of the DNA strand. This process is usually used to fill in a recessed end resulting from a restriction enzyme cleavage of DNA. This creates a blunt or flush end, as may. be required for further ligations. Treatment with Klenow is accomplished by reacting (generally for 15 minutes at 15° C.) the appropriate complementary deoxyribonucleotides with the DNA to be filled in under the catalytic activity (usually 10 units) of the Klenow fragment of E. coli DNA polymerase I ("Klenow"). Klenow and the other reagent needed are commercially available. The procedure has been published extensively. See for example T. Maniatis et al., 1982, Molecular Cloning, pp. 107-108.
"Digestion" of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction enzymes, and the sites for which each is specific is called a restriction site. "Partial" digestion refers to incomplete digestion by a restriction enzyme, i.e., conditions are chosen that result in cleavage of some but not all of the sites for a given restriction endonuclease in a DNA substrate. The various restriction enzymes. used herein are commercially available and their reaction conditions, cofactors and other requirements as established by the enzyme suppliers were used. Restriction enzymes commonly are designated by. abbreviations composed of a capital letter followed by other letters and then, generally, a number representing the microorganism from which each restriction enzyme originally was obtained. In general, about 1 μg of plasmid or DNA fragment is used with about 1 unit of enzyme in about 20 μl of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37° C. are ordinarily used, but may vary in accordance with the supplier's instructions. After incubation, protein is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme infrequently is followed with bacterial alkaline phosphatase hydrolysis of the terminal 5' phosphates to prevent the two restriction cleaved ends of a DNA fragment from "circularizing" or forming a closed loop that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion of plasmids is not followed by 5' terminal dephosphorylation. Procedures and reagents for dephosphorylation are conventional (T. Maniatis et al., Id., pp. 133-134).
"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on 6 percent polyacrylamide gel electrophoresis, identification of the fragment of interest by molecular weight (using DNA fragments of known molecular weight as markers), removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see R. Lawn et al., 1981, "Nucleic Acids Res." 9:6103-6114, and D. Goeddel et al., (1980) "Nucleic Acids Res." 8:4057.
"Southern Analysis" is a method by which the presence of DNA sequences in a digest or DNA-containing composition is confirmed by hybridization to a known, labelled oligonucleotide or DNA fragment. For the purposes herein, Southern analysis shall means separation of digests on 1 percent agarose and depurination as described by G. Wahl et al., 1979, "Proc. Nat. Acad. Sci. U.S.A." 76:3683-3687, transfer to nitrocellulose by the method of E. Southern, 1975, "J. Mol. Biol." 98:503-517, and hybridization as described by T. Maniatis et al., 1978, "Cell" 15:687-701.
"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or chromosomal integrant. Unless otherwise stated, the method used herein for transformation of E. coli is the CaCl2 method of Mandel et al., 1970, "J. Mol. Biol." 53:154, and for Bacillus, the method of Anagnostopoulos et al., 1961, "J. Bact." 81:791-746.
"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (T. Maniatis et al., Id., p. 146). Unless otherwise stated, ligation was accomplished using known buffers and conditions with 10 units of T4 DNA ligase ("ligase") per 0.5 μg of approximately equimolar amounts of the DNA fragments to be ligated. Plasmids from the transformants were prepared, analyzed by restriction mapping and/or sequenced by the method of Messing, et al., 1981, "Nucleic Acids Res.", 9:309.
"Preparation" of DNA from transformants means isolating plasmid DNA from microbial culture. Unless otherwise stated, the alkaline/SDS method of Maniatis et al., Id. p. 90, was used.
"Oligonucleotides" are short length single or double stranded polydeoxynucleotides which were chemically synthesized by the method of Crea et al., 1980, "Nucleic Acids Res." 8:2331-2348 (except that mesitylene nitrotriazole was used as a condensing agent) and then purified on polyacrylamide gels.
All literature citations are expressly incorporated by reference.
EXAMPLE 1 Preparation of a Genomic DNA Library from B. amyloliquifaciens and Isolation of its Subtilisin Gene
The known amino acid sequence of the extracellular B. amyloliquefaciens permits the construction of a suitable probe mixture. The sequence of the mature subtilisin is included (along with the additional information contributed by the present work) in FIG. 1. All codon ambiguity for the sequence of amino acids at position 117 through 121 is covered by a pool of eight oligonucleotides of the sequence ##STR2##
Chromosomal DNA isolated from B. amyloliquefaciens (ATCC No. 23844) as described by J. Marmur, "J. Mol, Biol.", 3:208, was partially digested by Sau 3A, and the fragments size selected and ligated into the BamH1 site of dephosphorylated pBS42. (pBS42 is shuttle vector containing origins of replication effective both in E. coli and Bacillus. It is prepared as described in Example 4). The Sau3A fragment containing vectors were transformed into E. coli K12 strain 294 (ATCC No. 31446) according to the method of M. Mandel, et al., 1970, "J. Mol. Bio." 53:154 using 80-400 nanograms of library DNA per 250 μL of competent cells.
Cells from the transformation mixture were plated at a density of 1-5×103 transformants per 15 Omm plate containing LB medium+12.5 μg/ml chloramphenicol, and grown overnight at 37° C. until visible colonies appeared. The plates were then replica plated onto BA85 nitrocellulose filters overlayed on LB/chloramphenicol plates. The replica plates were grown 10-12 hours at 37° C. and the filters transferred to fresh plates containing LB and 150 μg/ml spectinomycin to amplify the plasmid pool.
After overnight incubation at 37° C., filters were processed essentially as described by Grunstein and Hogness, 1975, "Proc. Natl. Acad. Sci. (USA)" 72: 3961. Out of approximately 20,000 successful transformants, 25 positive colonies were found. Eight of these positives were streaked to purify individual clones. 24 clones from each streak were grown in microtiter wells, stamped on to two replica filters, and probed as described above with either ##STR3## which differ by only one nucleotide. As shown in FIG. 2, pool 1 hybridized to a much greater extent to all positive clones than did pool 2, suggesting specific hybridization.
Four out of five miniplasmid preparations (Maniatis et al., Id.) from positive clones gave identical restriction digest patterns when digested with Sau3A or HincII. The plasmid isolated from one of these four identical colonies by the method of Maniatis et al., Id. had the entire correct gene sequence and was designated pS4. The characteristics of this plasmid as determined by restriction analysis are shown in FIG. 3.
EXAMPLE 2 Expression of the Subtilisin Gene
Bacillus subtilis I-168 (Catalog No. 1-A1, Bacillus Genetic Stock Center) was transformed with pS4 and and a single chloramphenicol resistant transformant then grown in minimal medium. After 24 hours, the culture was centrifuged and both the supernatant (10-200 μl) and pellet assayed for proteolytic activity by measuring the change in absorbance per minute at 412 nm using 1 ml of the chromogenic substrate succinyl-L-ala-ala-pro-phe-p-nitroanilide (0.2 μM) in 0.1M sodium phosphate (pH 8.0) at 25° C. A B. subtilis I-168 culture transformed with pBS42 used as a control showed less than 1/200 of the activity shown by the pS4 transformed culture. Greater than 95 percent of the protease activity of the pS4 culture was present in the supernatant, and was completely inhibited by treatment with phenylmethylsulfonyl fluoride (PMSF) but not by EDTA.
Aliquots of the supernatants were treated with PMSF and EDTA to inhibit all protease activity and analyzed by 12 percent SDS-PAGE according to the method of Laemmli, U.K., 1970 "Nature", 227: 680. To prepare the supernatants, 16 μL of supernatant was treated with 1mM PMSF, 10 mM EDTA for 10 minutes, and boiled with 4 μL of 5x concentrated SDS sample buffer minus β-mercaptoethanol. The results of Coomassie stain on runs using supernatants of cells transformed with pS4, pBS42, and untransformed B. amyloliquefaciens are shown in FIG. 4. Lane 3 shows authentic subtilisin from B. amyloliquefaciens. Lane 2 which is the supernatant from pBS42 transformed B. subtilis, does not give the 31,000 MW band associated with subtilisin which is exhibited by Lane 1 from pS4 transformed hosts. The approximately 31,000 MW band result from subtilisin is characteristic of the slower mobility shown by the known M.W. 27,500 subtilisin preparations in general.
EXAMPLE 3 Sequencing of the B. amyloliquefaciens Subtilisin Gene
The entire sequence of an EcoRI-BamHI fragment (wherein the EcoRI site was constructed by conversion of the HincII site) of pS4 was determined by the method of F. Sanger, 1977, "Proc. Natl. Acad. Sci (USA)", 74:5463. Referring to the restriction map shown in FIG. 3, the BamHI-PvuII fragment was found to hybridize with pool 1 oligonucleotides by Southern analysis. Data obtained from sequencing of this fragment directed the sequencing of the remaining fragments (e.g. PvuII-HincII and AvaI-AvaI). The results are shown in FIG. 1.
Examination of the sequence confirms the presence of codons for the mature subtilisin corresponding to that secreted by the B. amyloliquefaciens. Immediately upstream from this sequence is a series of 107 codons beginning with the GTG start codon at -107. Codon -107 to approximately codon -75 encodes an amino acid sequence whose characteristics correspond to that of known signal sequences. (Most such signal sequences are 18-30 amino acids in length, have hydrophobic cores, and terminate in a small hydrophobic amino acid.) Accordingly, examination of the sequence data would indicate that codons -107 to approximately -75 encode the signal sequence; the remaining intervening codons between -75 and -1 presumably encode a prosequence.
EXAMPLE 4 Construction of pBS42
pBS42 is formed by three-way ligation of fragments derived from pUB11, pC194, and pBR322 (see FIG. 5). The fragment from pUB110 is the approximately 2600 base pair fragment between the HpaII site at 1900 and the BamH1 site at 4500 and contains an origin of replication operable in Bacillus: T. Grycztan, et al., 1978 "J. Bacteriol.", 134: 318 (1978); A. Jalanko, et al., 1981 "Gene", 14: 325. The BamHI site was tested with Klenow. The pBR322 portion is the 1100 base pair fragment between the PvuII site at 2067 and the Sau3A site at 3223 which contains the E. coli origin of replication: F. Bolivar, et al., 1977 "Gene", 2: 95;-J Sutcliffe, 1978, Cold Spring Harbor Symposium 43: I, 77. The pC194 fragment is the 1200 base pair fragment between the HpaII site at 973 and the Sau3A site at 2006 which contains the gene for chloramphenicol resistance expressible in both E. coli and B subtilis; S. Ehrlich, "Proc. Natl. Acad. Sci. (USA)", 74:1680; S. Horynuchi et al., 1982, "J. Bacteriol." 150: 815.
pBS42 thus contains origins of replication operable both in E. coli and in Bacillus and an expressible gene for chloramphenicol resistance.
EXAMPLE 5 Isolation and Sequencing of the B. subtilis Subtilisin Gene
B. subtilis 1168 chromosomal DNA was digested with EcoRI and the fragments resolved on gel electrophoresis. A single 6 kb fragment hybridized to a [α-32 P] CTP nick translation - labeled fragment obtained from the C-terminus of the subtilisin structural gene in pS4, described above. The 6 kb fragment was electroluted and ligated into pBS42 which had been digested and EcoRI and treated with bacterial alkaline phosphatase. E. coli ATCC 31446 was transformed with the ligation mixture and transformants selected by growth on LB agar containing 12.5 μg chloramphenicol/ml. Plasmid DNA was prepared from a pooled suspension of 5,000 transformed colonies. This DNA was transformed into B. subtilis BG84, a protease deficient strain, the preparation of which is described in Example 8 below. Colonies which produced protease were screened by. plating on LB agar plus 1.5 percent w/w Carnation powdered nonfat skim milk and 5 μg chloramphenicol/ml (hereafter termed skim milk selection plates) and observing for zones of clearance evidencing proteolytic activity.
Plasmid DNA was prepared from protease producing colonies, digested with EcoRI, and examined by Southern analysis for the presence of the 6 kb EcoRI insert by hybridization to the 32 P-labelled C-terminus fragment of the subtilisin structural gene from B. amyloliquefaciens. A positive clone was identified and the plasmid was designated pS168.1. B. subtilis BG84 transformed with pS168.1 excreted serine protease at a level 5-fold over that produced in B. subtilis 1168. Addition of EDTA to the supernatants did not affect the assay results, but the addition of PMSF (phenylmethylsulfonyl fluoride) to the supernatants reduced protease activity to levels undetectable in the assay described in Example 8 for strain BG84.
A restriction map of the 6.5 kb EcoRI insert is shown in FIG. 6. The subtilisin gene was localized to within the 2.5 kb KpnI-EcoRI fragment by subcloning various restriction enzyme digests and testing for expression of subtilisin in B. subtilis BG84. Southern analysis with the labelled fragment from the C-terminus of the B. amyloliquefaciens subtilisin gene as a probe localized the C-terminus of the B. subtilis gene to within or part of the 631 by HincII fragment B in the center of this subclone (see FIG. 6). The tandem HincII fragments B, C, and D and HincII-EcoRI fragment E (FIG. 6) were ligated into the M13 vectors mp8 or mp9 and sequenced in known fashion (J. Messing et al., 1982, "Gene" 19:209-276) using dideoxy chain termination (F. Sanger et al., 1977, "Proc. Nat. Acad. Sci. U.S.A." 74:5463-5467). The sequence of this region is shown in FIG. 7. The first 23 amino acids are believed to be a signal peptide. The remaining 83 amino acids between the signal sequence and the mature coding sequence constitute the putative "pro" sequence. The overlined nucleotides at the 3' end of the gene are believed to be transcription terminator regions. Two possible Shine-Dalgarno sequences are underlined upstream from the mature start codon.
EXAMPLE 6 Manufacture of an Inactivating Mutation of the B. subtilis Subtilisin Gene
A two step ligation, shown in FIG. 8, was required to construct a plasmid carrying a defective gene which would integrate into the Bacillus chromosome. In the first step, pS168.1, which contained the 6.5 kb insert originally recovered from the B. subtilis genomic library as described in Example 5 above, was digested with EcoRI, the reaction products treated with Klenow, the DNA digested with HincII, and the 800 bp EcoRI-HincII fragment E (see FIG. 6) that contains, in part, the 5' end of the B. subtilis subtilisin gene, was recovered. This fragment was ligated into pJH101(pJH101is available from J. Hoch (Scripps) and is described by F. A. Ferrari et al., 1983, "J. Bact." 134:318-329) that had been digested with HincII and treated with bacterial alkaline phosphotase. The resultant plasmid, pIDV1, contained fragment E in the orientation shown in FIG. 8. In the second step, pS168.1 was digested with HincII and the 700 bp HincII fragment B, which contains the 3' end of the subtilisin gene, was recovered. pIDV1 was digested at its unique HincII site and fragment B ligated to the linearized plasmid, transformed in E. coli ATCC 31,446, and selected on LB plates containing 12.5 μg chloramphenicol/ml or 20 μg ampicillin/ml. One resulting plasmid, designated pIDV1.4, contained fragment B in the correct orientation with respect to fragment E. This plasmid pIDV1.4, shown in FIG. 8, is a deletion derivative of the subtilisin gene containing portions of the 5' and 3' flanking sequences as well.
B. subtilis BG77, a partial protease-deficient mutant (Prt+/-) prepared in Example 8 below was transformed with pIDV1.4. Two classes of chloramphenicol resistant (Cmr) transformants were obtained. Seventy-five percent showed the same level of proteases as BG77 (Prt+/-) and 25 percent were almost completely protease deficient (Prt-) as observed by relative zones of clearing on plates containing LB agar plus skim milk. The Cmr Prt- transformants could not be due to a single crossover integration of the plasmid at the homologous regions for fragment E or B because, in such a case, the gene would be uninterrupted and the phenotype would be Prt+/-. In fact, when either of fragments E or B were ligated independently into pJH101and subsequently transformed into B. subtilis BG77, the protease deficient phenotype was not observed. The Cmr phenotype of Cmr Prt- pIDV1.4 transformants was unstable in that Cms Prt- derivatives could be isolated from Cmr Prt.sup. - cultures at a frequency of about 0.1 percent after 10 generations of growth in minimal medium in the absence of antibiotic selection. One such derivative was obtained and designated BG2018. The deletion was transferred into IA84 (a BGSC strain carrying two auxotrophic mutations flanking the subtilisin gene) by PSB1 transduction. The derivative organism was designated BG2019.
EXAMPLE 7 Preparation of a Genomic DNA Library from B. subtilis and Isolation of its Neural Protease Gene
The partial amino acid sequence of a neutral protease of B. subtilis is disclosed by P. Levy et al. 1975, "Proc. Nat. Acad. Sci. USA" 72:4341-4345. A region of the enzyme (Asp Gln Met Ile Tyr Gly) was selected from this published sequence in which the least redundancy existed in the potential codons for the amino acids in the region. 24 combinations were necessary to cover all the potential coding sequences, as described below. ##STR4##
Four pools, each containing six alternatives, were prepared as described above in Example 1. The pools were labelled by phosphorylization with [γ-32 p] ATP.
The labelled pool containing sequences conforming closest to a unique sequence in a B. subtilis genome was selected by digesting B. subtilis (1A72, Bacillus Genetic Stock Center) DNA with various restriction enzymes, separating the digests on an electrophoresis gel, and hybridizing each of the four probe pools to each of the blotted digests under increasingly stringent conditions until a single band was seen to nybridize. Increasingly stringent conditions are those which tend to disfavor hybridization, e.g., increases in formamide concentration, decreases in salt concentration and increases in temperature. At 37° C. in a solution of 5× Denhardt's, 5× SSC, 50 mM NaPO4 pH 6.8 and 20 percent formamide, only pool 4 would hybridize to a blotted digest. These were selected as the proper hybridization conditions to be used for the neutral protease gene and pool 4 was used as the probe.
A lambda library of B. subtilis strain BGSC 1-A72 was prepared in conventional fashion by partial digestion of the Bacillus genomic DNA by Sau3A, separated of the partial digest by molecular weight on an electrophoresis gel, elution of 15-20 kb fragments (R. Lawn et al., 1981, "Nucleic Acids Res." 9:6103-6114), and ligation of the fragments to BamHI digested charon 30 phage using a Packagene kit from Promega Biotec.
E. coli DP50supF was used as the host for the phage library, although any known host for Charon lambda phage is satisfactory. The E. coli was plated with the library phage and cultured, after which plaques were assayed for the presence of the neutral protease gene by transfer to nitrocellulose and screening with probe pool 4 (Benton and Davis, 1977, "Science" 196:180-182). Positive plaques were purified through two rounds of single plaque purification, and two plaques were chosen for further study, designated γNPRG1 and γNPRG2. DNA was prepared from each phage by restriction enzyme hydrolysis and separation on electrophoresis gels. The separated fragments were blotted and hybridized to labelled pool 4 oligonucleotides. This disclosed that γNPRG1 contained a 2400 bp HindIII hybridizing fragment, but no 4300 EcoRI fragment, while γNPRG2 contained a 4300 bp EcoRI fragment, but no 2400 by HindIII fragment.
The 2400 bp γNPRG1 fragment was subcloned into the HindIII site of pJH101by the following method. γNPRG1 was digested by HindIII, the digest fractionated by electrophoresis and the 2400 by fragment recovered from the gel. The fragment was ligated to alkaline phosphatase-treated HindIII digested pJH101and the ligation mixture used to transform E. coli ATCC 31446 by the calcium chloride shock method of V. Herschfield et al., 1974, "Proc. Nat. Acad. Sci. (U.S.A.)" 79:3455-3459). Transformants were identified by selecting colonies capable of growth on plates containing LB medium plus 12.5 μg chloramphenicol/ml.
Transformants colonies yielded several plasmids. The orientation of the 2400 bp fragment in each plasmid was determined by conventional restriction analysis (orientation is the sense reading or transcriptional direction of the gene fragment in relation to the reading direction of the expression vector into which it is ligated.) Two plasmids with opposite orientations were obtained and designated pNPRsubH6 and pNPRsubH1.
The 4300 bp EcoRI fragment of γNPRG2 was subcloned into pBR325 by the method described above for the 2400 bp fragment except that γNPRG2 was digested with EcoRI and the plasmid was alkaline phosphatase-treated, EcoRI-digested pBR325. pBR325 is described by. F. Bolivar, 1978, "Gene" 4:121-136. Two plasmids were identified in which the 4300 bp insert was present in different orientations. These two plasmids were designated pNPRsubRI and pNPRsubRIb.
EXAMPLE 8 Characterization of B. subtilis Neutral Protease Gene
The pNPRsubH1 insert was sequentially digested with different restriction endonucleases and blot hybridized with labelled pool 4 in order to prepare a restriction map of the insert (for general procedures of restriction mapping see T. Maniatis et al., Id., p. 377). A 430 bp RsaI fragment was the smallest fragment that hybridized to probe pool 4. The RsaI fragment was ligated into the SmaI site of M13 mp8 (J. Messing et al., 1982, "Gene" 19:269-276 and J. Messing in Methods in Enzymology, 1983, R. Wu et al., Eds., 101:20-78) and the sequence determined by the chain-terminating dideoxy method (F. Sanger et al., 1977, "Proc. Nat. Acad. Sci. U.S.A." 74:5463-5467). Other restriction fragments from the pNPRsubH1 insert were ligated into appropriate sites in M13 mp8 or M13 mp9 vectors and the sequences determined. As required, dITP was used to reduce compression artifacts (D. Mills et al., 1979, "Proc. Nat. Acad. Sci. (U.S.A.)" 76:2232-2235). The restriction map for the pNPRsubH1 fragment is shown in FIG. 9. The sequences of the various fragments from restriction enzyme digests were compared and an open reading frame spanning a codon sequence translatable into the amino and carboxyl termini of the protease (P. Levy et al., Id.) was determined. An open reading frame is a DNA sequence commencing at a known point which in reading frame (every three nucleotides) does not contain any internal termination codons. The open reading frame extended past the amino terminus to the end of the 2400 by HindIII fragment. The 1300 bp BgIII - HindIII fragment was prepared from pNPRsubRIb (which contained the 4300 bp EcoRI fragment of γNPRG2) and cloned in M13 mp8. The sequence of this fragment, which contained the portion of the neutral protease leader region not encoded by the 2400 by fragment of pNPRsubH1, was determined for 400 nucleotides upstream from the HindIII site.
The entire nucleotide sequence as determined for this neutral protease gene, including the putative secretory leader and prepro sequence, are shown in FIG. 10. The numbers above the line refer to amino acid positions. The underlined nucleotides in FIG. 10 are believed to constitute the ribosome binding (Shine-Dalgarno) site, while the overlined nucleotides constitute a potential hairpin structure presumed to be a terminator. The first 27-28 of the deduced amino acids are believed to be the signal for the neutral protease, with a cleavage point at ala-27 or ala-28. The "pro" sequence of a proenzyme structure extends to the amino-terminal amino acid (ala-222) of the mature, active enzyme.
A high copy plasmid carrying the entire neutral protease gene was constructed by (FIG. 11) ligating the BG1II fragment of pNPRsubR1, which contains 1900 bp (FIG. 9), with the PvuII - HindIII fragment of pNPRsubH1, which contains 1400 bp. pBS42 (from Example 4 was digested with BamHI and treated with bacterial alkaline phosphatase to prevent plasmid recircularization. pNPRsubR1 was digested to Bg1II, the 1900 bp fragment was isolated from gel electrophoresis and ligated to the open BamHI sites of pBS42. The ligated plasmid was used to transform E. coli ATCC 31446 by the calcium chloride shock method (V. Hershfield et al., Id.), and transformed cells selected by growth on plates containing LB medium with 12.5 μg/ml chloramphenicol. A plasmid having the Bg1 II fragment in the orientation shown in FIG. 11 was isolated from the transformants and designated pNPRsubB1. pNPRsubB1 was digested (linearized) with EcoRI, repaired to flush ends by Kienow treatment and then digested with HindIII. The larger fragment from the HindIII digestion (containing the sequence coding for the amino terminal and upstream regions) was recovered.
The carboxyl terminal region of the gene was supplied by a fragment from pNPRsubH1, obtained by digestion of pNPRsubH1 with PvuII and HindIII and recovery of the 1400 bp fragment. The flush end PvuII and the HindIII site of the 1400 bp fragment was ligated, respectively, to the blunted EcoRI and the HindIII site of pNPRsubB1, as shown in FIG. 11. This construct was used to transform B. subtilis strain BG84 which otherwise excreted no proteolytic activity by the assays described below. Transformants were selected on plates containing LB medium plus 1.5 percent carnation powdered nonfat milk and 5 μg/ml chloramphenicol. Plasmids from colonies that cleared a large halo were analyzed. Plasmid pNPR10, incorporating the structural gene and flanking regions of the neutral protease gene, was determined by restriction analysis to have the structure shown in FIG. 11.
B. subtilis strain BG84 was produced by N-methyl-N'-nitro-N-nitrosoguanidine (NTG) mutagenesis of B. subtilis I168 according to the general technique of Adelberg et al., 1965, "Biochem. Biophys. Res. Commun." 18:788-795. Mutagenized strain I168 was plated on skim milk plates (without antibiotic). Colonies producing a smaller halo were picked for further analysis. Each colony was characterized for protease production on skim milk plates and amylase production on starch plates. One such isolate, which was partially protease deficient, amylase positive and capable of sporulation, was designated BG77. The protease deficiency mutation was designated prt-77. The prt-77 allele was moved to a spoOA background by congression as described below to produce strain BG84, a sporulation deficient strain.
              TABLE A                                                     
______________________________________                                    
Strain Relevant Genotype origin                                           
______________________________________                                    
I168   trpC2                                                              
JH703  trpC2, pheA12, spoOAΔ677                                     
                         Trousdale et al..sup.a                           
BG16   purB6, metB5, leuA8, lys-21,                                       
                         Pb 1665                                          
       hisA, thr-5 sacA321                                                
BG77   trpC2, prt-77     NTG × I168                                 
BG81   metB5, prt-77     BG16 DNA × BG77                            
BG84   spoOΔ677, prt-77                                             
                         JH703 DNA × BG81                           
______________________________________                                    
 .sup.a "Mol. Gen. Genetics" 173:61 (1979)                                
BG84 was completely devoid of protease activity on skim milk plates and does not produce detectable levels of either subtilisin or neutral protease when assayed by measuring the change in absorbance at 412 nm per minute upon incubation with 0.2 μm/ml succinyl (-L-ala-L-ala-L-pro-L-phe) p-nitroanilide (Vega) in 0.1M sodium phosphate, pH 8, at 25° C. BG84 was deposited in the ATCC as deposit number 39382 on July 21, 1983. Samples for subtilisin assay were taken from late logarithmic growth phase supernatants of cultures grown in modified Schaeffer's medium (T. Leighton et al., 1971, "J. Biol. Chem." 246:3189-3195).
EXAMPLE 9 Expression of the Neutral Protease Gene
BG84 transformed with pNPR10was inoculated into minimal medial supplemented with 0.1 percent casein hydrolysate and 10 μg chloramphenicol and cultured for 16 hours. 0.1 ml of culture supernatant was removed and added to a suspension of 1.4 mg/ml Azocoll proteolytic substrate (Sigma) in 10 mM Tris-HCl, 100 mM NaCl pH 6.8 and incubating with agitation. Undigested substrate was removed by centrifugation and the optical density read at 505 nm. Background values of an Azocoll substrate suspension were subtracted. The amount of protease excreted by a standard protease-expressing strain, BG16 was used to establish an arbitrary level of 100. The results with BG16, and with BG84 transformed with control and neutral protease gene-containing plasmids are shown in Table B in Example 12 below. Transformation of the excreted protease-devoid B. subtilis strain BG84 results in excretion of protease activity at considerably greater levels than in BG16, the wild-type strain.
EXAMPLE 10 Manufacture of an Inactivating Mutation of the Neutral Protease Gene
The two RsaI bonded regions in the 2400 bp insert of pNPRsubH1, totalling 527 bp, can be deleted in order to produce an incomplete structural gene. The translational products of this gene are enzymatically inactive. A plasmid having this deletion was constructed as follows. pJH101 was cleaved by digestion with HindIII and treated with bacterial alkaline phosphatase. The fragments of the neutral protease gene to be incorporated into linearized pJH101 were obtained by digesting pNPRsubH1 with HindIII and RsaI, and recovering the 1200 bp HindIII-RsaI and 680 bp RsaI-HindIII fragments by gel electrophoresis. These fragments were ligated into linearized pJH101 and used to transform E. coli ATCC 31446. Transformants were selected on plates containing LB medium and 20 μg ampicillin/ml. Plasmids were recovered from the transformants and assayed by restriction enzyme analysis to identify a plasmid having the two fragments in the same orientation as in the pNPRsubH1 starting plasmid. The plasmid lacking the internal RsaI fragments was designated pNPRsubH1Δ.
EXAMPLE 11 Replacement of the Neutral Protease Gene with a Deletion Mutant
Plasmid pNPRsubh1Δ was transformed into B. subtilis strain BG2019 (the subtilisin deleted mutant from Example 6) and chromosomal integrants were selected on skim milk plates. Two types of Cmr transformants were noted, those with parental levels of proteolysis surrounding the colony, and those with almost no zone of proteolysis. Those lacking a zone of proteolysis were picked, restreaked to purify individual colonies, and their protease deficient character on skim milk plates confirmed. One of the Cmr, proteolysis deficient colonies was chosen for further studies (designated BG22034). Spontaneous Cms revertants of BG2034 were isolated by overnight growth in LB media containing no Cm, plating for individual colonies, and replica plating on media with and without Cm. Three Cms revertants were isolated, two of which were protease proficient, one of which was protease deficient (designated BG2036). Hybridization analysis of BG2036 confirmed that the plasmid had been lost from this strain, probably by recombination, leaving only the deletion fragments of subtilisin and neutral protease.
EXAMPLE 12 Phenotype of Strains Lacing Functional Subtilisin and Neutral Protease
The growth, sporulation and expression of proteases was examined in strains lacking a functional gene for either the neutral or alkaline protease or both. The expression of proteases was examined by a zone of clearing surrounding a colony on a skim milk plate and by measurement of the protease levels in liquid culture supernatants (Table B). A strain (BG2035) carrying the subtilisin gene deletion, and showed a 30 percent reduction level of protease activity and a normal halo on milk plates. Strain BG2043, carrying the deleted neutral protease gene and active subtilisin gene, and constructed by transforming BG16 (Ex. 8). with DNA from BG2036 (Example 11), showed an 80 percent reduction in protease activity and only a small halo on the milk plate.
              TABLE B                                                     
______________________________________                                    
Effect of protease deletions                                              
on protease expression and sporulation.                                   
                     Protease Percent                                     
        Genotype.sup.a                                                    
                     activity.sup.b                                       
                              Sporulation                                 
______________________________________                                    
BG16      Wild type      100      40                                      
BG2035    aprΔ684  70       20                                      
BG2043    aprEΔ522 20       20                                      
BG2054    aprΔ684, nprEΔ522                                   
                         ND       45                                      
BG84(pBS42)                                                               
          spoOAΔ677, prt-77                                         
                         ND       --                                      
BG84(pNPR10)                                                              
          spoOAΔ677, prt-77                                         
                         3000     --                                      
______________________________________                                    
 .sup.a Only the loci relevant to the protease phenotype are shown.       
 .sup.b Protease activity is expressed in arbitrary units, BG16 was       
 assigned a level of 100.                                                 
 ND indicates the level of protease was not detectable in the assay used. 
Strain BG2054, considered equivalent to BG2036 (Example 11) in that it carried the foregoing deletions in both genes, showed no detectable protease activity in this assay and no detectable halo on milk plates. The deletion of either or both of the protease genes had no apparent effect on either growth or sporulation. Strains carrying these deletions had normal growth rates on both minimal glucose and LB media. The strains sporulated at frequencies comparable to the parent strain BG16. Examination of morphology of these strains showed no apparent differences from strains without such deletions.
EXAMPLE 13 Site-specific Saturation Mutagenesis of the B. Amyloliquefaciens Subtilisin Gene at Position 222; Preparation of the Gene for Cassette Insertion
pS4-5, a derivative of pS4 made according to Wells et al., "Nucleic Acids Res.", 1983, 11:7911-7924 was digested with EcoRI and BamHI, and the 1.5 kb EcoRIBamHI fragment recovered. This fragment was ligated into replicative form M-13 mp9 which had been digested with EcoRI and BamHI (Sanger et al., 1980, "J. Mol. Biol." 143 161-178. Messing et al, 1981, "Nucleic Acids Research", 9, 304-321. Messing, J. and Vieira, J. (1982) Gene 19, 269-276). The M-13 mp9 phage ligations, designated M-13 mp9 SUBT, were used to transform E. coli strain JM101 and single stranded phage DNA was prepared from a two mL overnight culture. An oligonucleotide primer was synthesized having the sequence 5'-GTACAACGGTACCTCACGCACGCTGCAGGAGCGGCTGC-3'. This primer conforms to the sequence of the subtilis gene fragment encoding amino acids 216-232 except that the 10 bp of codons for amino acids 222-225were deleted, and the codons for amino acids 220, 227 and 228 were mutated to introduce a KpnI site 5' to the met-222 codon and a PstI site 3' to the met×222 codon. See FIG. 12. Substituted nucleotides are denoted by asterisks, the underlined codons in line 2 represent the new restriction sites and the scored sequence in line 4 represents the inserted oligonucleotides. The primer (about 15 μM) was labelled with [32 p] by incubation with [γ32 p]-ATP (10 μL in 20 μL reaction)(Amersham 5000 Ci/mmol, 10218) and T4 polynucleotide kinase (10 units) followed by non-radioactive ATP (100 μM) to allow complete phosphorylation of the mutagenesis primer. The kinase was inactivated by heating the phosphorylation mixture at 68° C. for 15 min.
The primer was hybridized to M-13 mp9 SUBT as modified from Norris et al., 1983, "Nucleic Acids Res." 11, 5103-5112 by combining 5 μL of the labelled mutagenesis primer (˜3 μM), ˜1 μg M-13 mp9 SUBT template, 1 μL of 1 μM M-13 sequencing primer (17-mer), and 2.5 μL of buffer (0.3 M Tris pH 8, 40 mM MgCl2, 12 mM EDTA, 10 mM DTT, 0.5 mg/ml BSA). The mixture was heated to 68° C. for 10 minutes and cooled 10 minutes at room temperature. To the annealing mixture was added 3.6 μL of 0.25 mM dGTP, dCTP, dATP, and dTTP, 1.25 μL of 10 mM ATP, 1 μL ligase (4 units) and 1 μL Klenow (5 units). The primer extension and ligation reaction (total volume 25 μl) proceeded 2 hours at 14° C. The Klenow and ligase were inactivated by heating to 68° C. for 20 min. The heated reaction mixture was digested with BamH1 and EcoRI and an aliquot of the digest was applied to a 6 percent polyacrylamide gel and radioactive fragments were visualized by autoradiography. This showed the [32 p] mutagenesis primer had indeed been incorporated into the EcoRIBamH1 fragment containing the now mutated subtilisin gene.
The remainder of the digested reaction mixture was diluted to 200 μL with 10 mM Tris, pH 8, containing 1 mM EDTA, extracted once with a 1:1 (v:v), phenol/chloroform mixture, then once with chloroform, and the aqueous phase recovered. 15 μL of 5M ammonium acetate (pH 8) was added along with two volumes of ethanol to precipitate the DNA from the aqueous phase. The DNA was pelleted by centrifugation for five minutes in a microfuge and the supernatant was discarded. 300 μL of 70 percent ethanol was added to wash the DNA pellet, the wash was discarded and the pellet lyophilized.
pBS42 from example 4 above was digested with BamH1 and EcoRI and purified on an acrylamide gel to recover the vector. 0.5μg of the digested vector, 50 μM ATP and 6 units ligase were dissolved in 20 μl of ligation buffer. The ligation went overnight at 14° C. The DNA was transformed into E. coli 294 rec+ and the transformants grown in 4 ml of LB medium containing 12.5 μg/ml chloramphenicol. Plasmid DNA was prepared from this culture and digested with KpnI, EcoRI and BamHI. Analysis of the restriction fragments showed 30-50 percent of the molecules contained the expected KpnI site programmed by the mutagenesis primer. It was hypothesized that the plasmid population not including the KpnI site resulted from M-13 replication before bacterial repair of the mutagenesis site, thus producing a heterogenous population of KpnI+ and KnpI- plasmids in some of the transformants. In order to obtain a pure culture of the KpnI+ B plasmid, the DNA was transformed a second time into E. coli to clone plasmids containing the new KpnI site. DNA was prepared from 16 such transformants and six were found to contain the expected KpnI site.
Preparative amounts of DNA were made from one of these six transformants (designated pΔ222) and restriction analysis confirmed the presence and location of the expected KpnI and PstI sites. 40 μg of pΔ222 were digested in 300 μL of KpnI buffer plus 30 μL KpnI (300 units) for 1.5 h at 37° C. The DNA was precipitated with ethanol, washed with 70 percent ethanol, and lyophilized. The DNA pellet was taken up in 200 μL HindIII buffer and digested with 20 μL (500 units) PstI for 1.5 h at 37° C. The aqueous phase was extracted with phenol/CHCl3 and the DNA precipitated with ethanol. The DNA was dissolved in water and purified by polyacrylamide gel electrophoresis. Following electroelution of the vector band (120 v for 2 h at 0° C. in 0.1 times TBE (Maniatis et al., Id.)) the DNA was purified by phenol/CHCl3 extraction, ethanol precipitation and ethanol washing.
Although pΔ222 could be digested to completion (>98 percent) by either KnpI or Pst1 separately, exhaustive double digestion was incomplete (<<50 percent). This may have resulted from the fact that these sites were so close (10 bp) that digestion by KpnI allowed "breathing" of the DNA in the vicinity of the PstI site, i.e., strand separation or fraying. Since PstI will only cleave double stranded DNA, strand separation could inhibit subsequent PstI digestion.
EXAMPLE 14 Ligation of Oligonucleotide Casettes into the Subtilisin Gene
10 μM of four complementary oligonucleotide pools (A-D, Table C below) which were not 5' phosphorylated were annealed in 20 μl ligase buffer by heating for five minutes at 68° C. and then cooling for fifteen minutes at room temperature. 1 μM of each annealed oligonucleotide pool, ˜0.2 μg KpnI and PstI-digested pΔ222 obtained in Example 13, 0.5 mM ATP, ligase buffer and 6 units T4 DNA ligase in 20 μL total volume was reacted overnight at 14° C. to ligate the pooled cassettes in the vector. A large excess of cassettes (˜300×0 over the pΔ222 ends) was used in the ligation to help prevent intramolecular KpnI-KpnI ligation. The reaction was diluted by adding 25 μL of 10 mM Tris pH 8 containing 1 mM EDTA. The mixture was reannealed to avoid possible cassette concatemer formation by heating to 68° C. for five minutes and cooling for 15 minutes at room temperature. The ligation mixtures from each pool were transformed separately into E. coli 294 rec+ cells. A small aliquot from each transformation mixture was plated to determine the number of independent transformants. The large number of transformants indicated a high probability of multiple mutagenesis. The rest of the transformants (˜200-400 transformants) were cultured in 4 ml of LB medium plus 12.5 μg chloramphenicol/ml. DNA was prepared from each transformation pool (A-D). This DNA was digested with KnpI, ˜0.1 μg was used to retransform E coli rec+ and the mixture was plated to isolate individual colonies from each pool. Ligation of the cassettes into the gene and bacterial repair upon transformation destroyed the KnpI and PstI sites. Thus, only pΔ222 was cut when the transformant DNA was digested with KpnI. The cut plasmid would not transform E. coli. Individual transformants were grown in culture and DNA was prepared from 24 to 26 transformants per pool for direct plasmid sequencing. A synthetic oligonucleotide primer having the sequence 5'-GAGCTTGATGTCATGGC-3' was used to prime the dideoxy sequencing reaction. The mutants which were obtained are described in Table C below.
Two codon+222 mutants (i.e., gln and ile) were not found after the screening described. To obtain these a single 25 mer oligonucleotide was synthesized for each mutant corresponding to the top oligonucleotide strand in FIG. 12. Each was phosphorylated and annealed to the bottom strand of its respective nonphosphorylated oligonucleotide pool (i.e., pool A for gln and pool D for ile). This was ligated into KnpI and PstI digested pΔ222 and processed as described for the original oligonucleotide pools. The frequency of appearance for single mutants obtained in this way was 2/8 and 0/7 for gln and ile, respectively. To avoid this apparent bias the top strand was phosphorylated and annealed to its unphosphorylated complementary pool. The heterophosphorylated cassette was ligated into cut pΔ222 and processed as before. The frequency of appearance of gln and ile mutants was now 7/7 and 7/7, respectively.
The data in Table C demonstrate a bias in the frequency of mutants obtained from the pool. This probably resulted from unequal representation of oligonucleotides in the pool. This may have been caused by unequal coupling of the particular trimers over the mutagenesis codon in the pool. Such a bias problem could be remedied by appropriate adjustment of trimer levels during synthesis to reflect equal reaction. In any case, mutants which were not isolated in the primary screen were obtained by synthesizing a single strand oligonucleotide representing the desired mutation, phosphorylating both ends, annealing to the pool of non-phosphorylated complementary strands and ligating into the cassette site. A biased heteroduplex repair observed for the completely unphosphorylated cassette may result from the fact that position 222 is closer to the 5' end of the upper strand than it is to the 5' end of the lower strand (see FIG. 12). Because a gap exists at the unphosphorylated 5' ends and the mismatch bubble in the double stranded DNA is at position 222, excision repair of the top strand gap would more readily maintain a circularly hybridized duplex capable of replication. Consistent with this hypothesis is the fact that the top strand could be completely retained by selective 5' phosphorylation. In this case only the bottom strand contained a 5' gap which could promote excision repair. This method is useful in directing biased incorporation of synthetic oligonucleotide strands when employing mutagenic oligonucleotide cassettes.
EXAMPLE 15 Site-Specific Mutagenesis of the Subtilisin Gene at Position 166
The procedure of Examples 13-14 was followed in substantial detail, except that the mutagenesis primer differed (the 37 mer shown in FIG. 13 was used), the two restriction enzymes were SacI and XmaIII rather than PstI and KpnI and the resulting constructions differed, as shown in FIG. 13.
Bacillus strains excreting mutant subtilisins at position 166 were obtained as described below in Example 16. The mutant subtilisins exhibiting substitutions of ala, asp, gln, phe, his, lys, asn, arg, and val for the wild-type residue were recovered.
EXAMPLE 16 Preparation of Mutant Subtilisin Enzymes
B. subtilis strain BG2036 obtained by the method of Example 11 was transformed by the plasmids of Examples 14, 15 or 20 and by pS4-5 as a control. Transformants were plated or cultured in shaker flasks for 16 to 48 h at 37° C. in LB media plus 12.5 μg/ml chloramphenicol. Mutant enzymatically active subtilisin was recovered by dialyzing cell broth against 0.01M sodium phosphate buffer, pH 6.2. The dialyzed broth was then titrated to pH 6.2 with 1N HCl and loaded on a 2.5×2 cm column of CM cellulose (CM-52 Whatman). After washing with 0.01M sodium phosphate, pH 6.2, the subtilisins (except mutants at position +222) were eluted with the same buffer made 0.08N in NaCl. The mutant subtilisins at position +222 were each eluted with 0.1M sodium phosphate, pH 7.0. The purified mutant and wild type enzymes were then used in studies of oxidation stability, Km, Kcat, Kcat/Km ratio, pH optimum, and changes in substrate specificity.
              TABLE C                                                     
______________________________________                                    
Oligonucleotide Pool Organization                                         
and Frequency of Mutants Obtained                                         
Pool   Amino Acids     Codon-222.sup.a                                    
                                 Frequency.sup.b                          
______________________________________                                    
A      asp             GAT       2/25                                     
       met             ATG       3/25                                     
       cys             TGT       13/25                                    
       arg             AGA       2/25                                     
       gln             GAA       0/25                                     
       unexpected mutants.sup.a  5/25                                     
B      leu             CTT       1/25                                     
       pro             CCT       3/25                                     
       phe             TTC       6/25                                     
       tyr             TAC       5/25                                     
       his             CAC       1/25                                     
       unexpected mutants        9/25                                     
C      glu             GAA       3/17                                     
       ala             GCT       3/17                                     
       thr             ACA       1/17                                     
       lys             AAA       1/17                                     
       asn             AAC       1/17                                     
       unexpected mutants        8/17                                     
D      gly             GGC       1/23                                     
       trp             TGG       8/23                                     
       ile             ATC       0/23                                     
       ser             AGC       1/23                                     
       val             GTT       4/23                                     
       unexpected mutants        9/23                                     
______________________________________                                    
 .sup.a Codons were chosen based on frequent use in the closed subtilisin 
 gene sequence (Wells et al., 1983, id.).                                 
 .sup.b Frequency was determined from single track analysis by direct     
 plasmid sequencing.                                                      
 .sup.c Unexpected mutants generally comprised double mutants with changes
 in codons next to 222 or at the points of ligation. These were believed t
 result from impurities in the obigonucleotide pools and/or erroneous     
 repair of the gapped ends.                                               
EXAMPLE 17 Mutant Subtilisin Exhibiting Improved Oxidation Stability
Subtilisins having cysteine and alanine substituted at the 222 position for wild-type methionine (Example 16) were assayed for resistance to oxidation by incubating with various concentrations of sodium nypochloride (Clorox Bleach).
To a total volume of 400 μl of 0.1M, pH 7, NaPO4 buffer containing the indicated bleach concentrations (FIG. 14) sufficient enzyme was added to give a final concentration of 0.016 mg/ml of enzyme. The solutions were incubated at 25° C. for 10 min. and assayed for enzyme activity as follows: 120 μl of either ala+222 or wild type, or 100 μl of the cys+222 incubation mixture was combined with 890 μl 0.1M tris buffer at pH 8.6 and 10 μl of a sAAPFpN (Example 18) substrate solution (20 mg/ml in DMSO). The rate of increase in absorbance at 410 nm due to release of p-nitroaniline (Del Mar, E.G., et al., 1979 "Anal. Biochem." 99, 316-320) was monitored. The results are shown in FIG. 14. The alanine substitution produced considerably more stable enzyme than either the wild-type enzyme or a mutant in which a labile cysteine residue was substituted for methionine. Surprisingly, the alanine substitution did not substantially interfere with enzyme activity B against the assay substrate, yet conferred relative oxidation stability on the enzyme. The serine+222 mutant also exhibited improved oxidation stability.
EXAMPLE 18 Mutant Subtilisins Exhibiting Modified Kinetics and Substrate Specificity
Various mutants for glycine+166 were screened for modified Kcat, Km and Kcat/Km ratios. Kinetic parameters were obtained by analysis of the progress curves of the reactions. The rate of reaction was measured as a function of substrate concentration. Data was analyzed by fitting to the Michaelis-Menton equation using the non-linear regression algorithm of Marquardt (Marquardt, D. W. 1963, "J. Soc. Ind. Appl. Math." 11, 431-41). All reactions were conducted at 25° C. in 0.1M tris buffer, pH 8.6, containing benzoyl-L-Valyl-Glycyl-L-Arginyl-p-nitroanilide (BVGRpN; Vega Biochemicals) at initial concentrations of 0.0025M to 0.00026M (depending on the value of Km for the enzyme of interest--concentrations were adjusted in each measurement so as to exceed Km) or succinyl-L-Alanyl-L-Alanyl-L-Prolyl-L-Phenylalanyl-p-nitro-anilide (sAAPFpN; Vega Biochemicals) at initial concentrations of 0.0010M to 0.00028M (varying as described for BVGRpN).
The results obtained in these experiments were as follows:
              TABLE D                                                     
______________________________________                                    
Substrate                                                                 
        Enzyme     Kcat (s.sup.-1)                                        
                             Km (M)   Kcat/Km                             
______________________________________                                    
sAAPFpN gly - 166  37        1.4 × 10.sup.-4                        
                                      3 × 10.sup.5                  
        (wild type)                                                       
        ala + 166  19        2.7 × 10.sup.-5                        
                                      7 × 10.sup.5                  
        asp + 166  3         5.8 × 10.sup.-4                        
                                      5 × 10.sup.3                  
        glu + 166  11        3.4 × 10.sup.-4                        
                                      3 × 10.sup.4                  
        phe + 166  3         1.4 × 10.sup.-5                        
                                      2 × 10.sup.5                  
        hys + 166  15        1.1 × 10.sup.-4                        
                                      1 × 10.sup.5                  
        lys + 166  15        3.4 × 10.sup.-5                        
                                      4 × 10.sup.5                  
        asn + 166  26        1.4 × 10.sup.-4                        
                                      2 × 10.sup.5                  
        arg + 166  19        6.2 × 10.sup.-5                        
                                      3 × 10.sup.5                  
        val + 166  1         1.4 × 10.sup.-4                        
                                      1 × 10.sup.4                  
BVGRpN  Wild Type  2         1.1 × 10.sup.-3                        
                                      2 × 10.sup.3                  
        asp + 166  2         4.1 × 10.sup.-5                        
                                      5 × 10.sup.4                  
        glu + 166  2         2.7 × 10.sup.-5                        
                                      7 × 10.sup.4                  
        asn + 166  1         1.2 × 10.sup.-4                        
                                      8 × 10.sup.3                  
______________________________________                                    
The Kcat/Km ratio for each of the mutants varied from that of the wild-type enzyme. As a measure of catalytic efficiency, these ratios demonstrate that enzymes having much higher activity against a given substrate can be readily designed and selected by screening in accordance with the invention herein. For example, A166 exhibits over 2 times the activity of the wild type on sAAPFpN.
This data also demonstrates changes in substrate specificity upon mutation of the wild type enzyme. For example, the Kcat/Km ratio for the D166 and E166 mutants is higher than the wild type enzyme with the BVGpN substrate, but qualitatively opposite results were obtained upon incubation with sAAPFpN. Accordingly, the D166 and E166 mutants were relatively more specific for BVGRpN than for sAAPFpN.
EXAMPLE 19 Mutant Subtilisin Exhibiting Modified pH-Activity Profile
The pH profile of the Cys+222 mutant obtained in Example 16 was compared to that of the wild type enzyme. 10 μl of 60 mg/ml sAAPFpN in DMSO, 10 μl of Cys+222 (0.18 mg/ml) or wild type (0.5 mg/ml) and 980 μl of buffer (for measurements at pH 6.6, 7.0 and 7.6, 0.1M NaPO4 buffer; at pH 8.2, 8.6 and 9.2, 0.1M tris buffer; and at pH 9.6 and 10.0, 0.1M glycine buffer), after which the initial rate of change in absorbance at 410 nm per minute was measured at each pH and the data plotted in FIG. 15. The Cys+222 mutant exhibits a sharper pH optimum than the wild type enzyme.
EXAMPLE 20 Site-Specific Mutagenesis of the Subtilisin Gene at Position 169
The procedure of Examples 13-14 was followed in substantial detail, except that the mutagenesis primer differed (the primer shown in FIG. 16 was used), the two restriction enzymes were KpnI and EcoRV rather than PstI and KpnI and the resulting constructions differed, as shown in FIG. 16.
Bacillus strains excreting mutant subtilisins at position 169 were obtained as described below in Example 16. The mutant subtilisins exhibiting substitutions of ala and ser for the wild-type residue were recovered and assayed for changes in kinetic features. The assay employed SAAPFpN at pH 8.6 in the same fashion as set forth in Example 18. The results were as follows:
              TABLE E                                                     
______________________________________                                    
Enzyme    Kcat (s.sup.-1)                                                 
                       Km (M)    Kcst/Km                                  
______________________________________                                    
ala + 169 58           7.5 × 10.sup.-5                              
                                 8 × 10.sup.5                       
ser + 169 38           8.5 × 10.sup.-5                              
                                 4 × 10.sup.5                       
______________________________________                                    
EXAMPLE 21 Alterations in Specific Activity on a Protein Substrate
Position 166 mutants from Examples 15 and 16 were assayed for alteration of specific activity on a naturally occurring protein substrate. Because these mutant proteases could display altered specificity as well as altered specific activity, the substrate should contain sufficient different cleavage sites i.e., acidic, basic, neutral, and hydrophobic, so as not to bias the assay toward a protease with one type of specificity. The substrate should also contain no derivitized residues that result in the masking of certain cleavage sites. The widely used substrates such as hemoglobin, azocollogen, azocasein, dimetnyl casein, etc., were rejected on this basis. Bovine casein, αand α2 chains, was chosen as a suitable substrate.
A 1 percent casein (w/v) solution was prepared in a 100 mM Tris buffer, pH 8.0, 10 mM EDTA. The assay protocol is as follows:
790 μl 50 mM Tris pH 8.2
100 μl 1 percent casein (Sigma) solution
10 ηl test enzyme (10-200 μg).
This assay mixture was mixed and allowed to incubate at room temperature for 20 minutes. The reaction was terminated upon the addition of 100 μl 100 percent trichloroacetic acid, followed by. incubation for 15 minutes at room temperature. The precipitated protein was pelleted by centrifugation and the optical density of the supernatant was determined spectrophotometrically at 280 nm. The optical density is a reflection of the amount of unprecipitated, i.e., hydrolyzed, casein in the reaction mixture. The amount of casein hydrolysed by each mutant protease was compared to a series of standards containing various amounts of the wild type protease, and the activity is expressed as a percentage of the corresponding wild type activity. Enzyme activities were converted to specific activity by dividing the casein hydrolysis activity by the 280 nm absorbance of the enzyme solution used in the assay.
All of the mutants which were assayed showed less specific activity on casein than the wild type with the exception of Asn+166 which was 26 percent more active on casein than the wild type. The mutant showing the least specific activity was ile+166 at 0.184 of the wild type activity.

Claims (3)

    We claim: .[.1. A subtilisin enzyme having a different amino acid at a site +32, +155, +104, +222, +166, +64, +33, +169, +189, +217, or +157 than subtilisin naturally produced by Bacillus amyloliquefaciens..]. .[.2. A composition comprising an enzyme according to claim 1 in combination with a detergent..]. .[.3. A composition according to claim 2 wherein the detergent is a linear alkyl benzene sulfonate, alkyl benzene sulfate,
  1. sulfated linear alcohol, or ethoxylated linear alcohol..]. .Iadd.4. A substantially pure modified subtilisin substituted at the residue position equivalent to asp+32 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.5. A substantially pure modified subtilisin substituted at the residue position equivalent to asn+155 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B, with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.6. A substantially pure modified subtilisin substituted at the residue position equivalent to tyr+104 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen amino acids shown in FIG. 17. .Iaddend. .Iadd.7. A substantially pure modified subtilisin substituted at the residue position equivalent to met+222 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen amino acids as shown in FIG. 17. .Iaddend. .Iadd.8. A substantially pure modified subtilisin substituted at the residue position equivalent to gly+166 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.9. A substantially pure modified subtilisin substituted at the residue position equivalent to his+64 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG.
  2. 17. .Iaddend. .Iadd.10. A substantially pure modified subtilisin substituted at the residue position equivalent to ser+33 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids as shown in FIG. 17. .Iaddend. .Iadd.11. A substantially pure modified subtilisin substituted at the residue position equivalent to gly+169 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.12. A substantially pure modified subtilisin substituted at the residue position equivalent to phe+189 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.13. A substantially pure modified subtilisin substituted at the residue position equivalent to tyr+217 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.14. A substantially pure modified subtilisin substituted at the residue position equivalent to glu+156 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.15. A substantially pure modified subtilisin substituted at the position equivalent to ala+152 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B with one of the other nineteen naturally occurring amino acids shown in FIG. 17. .Iaddend. .Iadd.16. A modified subtilisin according to claim 7 wherein said subtilisin has an improved pH activity profile when compared to said subtilisin having the amino acid naturally occurring in said subtilisin at the residue position equivalent to met+222. .Iaddend. .Iadd.17. A modified subtilisin according to claim 8 wherein said subtilisin has improved substrate specificity when compared to said subtilisin having the amino acid naturally occurring in said subtilisin at the residue position equivalent to gly+166. .Iaddend. .Iadd.18. A modified subtilisin according to claim 7 wherein said subtilisin has improved oxidative stability when compared to said subtilisin having the amino acid naturally occurring in said subtilisin at the residue position equivalent to met+222. .Iaddend. .Iadd.19. A modified subtilisin according to claim 18 wherein the amino acid substituted at the residue position equivalent to met+222 is selected from the group consisting of ala, ser or cys. .Iaddend. .Iadd.20. A substantially pure modified subtilisin having improved oxidative stability wherein the stability is effected by deleting one or more methionine, tryptophan, cysteine or lysine residue in said subtilisin and substituting another amino acid other than one of methionine, tryptophan, cysteine or lysine, for said deleted amino acid
  3. residue. .Iaddend. .Iadd.21. A substantially pure modified subtilisin resulting from the expression of DNA which DNA encodes for the amino acid sequence of subtilisin substituted at the residue position equivalent to asp+32, asn+155, tyr+104, met+222, gly+166, his+64, ser+33, gly+169, phe+189, tyr+217, glu+156, or ala+152 of the Bacillus amyloliquefaciens subtilisin shown in FIG. 1B, wherein the substituted amino acid is one of the other nineteen naturally occurring amino acids shown in FIG. 17, and wherein said DNA is obtained by direct recombinant mutagenesis to a precursor DNA. .Iaddend. .Iadd.22. A composition comprising an enzyme according to any one of the claims 4-15 in combination with a detergent. .Iaddend. .Iadd.23. A composition according to claim 22 wherein the detergent is a linear alkyl benzene sulfonate, kyl benzene sulfate, sulfated linear alcohol, or ethoxylated linear alcohol. .Iaddend.
US07/556,918 1984-05-29 1990-07-20 Modified enzymes and methods for making same Expired - Lifetime USRE34606E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/556,918 USRE34606E (en) 1984-05-29 1990-07-20 Modified enzymes and methods for making same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/614,612 US4760025A (en) 1984-05-29 1984-05-29 Modified enzymes and methods for making same
US07/556,918 USRE34606E (en) 1984-05-29 1990-07-20 Modified enzymes and methods for making same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/614,612 Reissue US4760025A (en) 1983-06-24 1984-05-29 Modified enzymes and methods for making same

Publications (1)

Publication Number Publication Date
USRE34606E true USRE34606E (en) 1994-05-10

Family

ID=24462011

Family Applications (3)

Application Number Title Priority Date Filing Date
US06/614,612 Ceased US4760025A (en) 1983-06-24 1984-05-29 Modified enzymes and methods for making same
US07/521,010 Expired - Lifetime US5441882A (en) 1984-05-29 1990-05-09 Method for preparing modified subtilisins
US07/556,918 Expired - Lifetime USRE34606E (en) 1984-05-29 1990-07-20 Modified enzymes and methods for making same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US06/614,612 Ceased US4760025A (en) 1983-06-24 1984-05-29 Modified enzymes and methods for making same
US07/521,010 Expired - Lifetime US5441882A (en) 1984-05-29 1990-05-09 Method for preparing modified subtilisins

Country Status (1)

Country Link
US (3) US4760025A (en)

Cited By (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005295A3 (en) * 1994-08-11 1996-03-28 Genencor Int An improved cleaning composition
EP0704167A1 (en) 1994-08-19 1996-04-03 Finnfeeds International Ltd. An enzyme feed additive and animal feed including it
US5631217A (en) * 1990-12-21 1997-05-20 Novo Nordisk A/S Detergent compositions comprising a modified subtilisin
US5677272A (en) * 1993-10-14 1997-10-14 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US5679630A (en) * 1993-10-14 1997-10-21 The Procter & Gamble Company Protease-containing cleaning compositions
US5700676A (en) * 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
US5824522A (en) * 1990-12-07 1998-10-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Recombinant decarbamylases for producing D-α-amino acids
US5955340A (en) 1984-05-29 1999-09-21 Genencor International, Inc. Modified subtilisins having amino acid alterations
US5958739A (en) 1996-06-06 1999-09-28 Genencor International Inc. Mutant α-amylase
US6001586A (en) 1996-03-29 1999-12-14 Genencor International, Inc. Compartmentalization method for screening microorganisms
US6066611A (en) 1994-10-13 2000-05-23 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
WO2000071690A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 128 and 129
WO2000071688A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 126 and 127
WO2000071689A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 127 and 128
WO2000071691A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 125 and 126
WO2000071687A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 129 and 130
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US6197567B1 (en) * 1989-06-26 2001-03-06 Novo Nordisk A/S Modified subtilisins and detergent compositions containing same
US6271012B1 (en) * 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
US6287841B1 (en) 1988-02-11 2001-09-11 Genencor International, Inc. High alkaline serine protease
US6300116B1 (en) * 1996-11-04 2001-10-09 Novozymes A/S Modified protease having improved autoproteolytic stability
US6312936B1 (en) 1997-10-23 2001-11-06 Genencor International, Inc. Multiply-substituted protease variants
US6376450B1 (en) 1998-10-23 2002-04-23 Chanchal Kumar Ghosh Cleaning compositions containing multiply-substituted protease variants
WO2002040997A2 (en) 2000-10-02 2002-05-23 Genencor International, Inc. Production and use of proteins producing an altered immunogenic response
US6436690B1 (en) * 1993-09-15 2002-08-20 The Procter & Gamble Company BPN′ variants having decreased adsorption and increased hydrolysis wherein one or more loop regions are substituted
US6440717B1 (en) * 1993-09-15 2002-08-27 The Procter & Gamble Company BPN′ variants having decreased adsorption and increased hydrolysis
US6451574B1 (en) * 1995-03-09 2002-09-17 The Procter & Gamble Company Proteinase K variants having decreased adsorption and increased hydrolysis
US6455295B1 (en) * 1995-03-08 2002-09-24 The Procter & Gamble Company Subtilisin Carlsberg variants having decreased adsorption and increased hydrolysis
WO2002077187A3 (en) * 2001-03-23 2003-04-24 Genencor Int Proteins producing an altered immunogenic response and methods of making and using the same
US6558938B1 (en) 1997-08-29 2003-05-06 Novozymes, A/S Protease variants and compositions
US6586221B2 (en) 1993-10-14 2003-07-01 Genencor International, Inc. Subtilisin variants multiply-substituted subtilising variants having a substitution at position 76
US6599730B1 (en) * 1994-05-02 2003-07-29 Procter & Gamble Company Subtilisin 309 variants having decreased adsorption and increased hydrolysis
WO2003062380A2 (en) 2002-01-16 2003-07-31 Genencor International, Inc. Multiply-substituted protease variants
US6605458B1 (en) 1997-11-21 2003-08-12 Novozymes A/S Protease variants and compositions
US20030180281A1 (en) * 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20030216277A1 (en) * 2001-07-20 2003-11-20 Becker Nathaniel T. Stabilization of enzymes
WO2004010930A2 (en) 2002-07-30 2004-02-05 Genencor International, Inc. Reduced aerosol generating formulations
US6727085B2 (en) 1999-12-15 2004-04-27 Fanoe Tina Sejersgaard Subtilase variants having an improved wash performance on egg stains
US20040091474A1 (en) * 2001-01-08 2004-05-13 Health Protection Agency Degradation and detection of TSE infectivity
US20040105874A1 (en) * 2002-03-11 2004-06-03 Bott Richard R. Preparations for topical skin use and treatment
US6773907B2 (en) 1997-11-21 2004-08-10 Peter Kamp Hansen Subtilase enzymes
US6777218B1 (en) 2000-03-14 2004-08-17 Novozymes A/S Subtilase enzymes having an improved wash performance on egg stains
US6780629B2 (en) 1997-11-21 2004-08-24 Novozymes A/S Subtilase enzymes
US20040234649A1 (en) * 2003-03-10 2004-11-25 Broin And Associates, Inc. Method for producing ethanol using raw starch
US6831053B1 (en) 1998-10-23 2004-12-14 The Procter & Gamble Company Bleaching compositions comprising multiply-substituted protease variants
US20050059567A1 (en) * 2003-09-11 2005-03-17 The Procter & Gamble Company Methods of formulating enzyme cocktails, enzyme cocktails for the removal of egg-based and grass-based stains and/or soils, compositions and products comprising same
US6872696B2 (en) 2000-10-27 2005-03-29 Genencor International, Inc. Particle with substituted polyvinyl alcohol coating
WO2005040372A1 (en) 2003-10-23 2005-05-06 Novozymes A/S Protease with improved stability in detergents
US20050164257A1 (en) * 1998-04-15 2005-07-28 Estell David A. Proteins producing an altered immunogenic response and methods of making and using the same
US20050233030A1 (en) * 2004-03-10 2005-10-20 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20050239181A1 (en) * 2004-03-10 2005-10-27 Broin And Associates, Inc. Continuous process for producing ethanol using raw starch
US20060073559A1 (en) * 2002-03-29 2006-04-06 Eugenio Ferrari Ehanced protein expression in bacillus
US7129076B2 (en) 1997-10-23 2006-10-31 Genencor International, Inc. Multiply-substituted protease variants with altered net charge for use in detergents
US20070037267A1 (en) * 2005-05-02 2007-02-15 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
EP1803817A1 (en) 1998-12-18 2007-07-04 Novozymes A/S Subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid residue in an active site loop region
US20070178567A1 (en) * 2005-10-10 2007-08-02 Lewis Stephen M Methods and systems for producing ethanol using raw starch and selecting plant material
US7297354B2 (en) 2000-04-26 2007-11-20 Land O'lakes, Inc. Protein material
US20080004186A1 (en) * 2006-06-23 2008-01-03 Estell David A Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
US20080063774A1 (en) * 2003-11-19 2008-03-13 Wolfgang Aehle Multiple mutation variants of serine protease
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
US20080108126A1 (en) * 2006-08-23 2008-05-08 George England Pullulanase variants with increased productivity
US20080124783A1 (en) * 2002-01-16 2008-05-29 Poulose Ayrookaran J Multiply-substituted protease variants
US20080199417A1 (en) * 2005-05-23 2008-08-21 Dow Corning Corporation Personal Care Composition Comprising Saccharide-Siloxane Copolymers
US20080209645A1 (en) * 2005-05-23 2008-09-04 Dow Corning Corporation Surface Treatment Compositions Comprising Saccharide-Siloxane Copolymers
WO2008134343A1 (en) 2007-04-30 2008-11-06 Danisco Us Inc., Genencor Division Use of protein hydrolysates to stabilize metalloprotease detergent formulations
EP1997897A1 (en) 1998-04-15 2008-12-03 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20090075332A1 (en) * 2007-03-12 2009-03-19 Eugenio Ferrari Modified Proteases
US20090111161A1 (en) * 2007-10-30 2009-04-30 Jones Brian E Streptomyces protease
US20090120873A1 (en) * 2007-09-12 2009-05-14 Becker Nathaniel T Filtration with internal fouling control
WO2009094084A1 (en) 2007-12-21 2009-07-30 Danisco Us Inc., Genencor Division Enhanced protein production in bacillus
US20090199877A1 (en) * 2008-02-08 2009-08-13 Piotr Koch Process for making a water-soluble pouch
US20090258380A1 (en) * 2005-12-06 2009-10-15 Harding Fiona A Perhydrolase Epitopes
US20090258058A1 (en) * 2006-05-23 2009-10-15 Dow Corning Corporation Novel silicone film former for delivery of actives
WO2009149144A2 (en) 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
US20100105598A1 (en) * 2006-10-16 2010-04-29 Pieter Augustinus Non-Phosphate Dish Detergents
US20100192985A1 (en) * 2008-11-11 2010-08-05 Wolfgang Aehle Compositions and methods comprising serine protease variants
US20100192986A1 (en) * 2008-02-08 2010-08-05 Anju Deepali Massey Brooker Water-soluble pouch
US20100227369A1 (en) * 2009-03-03 2010-09-09 Narendranath Neelakantam V System for Fermentation of Biomass for the Production of Ethanol
US20100233771A1 (en) * 2009-03-03 2010-09-16 Mcdonald William F System for pre-treatment of biomass for the production of ethanol
WO2010115021A2 (en) 2009-04-01 2010-10-07 Danisco Us Inc. Compositions and methods comprising alpha-amylase variants with altered properties
WO2010144283A1 (en) 2009-06-11 2010-12-16 Danisco Us Inc. Bacillus strain for increased protein production
US20110008866A1 (en) * 2006-03-31 2011-01-13 Dibel Kevin R Tangential Flow Filtration Apparatuses, Systems, and Processes for the Separation of Compounds
US20110045571A1 (en) * 2009-04-24 2011-02-24 Danisco Us Inc. Proteases With Modified Pro Regions
WO2011072099A2 (en) 2009-12-09 2011-06-16 Danisco Us Inc. Compositions and methods comprising protease variants
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
WO2011084412A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing thermobifida fusca lipase and methods of use thereof
US20110195059A1 (en) * 2007-12-20 2011-08-11 Danisco Us Inc. Enzymatic Prevention and Control of Biofilm
WO2011130222A2 (en) 2010-04-15 2011-10-20 Danisco Us Inc. Compositions and methods comprising variant proteases
WO2011140364A1 (en) 2010-05-06 2011-11-10 Danisco Us Inc. Compositions and methods comprising subtilisin variants
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
US8183024B2 (en) 2008-11-11 2012-05-22 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
EP2460823A1 (en) 2007-05-10 2012-06-06 Danisco US Inc. A modified secretion system to increase expression of polypeptides in bacteria
EP2500423A2 (en) 2003-02-26 2012-09-19 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
WO2012149317A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing bacillus agaradhaerens mannanase and methods of use thereof
WO2012149333A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing bacillus sp. mannanase and methods of use thereof
WO2012149325A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof
WO2012151534A1 (en) 2011-05-05 2012-11-08 Danisco Us Inc. Compositions and methods comprising serine protease variants
WO2012151480A2 (en) 2011-05-05 2012-11-08 The Procter & Gamble Company Compositions and methods comprising serine protease variants
WO2013033318A1 (en) 2011-08-31 2013-03-07 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US8450094B1 (en) 2009-03-03 2013-05-28 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
WO2013086219A1 (en) 2011-12-09 2013-06-13 Danisco Us Inc. Ribosomal promotors from b. subtilis for protein production in microorganisms
WO2013090053A1 (en) 2011-12-13 2013-06-20 Danisco Us Inc. Enzyme cocktails prepared from mixed cultures
WO2013096653A1 (en) 2011-12-22 2013-06-27 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US8530219B2 (en) 2008-11-11 2013-09-10 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
US8535927B1 (en) 2003-11-19 2013-09-17 Danisco Us Inc. Micrococcineae serine protease polypeptides and compositions thereof
WO2013138288A1 (en) 2012-03-16 2013-09-19 Monosol, Llc. Water soluble compositions incorporating enzymes, and method of making same
WO2013158364A1 (en) 2012-04-16 2013-10-24 Monosol, Llc Powdered pouch and method of making same
WO2014059360A1 (en) 2012-10-12 2014-04-17 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2014071410A1 (en) 2012-11-05 2014-05-08 Danisco Us Inc. Compositions and methods comprising thermolysin protease variants
US8753861B2 (en) 2008-11-11 2014-06-17 Danisco Us Inc. Protease comprising one or more combinable mutations
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
WO2014099525A1 (en) 2012-12-21 2014-06-26 Danisco Us Inc. Paenibacillus curdlanolyticus amylase, and methods of use, thereof
WO2014099523A1 (en) 2012-12-21 2014-06-26 Danisco Us Inc. Alpha-amylase variants
US8853372B2 (en) 2010-08-23 2014-10-07 Dow Corning Corporation Saccharide siloxanes stable in aqueous environments and methods for the preparation and use of such saccharide siloxanes
WO2014164800A1 (en) 2013-03-11 2014-10-09 Danisco Us Inc. Alpha-amylase combinatorial variants
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194034A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194054A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194032A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
US8907026B2 (en) 2004-12-23 2014-12-09 Dow Corning Corporation Crosslinkable saccharide-siloxane compositions, and networks, coatings and articles formed therefrom
US8927250B2 (en) 2005-02-18 2015-01-06 Danisco Us Inc. Polypeptides having alpha-amylase and granular starch hydrolyzing activity
WO2015038792A1 (en) 2013-09-12 2015-03-19 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
WO2015057619A1 (en) 2013-10-15 2015-04-23 Danisco Us Inc. Clay granule
WO2015073772A1 (en) 2013-11-14 2015-05-21 Danisco Us Inc. Stable enzymes by glycation reduction
WO2015089447A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of the bacillus gibsonii-clade
WO2015089441A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of bacillus species
WO2015095358A1 (en) 2013-12-18 2015-06-25 E. I. Du Pont De Nemours And Company Cationic poly alpha-1,3-glucan ethers
US9068206B1 (en) 2009-03-03 2015-06-30 Poet Research, Inc. System for treatment of biomass to facilitate the production of ethanol
WO2015102814A1 (en) 2013-12-31 2015-07-09 Danisco Us Inc. Enhanced protein expression
WO2015123323A1 (en) 2014-02-14 2015-08-20 E. I. Du Pont De Nemours And Company Poly-alpha-1,3-1,6-glucans for viscosity modification
WO2015138283A1 (en) 2014-03-11 2015-09-17 E. I. Du Pont De Nemours And Company Oxidized poly alpha-1,3-glucan as detergent builder
WO2015195777A1 (en) 2014-06-19 2015-12-23 E. I. Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
WO2015195960A1 (en) 2014-06-19 2015-12-23 E. I. Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
WO2016061438A1 (en) 2014-10-17 2016-04-21 Danisco Us Inc. Serine proteases of bacillus species
WO2016065238A1 (en) 2014-10-24 2016-04-28 Danisco Us Inc. Method for producing alcohol by use of a tripeptidyl peptidase
WO2016069552A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
WO2016069569A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069548A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069544A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016100128A1 (en) 2014-12-19 2016-06-23 Danisco Us Inc Enhanced protein expression
WO2016106011A1 (en) 2014-12-23 2016-06-30 E. I. Du Pont De Nemours And Company Enzymatically produced cellulose
WO2016145428A1 (en) 2015-03-12 2016-09-15 Danisco Us Inc Compositions and methods comprising lg12-clade protease variants
WO2016201044A1 (en) 2015-06-09 2016-12-15 Danisco Us Inc Osmotic burst encapsulates
WO2016205755A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2016205710A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
WO2017079756A1 (en) 2015-11-05 2017-05-11 Danisco Us Inc Paenibacillus and bacillus spp. mannanases
WO2017079751A1 (en) 2015-11-05 2017-05-11 Danisco Us Inc Paenibacillus sp. mannanases
WO2017083229A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
WO2017083226A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
WO2017106676A1 (en) 2015-12-18 2017-06-22 Danisco Us Inc Polypeptides with endoglucanase activity and uses thereof
US9725685B2 (en) 2014-01-30 2017-08-08 The Procter & Gamble Company Unit dose article
WO2017152169A1 (en) 2016-03-04 2017-09-08 Danisco Us Inc. Engineered ribosomal promoters for protein production in microorganisms
WO2017192692A1 (en) 2016-05-03 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017210295A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
WO2017219011A1 (en) 2016-06-17 2017-12-21 Danisco Us Inc Protease variants and uses thereof
WO2018085524A2 (en) 2016-11-07 2018-05-11 Danisco Us Inc Laundry detergent composition
WO2018118917A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2018156705A1 (en) 2017-02-24 2018-08-30 Danisco Us Inc. Compositions and methods for increased protein production in bacillus licheniformis
WO2018169750A1 (en) 2017-03-15 2018-09-20 Danisco Us Inc Trypsin-like serine proteases and uses thereof
WO2018183662A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Delayed release enzyme formulations for bleach-containing detergents
WO2018184004A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Alpha-amylase combinatorial variants
WO2019006077A1 (en) 2017-06-30 2019-01-03 Danisco Us Inc Low-agglomeration, enzyme-containing particles
WO2019036721A2 (en) 2017-08-18 2019-02-21 Danisco Us Inc Alpha-amylase variants
WO2019040412A1 (en) 2017-08-23 2019-02-28 Danisco Us Inc Methods and compositions for efficient genetic modifications of bacillus licheniformis strains
WO2019055261A1 (en) 2017-09-13 2019-03-21 Danisco Us Inc Modified 5'-untranslated region (utr) sequences for increased protein production in bacillus
WO2019089898A1 (en) 2017-11-02 2019-05-09 Danisco Us Inc Freezing point depressed solid matrix compositions for melt granulation of enzymes
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019125683A1 (en) 2017-12-21 2019-06-27 Danisco Us Inc Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant
WO2019135868A1 (en) 2018-01-03 2019-07-11 Danisco Us Inc Mutant and genetically modified bacillus cells and methods thereof for increased protein production
WO2019245705A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3587569A1 (en) 2014-03-21 2020-01-01 Danisco US Inc. Serine proteases of bacillus species
WO2020028443A1 (en) 2018-07-31 2020-02-06 Danisco Us Inc Variant alpha-amylases having amino acid substitutions that lower the pka of the general acid
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2020047215A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Enzyme-containing granules
WO2020068486A1 (en) 2018-09-27 2020-04-02 Danisco Us Inc Compositions for medical instrument cleaning
WO2020077331A2 (en) 2018-10-12 2020-04-16 Danisco Us Inc Alpha-amylases with mutations that improve stability in the presence of chelants
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
US10683528B2 (en) 2014-12-16 2020-06-16 Danisco Us Inc Enhanced protein expression
EP3696264A1 (en) 2013-07-19 2020-08-19 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2020247582A1 (en) 2019-06-06 2020-12-10 Danisco Us Inc Methods and compositions for cleaning
WO2021080948A2 (en) 2019-10-24 2021-04-29 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2021146255A1 (en) 2020-01-13 2021-07-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2021146411A1 (en) 2020-01-15 2021-07-22 Danisco Us Inc Compositions and methods for enhanced protein production in bacillus licheniformis
EP3872174A1 (en) 2015-05-13 2021-09-01 Danisco US Inc. Aprl-clade protease variants and uses thereof
EP3901257A1 (en) 2015-12-09 2021-10-27 Danisco US Inc. Alpha-amylase combinatorial variants
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
WO2022165107A1 (en) 2021-01-29 2022-08-04 Danisco Us Inc Compositions for cleaning and methods related thereto
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023023644A1 (en) 2021-08-20 2023-02-23 Danisco Us Inc. Polynucleotides encoding novel nucleases, compositions thereof and methods thereof for eliminating dna from protein preparations
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
WO2023039270A2 (en) 2021-09-13 2023-03-16 Danisco Us Inc. Bioactive-containing granules
EP4163305A1 (en) 2013-12-16 2023-04-12 Nutrition & Biosciences USA 4, Inc. Use of poly alpha-1,3-glucan ethers as viscosity modifiers
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2023250301A1 (en) 2022-06-21 2023-12-28 Danisco Us Inc. Methods and compositions for cleaning comprising a polypeptide having thermolysin activity
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024050339A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Mannanase variants and methods of use
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto

Families Citing this family (427)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US5244791A (en) * 1984-05-29 1993-09-14 Genecor International, Inc. Methods of ester hydrolysis
US5155033A (en) * 1989-01-06 1992-10-13 Genencor, Inc. Subtilisins modified at position 225 resulting in a shift in catalytic activity
US5185258A (en) 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
US5182204A (en) * 1984-05-29 1993-01-26 Genencor International, Inc. Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors
US5371190A (en) * 1984-05-29 1994-12-06 Genencor International, Inc. Substrate assisted catalysis
US5371008A (en) * 1984-05-29 1994-12-06 Genencor International, Inc. Substrate assisted catalysis
US5352594A (en) * 1984-05-29 1994-10-04 Genecor, Inc. Selection and method of making enzymes for perhydrolysis system and for altering substrate specificity, specific activity and catalytic efficiency
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
WO1987004461A1 (en) * 1986-01-15 1987-07-30 Amgen THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US5013657A (en) * 1988-04-12 1991-05-07 Bryan Philip N Subtilisin mutations
US4990452A (en) * 1986-02-12 1991-02-05 Genex Corporation Combining mutations for stabilization of subtilisin
US4980288A (en) * 1986-02-12 1990-12-25 Genex Corporation Subtilisin with increased thermal stability
DE3788592T2 (en) * 1986-05-07 1994-04-28 Eniricerche Spa Plasmid vector for expression in the bacillus, its application for the cloning of the human growth hormone gene and method for the production of the hormone.
US4960700A (en) * 1986-12-24 1990-10-02 Genentech, Inc. Compositions and methods for the synthesis and assay of a mammalian enkephalinase
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US5260207A (en) * 1987-04-06 1993-11-09 Enzon Labs Inc. Engineering of electrostatic interactions at metal ion binding sites for the stabilization of proteins
US4914031A (en) * 1987-04-10 1990-04-03 Amgen, Inc. Subtilisin analogs
DK571587D0 (en) * 1987-11-02 1987-11-02 Novo Industri As ENZYMATIC DETERGENT COMPOSITION
DK6488D0 (en) * 1988-01-07 1988-01-07 Novo Industri As ENZYMES
CN1056187C (en) * 1988-02-11 2000-09-06 金克克国际有限公司 Proteolytic enzymes and their use in detergents
US5324653A (en) * 1988-02-11 1994-06-28 Gist-Brocades N.V. Recombinant genetic means for the production of serine protease muteins
US5116741A (en) * 1988-04-12 1992-05-26 Genex Corporation Biosynthetic uses of thermostable proteases
US5246849A (en) * 1988-04-12 1993-09-21 Enzon, Inc. Thermally stable serine proteases
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
US5238831A (en) * 1989-04-28 1993-08-24 Gist-Brocades Stabilization of carboxyl esterase
AU618675B2 (en) * 1989-05-17 1992-01-02 Amgen, Inc. Multiply mutated subtilisins
DK316989D0 (en) * 1989-06-26 1989-06-26 Novo Nordisk As ENZYMES
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
DE69033388T2 (en) * 1989-08-25 2000-05-11 Henkel Research Corp ALKALINE PROTEOLYTIC ENZYME AND METHOD FOR PRODUCING THE SAME
US5352603A (en) * 1989-08-31 1994-10-04 Kali-Chemie Ag Highly alkaline proteases
JP3022984B2 (en) * 1989-11-28 2000-03-21 サントリー株式会社 Bacterial collagenase gene
JPH0817701B2 (en) * 1990-03-23 1996-02-28 キッコーマン株式会社 Alkaline protease, alkaline protease gene, novel recombinant DNA, method for producing alkaline protease, and DNA fragment for gene expression
JP3362847B2 (en) * 1990-08-09 2003-01-07 ジェネンテック インコーポレイテッド Serine protease variants with peptide ligase activity
US5629173A (en) * 1990-08-09 1997-05-13 Genentech, Inc. Methods of use of serine protease variants having peptide ligase activity
DK271490D0 (en) * 1990-11-14 1990-11-14 Novo Nordisk As detergent composition
US5733473A (en) * 1990-11-14 1998-03-31 The Procter & Gamble Company Liquid detergent composition containing lipase and protease
EP0486073B1 (en) * 1990-11-14 1996-07-24 The Procter & Gamble Company Liquid detergent composition containing lipase and protease
US5863783A (en) * 1991-03-27 1999-01-26 Gist-Brocades, N.V. Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin
US5340735A (en) * 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
US5646028A (en) * 1991-06-18 1997-07-08 The Clorox Company Alkaline serine protease streptomyces griseus var. alkaliphus having enhanced stability against urea or guanidine
EP0995801A1 (en) * 1991-07-27 2000-04-26 Genencor International GmbH Process for increasing the stability of enzymes and stabilized enzymes
SK43094A3 (en) * 1991-10-16 1994-09-07 Unilever Nv Aqueous enzymatic detergent compositions
US6300122B1 (en) 1991-12-20 2001-10-09 Genencor International Method for applying enzyme to non-finished cellulosic-containing fabrics to improve appearance and feel characteristics
US5316935A (en) * 1992-04-06 1994-05-31 California Institute Of Technology Subtilisin variants suitable for hydrolysis and synthesis in organic media
US6251144B1 (en) 1992-06-12 2001-06-26 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric and garments
GB9220669D0 (en) * 1992-09-30 1992-11-11 Unilever Plc Detergent composition
US5989887A (en) * 1992-11-25 1999-11-23 Dsm N.V. Cloning and expression of DNA molecules incoding arabinan-degrading enzymes of fungal origin
PL310326A1 (en) 1993-02-11 1995-12-11 Genencor Int Novel oxidation-stable mutants of alpha-amylase as well as detergent and starch liquefaction compositions containing them
DK39093D0 (en) * 1993-04-01 1993-04-01 Novo Nordisk As ENZYME
DE69331531T2 (en) * 1993-06-11 2002-07-11 Genencor Int ENZYMATIC METHOD AND USE OF ENZYMES FOR GENERATING STONEWASH APPEARANCE ON INDIGO-DYED FABRIC
EP1707624A3 (en) 1993-10-08 2007-01-03 Novozymes A/S Amylase variants
US5932532A (en) * 1993-10-14 1999-08-03 Procter & Gamble Company Bleach compositions comprising protease enzyme
DK1921148T3 (en) 1994-02-24 2011-09-26 Henkel Ag & Co Kgaa Enhanced enzymes and detergents containing these
ES2364776T3 (en) 1994-02-24 2011-09-14 HENKEL AG &amp; CO. KGAA IMPROVED AND DETERGENT ENZYMES THAT CONTAIN THEM.
AR000862A1 (en) 1995-02-03 1997-08-06 Novozymes As VARIANTS OF A MOTHER-AMYLASE, A METHOD TO PRODUCE THE SAME, A DNA STRUCTURE AND A VECTOR OF EXPRESSION, A CELL TRANSFORMED BY SUCH A DNA STRUCTURE AND VECTOR, A DETERGENT ADDITIVE, DETERGENT COMPOSITION, A COMPOSITION FOR AND A COMPOSITION FOR THE ELIMINATION OF
US5780285A (en) * 1995-03-03 1998-07-14 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing dibasic residues
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
KR19980702782A (en) * 1995-03-09 1998-08-05 혼 마가렛 에이. Starch Liquefaction Method
US6475765B1 (en) 1995-03-09 2002-11-05 Procter & Gamble Company Subtilisin DY variants having decreased adsorption and increased hydrolysis
DE19530816A1 (en) 1995-08-23 1997-02-27 Cognis Bio Umwelt Use of mutant subtilisin protease in cosmetic products
US5795761A (en) * 1996-01-11 1998-08-18 Rutgers, The State University Of New Jersey Mutants of 2,5-diketo-D-gluconic acid (2,5-DKG) reductase A
AU2692897A (en) 1996-04-30 1997-11-19 Novo Nordisk A/S Alpha-amylase mutants
US5817490A (en) * 1996-05-17 1998-10-06 Eastman Chemical Company Enzymatic process for the manufacture of ascorbic acid 2-keto-L-gulonic acid and esters of 2-keto-L-gulonic acid
US6385546B1 (en) 1996-11-15 2002-05-07 Rutgers, The University Of New Jersey Stabilizing and destabilizing proteins
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
GB9719637D0 (en) * 1997-09-15 1997-11-19 Genencor Int Bv Proteases from gram-positive organisms
US6300117B1 (en) * 1997-09-15 2001-10-09 Genencor International, Inc. Proteases from gram-positive organisms
ES2436066T3 (en) 1997-10-13 2013-12-26 Novozymes A/S Alpha-amylase mutants
DK1037968T4 (en) 1997-12-20 2014-03-10 Genencor Int Matrixgranule
WO1999032612A1 (en) 1997-12-20 1999-07-01 Genencor International, Inc. Fluidized bed matrix granule
AU2089499A (en) 1997-12-20 1999-07-12 Genencor International, Inc. Accelerated stability test
ES2276482T3 (en) 1997-12-20 2007-06-16 Genencor International, Inc. Granule with hydrated barrier material.
EP1042501B2 (en) * 1997-12-24 2011-03-30 Genencor International, Inc. Method for assaying the wash performance of an enzyme.
DE69942995D1 (en) 1998-02-27 2011-01-13 Novozymes As MALTOGENIC ALPHA-AMYLASE VARIANTS
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
KR20010034697A (en) 1998-03-26 2001-04-25 데이비드 엠 모이어 Serine protease variants having amino acid substitutions
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6642011B2 (en) 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
AU1240900A (en) 1998-10-27 2000-05-15 Genencor International, Inc. Matrix granule
AU1622300A (en) 1998-11-13 2000-06-05 Douglas A. Dale Fluidized bed low density granule
DK2290059T3 (en) 1998-11-27 2016-02-22 Novozymes As Lipolytic enzyme VERSIONS
US6579841B1 (en) 1998-12-18 2003-06-17 Genencor International, Inc. Variant EGIII-like cellulase compositions
WO2000040689A2 (en) 1999-01-08 2000-07-13 Genencor International, Inc. Low-density compositions and particulates including same
CN1252256C (en) 1999-03-30 2006-04-19 诺维信公司 Alpha-amylase variants
CN1234854C (en) 1999-03-31 2006-01-04 诺维信公司 Polypeptides having alkaline alpha-amylase activity and uncleic acids encoding same
JP4750284B2 (en) 1999-03-31 2011-08-17 ノボザイムス アクティーゼルスカブ Polypeptides having alkaline α-amylase activity and nucleic acids encoding them
AU5279100A (en) * 1999-05-19 2000-12-05 Midwest Research Institute E1 endoglucanase variants y245g, y82r and w42r
CA2374009A1 (en) 1999-07-09 2001-01-18 Novozymes A/S Glucoamylase variant
CZ2002171A3 (en) 1999-07-22 2002-06-12 The Procter & Gamble Company Proteinase conjugate, cleansing agent and preparation for personal hygiene
AU5928100A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
CZ2002212A3 (en) 1999-07-22 2002-07-17 The Procter & Gamble Company Variants of subtilisin protease having amino acid substitutions in defined epitope regions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
WO2001016285A2 (en) 1999-08-31 2001-03-08 Novozymes A/S Novel proteases and variants thereof
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
US20030039659A1 (en) * 1999-09-24 2003-02-27 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
CA2387511A1 (en) 1999-10-15 2001-04-26 Genencor International, Inc. Protein-containing granules and granule formulations
EP1980614A3 (en) 1999-11-10 2009-04-08 Novozymes A/S Fungamyl-like Alpha-Amylase Variants
US6350599B1 (en) 2000-01-12 2002-02-26 Novozymes A/S Pullulanase variants and methods for preparing such variants with predetermined properties
DK1360500T3 (en) * 2000-04-14 2010-05-25 Genencor Int Selective targeting method
US7129326B2 (en) * 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
WO2002010183A1 (en) * 2000-07-31 2002-02-07 Menzel, Rolf Compositions and methods for directed gene assembly
CA2702204C (en) 2000-08-01 2011-09-06 Novozymes A/S Alpha-amylase mutants with altered properties
US6623949B1 (en) * 2000-08-04 2003-09-23 Genencor International, Inc. Variant EGIII-like cellulase compositions
US6635465B1 (en) 2000-08-04 2003-10-21 Genencor International, Inc. Mutant EGIII cellulase, DNA encoding such EGIII compositions and methods for obtaining same
US6541234B1 (en) * 2000-09-11 2003-04-01 University Of Maryland Biotechnology Institute Calcium free subtilisin mutants
US20030206896A1 (en) * 2000-09-13 2003-11-06 O'prey Conor James Cosmetic method
US6541235B1 (en) * 2000-09-29 2003-04-01 University Of Maryland Biotechnology Institute Calcium free subtilisin mutants
EP1975229A3 (en) 2000-10-13 2009-03-18 Novozymes A/S Alpha-amylase variant with altered properties
US6803222B2 (en) * 2000-11-22 2004-10-12 Kao Corporation Alkaline proteases
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US8076113B2 (en) 2001-04-02 2011-12-13 Danisco Us Inc. Method for producing granules with reduced dust potential comprising an antifoam agent
KR20080113283A (en) * 2001-04-04 2008-12-29 제넨코 인터내셔날 인코포레이티드 Methods for the production of products in host cells
ATE421577T1 (en) * 2001-04-04 2009-02-15 Genencor Int UNCOUPLED ANABOLIC AND CATABOLIC METABOLIC PATHWAYS IN HOST CELLS
DE10121463A1 (en) * 2001-05-02 2003-02-27 Henkel Kgaa New alkaline protease variants and washing and cleaning agents containing these new alkaline protease variants
AU2002254876A1 (en) 2001-05-15 2002-11-25 Novozymes A/S Alpha-amylase variant with altered properties
AU2002344842A1 (en) * 2001-06-22 2003-01-08 Genencor International, Inc. Highly impact-resistant granules
DE10153792A1 (en) * 2001-10-31 2003-05-22 Henkel Kgaa New alkaline protease variants and washing and cleaning agents containing these new alkaline protease variants
AU2002353178C1 (en) * 2001-12-31 2011-02-03 Genencor International, Inc. Proteases producing an altered immunological response and methods of making and using the same
CA2795814A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunogenic response and methods of making and using the same
ATE457352T1 (en) * 2002-02-26 2010-02-15 Genencor Int SUBTILISIN CARLSBERG PROTEINS WITH REDUCED IMMUNOGENICITY
ATE378595T1 (en) * 2002-02-26 2007-11-15 Genencor Int POPULATION-BASED ASSESSMENTS AND MEANS FOR DETERMINING THE RANKING OF THE RELATIVE IMMUNOGENICITY OF PROTEINS
WO2004033421A2 (en) * 2002-10-04 2004-04-22 Genencor International, Inc. Improved production of bacterial strains
EP2431048B1 (en) 2002-10-08 2015-03-11 Danisco US Inc. Phenolic binding peptides
ATE393816T1 (en) * 2002-12-24 2008-05-15 Genencor Int PLASTICIZED, MECHANICALLY STABLE, ROBUST GRANULES
DE602004031589D1 (en) 2003-01-07 2011-04-14 Dyax Corp Kunitz DOMAIN LIBRARY
US20070025974A1 (en) * 2003-02-26 2007-02-01 Hardings Fiona A Amylases producing an altered immunogenic response and methods of making and using the same
AU2003213273A1 (en) 2003-02-26 2004-09-28 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
US20070213518A1 (en) * 2003-05-12 2007-09-13 Jones Brian E Novel Lipolytic Enzyme Lip2
WO2004101760A2 (en) * 2003-05-12 2004-11-25 Genencor International, Inc. Novel lipolytic enzyme elip
EP1625202A4 (en) * 2003-05-12 2010-10-20 Genencor Int Novel lipolytic enzyme lip1
EP1625211B1 (en) * 2003-05-22 2014-11-19 Danisco US Inc. Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters
US7883883B2 (en) 2003-06-25 2011-02-08 Novozymes A/S Enzymes for starch processing
CA2533936C (en) 2003-07-30 2013-09-10 Genencor International, Inc. Metabolically engineered bacterial strains having enhanced 2-keto-d-gluconate accumulation
BRPI0509671A (en) * 2004-04-08 2007-10-30 Genencor Internation Inc mutant alpha-amylases
JP2007532114A (en) * 2004-04-09 2007-11-15 ジェネンコー・インターナショナル・インク PckA modification and enhanced protein expression in Bacillus
WO2005119259A2 (en) * 2004-04-26 2005-12-15 Genencor International, Inc. Population based prediction methods for immune response determinations and methods for verifying immunological response data
US20090060933A1 (en) * 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
CN113549606A (en) 2004-07-05 2021-10-26 诺维信公司 Alpha-amylase variants with altered properties
DK1926753T3 (en) 2004-12-22 2011-03-14 Novozymes As Hybrid enzymes consisting of an endoamylase as first amino acid sequence and a carbohydrate binding module as second amino acid sequence
MX2007007107A (en) 2004-12-22 2007-08-08 Novozymes North America Inc Polypeptides having glucoamylase activity and polynucleotides encoding same.
EP2314668B1 (en) * 2005-04-12 2016-11-09 Danisco US Inc. Gene inactivated mutants with altered protein production
WO2007010603A1 (en) * 2005-07-20 2007-01-25 Nissin Dental Products Inc. Multilayered model tooth for dental training
US20080280328A1 (en) 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
US7629158B2 (en) * 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
US20080299622A1 (en) * 2007-02-07 2008-12-04 Paulson Bradley A Starch Hydrolysis Using Phytase with an Alpha Amylase
RU2009137386A (en) * 2007-03-09 2011-04-20 ДАНИСКО ЮЭс ИНК., ДЖЕНЕНКОР ДИВИЖН (US) AMILASE VARIANTS OF BACILLUS ALKALYPHIC SPECIES, COMPOSITIONS CONTAINING AMILASE OPTIONS AND METHODS OF APPLICATION
ES2519466T3 (en) 2007-03-09 2014-11-07 Novozymes A/S Thermostable asparagininases
US8021436B2 (en) 2007-09-27 2011-09-20 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a xyloglucan conjugate
CA2702949C (en) 2007-10-18 2017-04-04 Danisco Us Inc. Enzyme blends for fermentation
CN101883841A (en) * 2007-11-05 2010-11-10 丹尼斯科美国公司 The variant of bacillus licheniformis alpha-amylase with Ca-dependent of enhanced thermostability and/or minimizing
JP5520828B2 (en) * 2007-11-05 2014-06-11 ダニスコ・ユーエス・インク Bacillus sp. TS-23 alpha-amylase variants with altered characteristics
KR20100085964A (en) * 2007-11-05 2010-07-29 다니스코 유에스 인크. Alpha-amylase variants with altered properties
WO2009100102A2 (en) 2008-02-04 2009-08-13 Danisco Us Inc., Genencor Division Ts23 alpha-amylase variants with altered properties
CA2714277A1 (en) * 2008-02-06 2009-08-13 Danisco Us Inc. Ph adjustment free system for producing fermentable sugars and alcohol
US20110065163A1 (en) 2008-02-14 2011-03-17 Becker Nathaniel T Small Enzyme-Containing Granules
US20090209447A1 (en) * 2008-02-15 2009-08-20 Michelle Meek Cleaning compositions
AR070498A1 (en) * 2008-02-29 2010-04-07 Procter & Gamble DETERGENT COMPOSITION THAT LIPASA INCLUDES
AR070497A1 (en) * 2008-02-29 2010-04-07 Procter & Gamble DETERGENT COMPOSITION THAT LIPASA INCLUDES
US8354256B2 (en) 2008-03-11 2013-01-15 Danisco Us Inc. Glucoamylase and Buttiauxiella phytase during saccharification
EP2100947A1 (en) 2008-03-14 2009-09-16 The Procter and Gamble Company Automatic dishwashing detergent composition
EP2100948A1 (en) * 2008-03-14 2009-09-16 The Procter and Gamble Company Automatic dishwashing detergent composition
US20090233830A1 (en) 2008-03-14 2009-09-17 Penny Sue Dirr Automatic detergent dishwashing composition
MX2010010310A (en) * 2008-03-28 2010-10-08 Danisco Us Inc Method for amplifying locus in bacterial cell.
US20090253173A1 (en) * 2008-04-08 2009-10-08 Danisco Us Inc., Genencor Division Filamentous fungi with inactivated protease genes for altered protein production
CA2723164A1 (en) * 2008-04-30 2009-11-05 Danisco Us Inc. Enhanced fermentation process using molasses
CA2725737A1 (en) * 2008-05-29 2009-12-10 Danisco Us Inc. Process for alcohol and co-product production from grain sorghum
EP2166092A1 (en) 2008-09-18 2010-03-24 The Procter and Gamble Company Detergent composition
EP2166075A1 (en) * 2008-09-23 2010-03-24 The Procter and Gamble Company Cleaning composition
EP2166073A1 (en) * 2008-09-23 2010-03-24 The Procter & Gamble Company Cleaning composition
EP2166076A1 (en) * 2008-09-23 2010-03-24 The Procter & Gamble Company Cleaning composition
CA2738447C (en) 2008-09-25 2019-01-08 Danisco Us Inc. Alpha-amylase blends and methods for using said blends
US20100267304A1 (en) * 2008-11-14 2010-10-21 Gregory Fowler Polyurethane foam pad and methods of making and using same
US20100125046A1 (en) 2008-11-20 2010-05-20 Denome Frank William Cleaning products
PL2213713T3 (en) 2009-02-02 2014-07-31 Procter & Gamble Liquid hand dishwashing detergent composition
EP3023483A1 (en) 2009-02-02 2016-05-25 The Procter and Gamble Company Liquid hand diswashing detergent composition
ES2488117T3 (en) 2009-02-02 2014-08-26 The Procter & Gamble Company Liquid detergent composition for dishwashing by hand
EP2216391A1 (en) 2009-02-02 2010-08-11 The Procter & Gamble Company Liquid hand dishwashing detergent composition
EP2216392B1 (en) * 2009-02-02 2013-11-13 The Procter and Gamble Company Liquid hand dishwashing detergent composition
EP2216390B1 (en) 2009-02-02 2013-11-27 The Procter and Gamble Company Hand dishwashing method
GB0901966D0 (en) 2009-02-05 2009-03-11 Danisco Composition
EP2216393A1 (en) 2009-02-09 2010-08-11 The Procter & Gamble Company Detergent composition
WO2010132540A2 (en) * 2009-05-12 2010-11-18 Danisco Us Inc. Ethanol yields in fermentation from an improved liquefaction process
WO2011005804A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company Method of laundering fabric using a liquid laundry detergent composition
EP2451922A1 (en) 2009-07-09 2012-05-16 The Procter & Gamble Company Method of laundering fabric using a compacted liquid laundry detergent composition
MX342487B (en) 2009-07-09 2016-09-29 The Procter & Gamble Company * A mildly alkaline, low-built, solid fabric treatment detergent composition comprising phthalimido peroxy caproic acid.
WO2011005913A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company A catalytic laundry detergent composition comprising relatively low levels of water-soluble electrolyte
EP2451923A1 (en) 2009-07-09 2012-05-16 The Procter & Gamble Company Method of laundering fabric using a liquid laundry detergent composition
BR112012000520A2 (en) 2009-07-09 2016-02-16 Procter & Gamble laundry detergent catalyst composition comprising relatively low levels of water-soluble electrolyte
EP2292725B2 (en) 2009-08-13 2022-08-24 The Procter & Gamble Company Method of laundering fabrics at low temperature
CA2782613C (en) 2009-12-09 2016-08-23 The Procter & Gamble Company Fabric and home care products
EP2333040B2 (en) 2009-12-10 2019-11-13 The Procter & Gamble Company Detergent composition
ES2422593T3 (en) 2009-12-10 2013-09-12 Procter & Gamble Method and use of a dishwasher composition
EP2333039B2 (en) 2009-12-10 2020-11-11 The Procter & Gamble Company Method and use of a dishwasher composition
PL2333042T3 (en) 2009-12-10 2015-12-31 Procter & Gamble Automatic dishwashing product and use thereof
WO2011076897A1 (en) 2009-12-22 2011-06-30 Novozymes A/S Use of amylase variants at low temperature
MX2012007709A (en) 2010-01-04 2012-08-15 Novozymes As Alpha-amylase variants and polynucleotides encoding same.
CN102869759B (en) 2010-02-10 2015-07-15 诺维信公司 Variants and compositions comprising variants with high stability in presence of a chelating agent
EP2357220A1 (en) 2010-02-10 2011-08-17 The Procter & Gamble Company Cleaning composition comprising amylase variants with high stability in the presence of a chelating agent
ES2401126T3 (en) 2010-02-25 2013-04-17 The Procter & Gamble Company Detergent composition
EP2365059A1 (en) 2010-03-01 2011-09-14 The Procter & Gamble Company Solid laundry detergent composition comprising C.I. fluorescent brightener 260 in alpha-crystalline form
EP2365054A1 (en) 2010-03-01 2011-09-14 The Procter & Gamble Company Solid laundry detergent composition comprising secondary alcohol-based detersive surfactant
EP2363456A1 (en) 2010-03-01 2011-09-07 The Procter & Gamble Company Solid laundry detergent composition comprising brightener in micronized particulate form
EP2377914B1 (en) 2010-04-19 2016-11-09 The Procter & Gamble Company Mildly alkaline, low-built, solid fabric treatment detergent composition comprising perhydrolase
EP2380957A1 (en) 2010-04-19 2011-10-26 The Procter & Gamble Company Solid laundry detergent composition having a dynamic in-wash ph profile
EP2365058A1 (en) 2010-03-01 2011-09-14 The Procter & Gamble Company Solid laundry detergent composition having an excellent anti-encrustation profile
US20120067373A1 (en) 2010-04-15 2012-03-22 Philip Frank Souter Automatic Dishwashing Detergent Composition
US8889612B2 (en) 2010-04-19 2014-11-18 The Procter & Gamble Company Method of laundering fabric using a compacted liquid laundry detergent composition
US20110257060A1 (en) 2010-04-19 2011-10-20 Robert Richard Dykstra Laundry detergent composition comprising bleach particles that are suspended within a continuous liquid phase
US20110257069A1 (en) 2010-04-19 2011-10-20 Stephen Joseph Hodson Detergent composition
US20110257062A1 (en) 2010-04-19 2011-10-20 Robert Richard Dykstra Liquid laundry detergent composition comprising a source of peracid and having a ph profile that is controlled with respect to the pka of the source of peracid
EP2380481B1 (en) 2010-04-23 2014-12-31 The Procter and Gamble Company Automatic dishwashing product
EP2380478A1 (en) 2010-04-23 2011-10-26 The Procter & Gamble Company Automatic dishwashing product
EP2380962B1 (en) 2010-04-23 2016-03-30 The Procter and Gamble Company Particle
ES2682051T3 (en) 2010-04-23 2018-09-18 The Procter & Gamble Company Detergent composition
EP2383329A1 (en) 2010-04-23 2011-11-02 The Procter & Gamble Company Particle
PL2380963T3 (en) 2010-04-23 2016-07-29 Procter & Gamble Method of perfuming
EP2395070A1 (en) 2010-06-10 2011-12-14 The Procter & Gamble Company Liquid laundry detergent composition comprising lipase of bacterial origin
EP2395071A1 (en) 2010-06-10 2011-12-14 The Procter & Gamble Company Solid detergent composition comprising lipase of bacterial origin
EP2585573A1 (en) 2010-06-23 2013-05-01 The Procter and Gamble Company Product for pre-treatment and laundering of stained fabric
EP2412792A1 (en) 2010-07-29 2012-02-01 The Procter & Gamble Company Liquid detergent composition
US8685171B2 (en) 2010-07-29 2014-04-01 The Procter & Gamble Company Liquid detergent composition
WO2012019169A1 (en) 2010-08-06 2012-02-09 Danisco Us Inc. Production of isoprene under neutral ph conditions
US20120034659A1 (en) 2010-08-06 2012-02-09 Danisco Us Inc. NEUTRAL pH SACCHARIFICATION AND FERMENTATION
WO2011026154A2 (en) 2010-10-29 2011-03-03 The Procter & Gamble Company Cleaning and/or treatment compositions
WO2012057781A1 (en) 2010-10-29 2012-05-03 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a fungal serine protease
US20140371435A9 (en) 2011-06-03 2014-12-18 Eduardo Torres Laundry Care Compositions Containing Thiophene Azo Dyes
EP2537918A1 (en) 2011-06-20 2012-12-26 The Procter & Gamble Company Consumer products with lipase comprising coated particles
US20120324655A1 (en) 2011-06-23 2012-12-27 Nalini Chawla Product for pre-treatment and laundering of stained fabric
EP2540824A1 (en) 2011-06-30 2013-01-02 The Procter & Gamble Company Cleaning compositions comprising amylase variants reference to a sequence listing
EP2551335A1 (en) 2011-07-25 2013-01-30 The Procter & Gamble Company Enzyme stabilized liquid detergent composition
MX2014001098A (en) 2011-07-27 2014-09-12 Procter & Gamble Multiphase liquid detergent composition.
EP2739742A1 (en) 2011-08-05 2014-06-11 Danisco US Inc. PRODUCTION OF ISOPRENOIDS UNDER NEUTRAL pH CONDITIONS
PL2584028T3 (en) 2011-10-19 2017-10-31 Procter & Gamble Particle
PL2623586T3 (en) 2012-02-03 2018-01-31 Procter & Gamble Compositions and methods for surface treatment with lipases
EP2828340A1 (en) 2012-03-19 2015-01-28 The Procter & Gamble Company Laundry care compositions containing dyes
US9909109B2 (en) 2012-04-02 2018-03-06 Novozymes A/S Lipase variants and polynucleotides encoding same
EP2674475A1 (en) 2012-06-11 2013-12-18 The Procter & Gamble Company Detergent composition
MX2015000312A (en) 2012-07-12 2015-04-10 Novozymes As Polypeptides having lipase activity and polynucleotides encoding same.
EP2712915A1 (en) 2012-10-01 2014-04-02 The Procter and Gamble Company Methods of treating a surface and compositions for use therein
WO2014100100A1 (en) 2012-12-20 2014-06-26 The Procter & Gamble Company Detergent composition with silicate coated bleach
HUE052331T2 (en) 2013-02-19 2021-04-28 Procter & Gamble Method of laundering a fabric
EP2767579B1 (en) 2013-02-19 2018-07-18 The Procter and Gamble Company Method of laundering a fabric
EP2767582A1 (en) 2013-02-19 2014-08-20 The Procter and Gamble Company Method of laundering a fabric
CN105026539A (en) 2013-03-05 2015-11-04 宝洁公司 Mixed sugar compositions
WO2014143773A1 (en) 2013-03-15 2014-09-18 Lubrizol Advanced Materials, Inc. Itaconic acid polymers
CN105051174B (en) 2013-03-21 2018-04-03 诺维信公司 Polypeptide and their polynucleotides of coding with lipase active
CN105102600A (en) 2013-03-28 2015-11-25 宝洁公司 Cleaning compositions containing polyetheramine, soil release polymer, and carboxymethylcellulose
EP2796556A1 (en) 2013-04-25 2014-10-29 Rijksuniversiteit Groningen Improved means and methods for expressing recombinant proteins
CN105229116A (en) 2013-05-28 2016-01-06 宝洁公司 Comprise the surface treating composition of photochromic dyes
WO2015042086A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care composition comprising carboxylate dye
CA2921433A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care composition comprising carboxylate dye
US9834682B2 (en) 2013-09-18 2017-12-05 Milliken & Company Laundry care composition comprising carboxylate dye
AR098668A1 (en) 2013-09-18 2016-06-08 Procter & Gamble COMPOSITIONS CONTAINING COLORS FOR CLOTHING CARE
WO2015042013A1 (en) 2013-09-18 2015-03-26 Lubrizol Advanced Materials, Inc. Stable linear polymers
EP2857485A1 (en) 2013-10-07 2015-04-08 WeylChem Switzerland AG Multi-compartment pouch comprising alkanolamine-free cleaning compositions, washing process and use for washing and cleaning of textiles and dishes
EP2857486A1 (en) 2013-10-07 2015-04-08 WeylChem Switzerland AG Multi-compartment pouch comprising cleaning compositions, washing process and use for washing and cleaning of textiles and dishes
EP2857487A1 (en) 2013-10-07 2015-04-08 WeylChem Switzerland AG Multi-compartment pouch comprising cleaning compositions, washing process and use for washing and cleaning of textiles and dishes
WO2015112339A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Fabric treatment composition
WO2015112340A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Method of treating textile fabrics
EP3097175B1 (en) 2014-01-22 2018-10-17 The Procter and Gamble Company Fabric treatment composition
EP3097172A1 (en) 2014-01-22 2016-11-30 The Procter & Gamble Company Method of treating textile fabrics
US10752562B2 (en) 2014-02-25 2020-08-25 The Procter & Gamble Company Process for making renewable surfactant intermediates and surfactants from fats and oils and products thereof
WO2015130669A1 (en) 2014-02-25 2015-09-03 The Procter & Gamble Company A process for making renewable surfactant intermediates and surfactants from fats and oils and products thereof
US9719050B2 (en) 2014-02-26 2017-08-01 The Procter & Gamble Company Anti-foam compositions comprising an organomodified silicone comprising one or more 2-phenylpropylmethyl moieties
EP3116924B1 (en) 2014-03-14 2020-08-19 Lubrizol Advanced Materials, Inc. Itaconic acid polymers and copolymers
EP3122850A1 (en) 2014-03-27 2017-02-01 The Procter & Gamble Company Cleaning compositions containing a polyetheramine
CA2941253A1 (en) 2014-03-27 2015-10-01 Frank Hulskotter Cleaning compositions containing a polyetheramine
EP2924105A1 (en) 2014-03-28 2015-09-30 The Procter and Gamble Company Water soluble unit dose article
EP2924108A1 (en) 2014-03-28 2015-09-30 The Procter and Gamble Company Water soluble unit dose article
JP2017511148A (en) 2014-04-17 2017-04-20 ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Recombinant host cells modified to overexpress helper proteins
JP2017511147A (en) 2014-04-17 2017-04-20 ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Recombinant host cell for expressing the target protein
MX2016014383A (en) 2014-05-06 2017-01-20 Milliken & Co Laundry care compositions.
WO2015187757A1 (en) 2014-06-06 2015-12-10 The Procter & Gamble Company Detergent composition comprising polyalkyleneimine polymers
EP2987848A1 (en) 2014-08-19 2016-02-24 The Procter & Gamble Company Method of laundering a fabric
EP2987849A1 (en) 2014-08-19 2016-02-24 The Procter and Gamble Company Method of Laundering a Fabric
RU2691100C9 (en) 2014-09-10 2019-10-11 Басф Се Encapsulated cleaning composition
US9617502B2 (en) 2014-09-15 2017-04-11 The Procter & Gamble Company Detergent compositions containing salts of polyetheramines and polymeric acid
US20160090552A1 (en) 2014-09-25 2016-03-31 The Procter & Gamble Company Detergent compositions containing a polyetheramine and an anionic soil release polymer
CN107075423A (en) 2014-09-25 2017-08-18 宝洁公司 Cleasing compositions comprising polyetheramine
US9388368B2 (en) 2014-09-26 2016-07-12 The Procter & Gamble Company Cleaning compositions containing a polyetheramine
CA2967658A1 (en) 2014-11-17 2016-05-26 The Procter & Gamble Company Benefit agent delivery compositions
KR20170116159A (en) 2015-02-19 2017-10-18 다니스코 유에스 인크. Improved protein expression
EP3674387A1 (en) 2015-04-29 2020-07-01 The Procter & Gamble Company Method of treating a fabric
US20160319224A1 (en) 2015-04-29 2016-11-03 The Procter & Gamble Company Method of treating a fabric
DK3088502T3 (en) 2015-04-29 2018-08-13 Procter & Gamble PROCEDURE FOR TREATING A TEXTILE SUBSTANCE
CN107624127A (en) 2015-04-29 2018-01-23 宝洁公司 The method for handling fabric
ES2682178T3 (en) 2015-04-29 2018-09-19 The Procter & Gamble Company Detergent composition
JP6866302B2 (en) 2015-05-04 2021-04-28 ミリケン・アンド・カンパニーMilliken & Company Leukotriphenylmethane dye as a bluish agent in laundry care compositions
TR201906836T4 (en) 2015-06-02 2019-05-21 Unilever Nv Laundry detergent composition.
US10941372B2 (en) 2015-06-11 2021-03-09 Conopco, Inc. Laundry detergent composition
WO2016206837A1 (en) 2015-06-26 2016-12-29 Unilever Plc Laundry detergent composition
AU2016326867B2 (en) 2015-09-22 2018-09-13 F. Hoffmann-La Roche Ag OmpG variants
EP3205393A1 (en) 2016-02-12 2017-08-16 Basf Se Process for preparation of microcapsules
EP3205392A1 (en) 2016-02-12 2017-08-16 Basf Se Microcapsules and process for preparation of microcapsules
CN108603140B (en) 2016-02-17 2020-09-08 荷兰联合利华有限公司 Whitening composition
WO2017140391A1 (en) 2016-02-17 2017-08-24 Unilever Plc Whitening composition
EP3929283A1 (en) 2016-02-29 2021-12-29 Genia Technologies, Inc. Polymerase variants
CN109477038A (en) 2016-03-09 2019-03-15 巴斯夫欧洲公司 Capsule type laundry cleaning compositions
CN108884415A (en) 2016-03-21 2018-11-23 荷兰联合利华有限公司 Laundry detergent composition
BR112018070468B1 (en) 2016-04-08 2022-07-12 Unilever Ip Holdings B.V AQUEOUS LIQUID DETERGENT COMPOSITION FOR WASHING CLOTHES AND DOMESTIC FABRIC TREATMENT METHOD
WO2017182295A1 (en) 2016-04-18 2017-10-26 Basf Se Liquid cleaning compositions
EP3275985A1 (en) 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275988B1 (en) 2016-07-26 2020-07-08 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275986B1 (en) 2016-07-26 2020-07-08 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275987A1 (en) 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275989A1 (en) 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
US20180119065A1 (en) 2016-11-01 2018-05-03 The Procter & Gamble Company Leuco colorants as bluing agents in laundry care compositions
EP3535319A1 (en) 2016-11-01 2019-09-11 Milliken & Company Leuco colorants as bluing agents in laundry care compositions
WO2018085315A1 (en) 2016-11-01 2018-05-11 The Procter & Gamble Company Leuco colorants as bluing agents in laundry care compositions, packaging, kits and methods thereof
US20180119056A1 (en) 2016-11-03 2018-05-03 Milliken & Company Leuco Triphenylmethane Colorants As Bluing Agents in Laundry Care Compositions
WO2018093752A1 (en) 2016-11-15 2018-05-24 Danisco Us Inc. Filamentous fungi with improved protein production
JP6907318B2 (en) 2016-12-02 2021-07-21 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company Cleaning composition containing enzymes
US10550443B2 (en) 2016-12-02 2020-02-04 The Procter & Gamble Company Cleaning compositions including enzymes
CN110023476B (en) 2016-12-02 2021-07-06 宝洁公司 Cleaning compositions comprising enzymes
EP3555255B1 (en) 2016-12-15 2020-06-24 Unilever PLC Laundry detergent composition
EP3339423A1 (en) 2016-12-22 2018-06-27 The Procter & Gamble Company Automatic dishwashing detergent composition
FI3357994T3 (en) 2017-02-01 2023-11-22 Procter & Gamble Cleaning compositions comprising amylase variants
JP7189145B2 (en) 2017-03-29 2022-12-13 ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Recombinant host cells with altered membrane lipid composition
WO2019008036A1 (en) 2017-07-07 2019-01-10 Unilever Plc Whitening composition
WO2019008035A1 (en) 2017-07-07 2019-01-10 Unilever Plc Laundry cleaning composition
TWI715878B (en) 2017-10-12 2021-01-11 美商美力肯及公司 Leuco colorants and compositions
JP6945947B2 (en) 2017-10-12 2021-10-06 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company Leuco colorant combined with a second whitening agent as a bluing agent in the laundry care composition
JP6993503B2 (en) 2017-10-12 2022-01-13 ザ プロクター アンド ギャンブル カンパニー Leuco colorant as a bluish agent in laundry care compositions
CA3075090A1 (en) 2017-10-12 2019-04-18 The Procter & Gamble Company Leuco colorants as bluing agents in laundry care compositions
CN111511842B (en) 2017-11-01 2022-01-11 美利肯公司 Leuco compounds, colorant compounds and compositions containing the same
WO2019105675A1 (en) 2017-11-30 2019-06-06 Unilever Plc Detergent composition comprising protease
EP3502245A1 (en) 2017-12-19 2019-06-26 The Procter & Gamble Company Automatic dishwashing detergent composition
EP3502246A1 (en) 2017-12-19 2019-06-26 The Procter & Gamble Company Automatic dishwashing detergent composition
EP3502244A1 (en) 2017-12-19 2019-06-26 The Procter & Gamble Company Automatic dishwashing detergent composition
EP3502227A1 (en) 2017-12-19 2019-06-26 The Procter & Gamble Company Automatic dishwashing detergent composition
CN111556891B (en) 2018-01-26 2021-11-05 宝洁公司 Water-soluble unit dose articles comprising enzymes
CA3089281A1 (en) 2018-02-28 2019-09-06 The Procter & Gamble Company Cleaning compositions containing a glycogen debranching enzyme
CA3089284A1 (en) 2018-02-28 2019-09-06 The Procter & Gamble Company Methods of cleaning using a glycogen debranching enzyme
WO2019219531A1 (en) 2018-05-17 2019-11-21 Unilever Plc Cleaning composition
JP2021527413A (en) 2018-06-19 2021-10-14 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company Automatic dishwashing detergent composition
CN112204138A (en) 2018-06-19 2021-01-08 宝洁公司 Automatic dishwashing detergent composition
US20200032178A1 (en) 2018-07-27 2020-01-30 The Procter & Gamble Company Water-soluble unit dose articles comprising water-soluble fibrous structures and particles
WO2020058024A1 (en) 2018-09-17 2020-03-26 Unilever Plc Detergent composition
BR112021009789A2 (en) 2018-11-20 2021-08-17 Unilever Ip Holdings B.V. detergent composition, method of treating a fabric substrate and use of an esterase enzyme
WO2020104159A1 (en) 2018-11-20 2020-05-28 Unilever Plc Detergent composition
EP3884023A1 (en) 2018-11-20 2021-09-29 Unilever Global Ip Limited Detergent composition
EP3884024A1 (en) 2018-11-20 2021-09-29 Unilever Global Ip Limited Detergent composition
EP3884022A1 (en) 2018-11-20 2021-09-29 Unilever Global Ip Limited Detergent composition
CA3127169A1 (en) 2019-03-14 2020-09-17 The Procter & Gamble Company Cleaning compositions comprising enzymes
CA3127171A1 (en) 2019-03-14 2020-09-17 The Procter & Gamble Company Method for treating cotton
US20200291332A1 (en) 2019-03-14 2020-09-17 The Procter & Gamble Company Cleaning compositions comprising enzymes
CN113825829A (en) 2019-05-16 2021-12-21 联合利华知识产权控股有限公司 Laundry compositions
EP3741283A1 (en) 2019-05-22 2020-11-25 The Procter & Gamble Company Automatic dishwashing method
EP3976775A1 (en) 2019-05-24 2022-04-06 The Procter & Gamble Company Automatic dishwashing detergent composition
EP3986996A1 (en) 2019-06-24 2022-04-27 The Procter & Gamble Company Cleaning compositions comprising amylase variants
EP3990604B1 (en) 2019-06-28 2022-12-14 Unilever Global IP Limited Detergent composition
WO2020259949A1 (en) 2019-06-28 2020-12-30 Unilever Plc Detergent composition
CN113891930A (en) 2019-06-28 2022-01-04 联合利华知识产权控股有限公司 Detergent composition
WO2020260038A1 (en) 2019-06-28 2020-12-30 Unilever Plc Detergent composition
US20220372397A1 (en) 2019-06-28 2022-11-24 Conopco, Inc., D/B/A Unilever Detergent composition
WO2020260006A1 (en) 2019-06-28 2020-12-30 Unilever Plc Detergent compositions
CN114364776A (en) 2019-09-02 2022-04-15 联合利华知识产权控股有限公司 Detergent composition
CN114423851A (en) 2019-09-19 2022-04-29 联合利华知识产权控股有限公司 Detergent composition
AR120142A1 (en) 2019-10-07 2022-02-02 Unilever Nv DETERGENT COMPOSITION
US11492571B2 (en) 2019-10-24 2022-11-08 The Procter & Gamble Company Automatic dishwashing detergent composition comprising a protease
US20210122998A1 (en) 2019-10-24 2021-04-29 The Procter & Gamble Company Automatic dishwashing detergent composition comprising an amylase
EP3835396A1 (en) 2019-12-09 2021-06-16 The Procter & Gamble Company A detergent composition comprising a polymer
EP4097206B1 (en) 2020-01-29 2023-08-09 Unilever IP Holdings B.V. Laundry detergent product
EP3862412A1 (en) 2020-02-04 2021-08-11 The Procter & Gamble Company Detergent composition
WO2021247801A1 (en) 2020-06-05 2021-12-09 The Procter & Gamble Company Detergent compositions containing a branched surfactant
CN115698246A (en) 2020-06-08 2023-02-03 联合利华知识产权控股有限公司 Method for increasing protease activity
US20230287383A1 (en) 2020-07-03 2023-09-14 Engenes Biotech Gmbh PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF
WO2022031309A1 (en) 2020-08-04 2022-02-10 The Procter & Gamble Company Automatic dishwashing method
WO2022031310A1 (en) 2020-08-04 2022-02-10 The Procter & Gamble Company Automatic dishwashing method
WO2022031311A1 (en) 2020-08-04 2022-02-10 The Procter & Gamble Company Automatic dishwashing method
CA3187735A1 (en) 2020-08-04 2022-02-10 Nina Elizabeth GRAY Automatic dishwashing method and pack
US20230287300A1 (en) 2020-08-28 2023-09-14 Conopco, Inc., D/B/A Unilever Surfactant and detergent composition
WO2022043042A1 (en) 2020-08-28 2022-03-03 Unilever Ip Holdings B.V. Detergent composition
CN116096845A (en) 2020-08-28 2023-05-09 联合利华知识产权控股有限公司 Detergent composition
CN116096703A (en) 2020-08-28 2023-05-09 联合利华知识产权控股有限公司 Surfactant and detergent composition
WO2022043045A1 (en) 2020-08-28 2022-03-03 Unilever Ip Holdings B.V. Detergent composition
US20230392018A1 (en) 2020-10-27 2023-12-07 Milliken & Company Compositions comprising leuco compounds and colorants
CA3196356A1 (en) 2020-10-29 2022-05-05 Catherine Jones Cleaning compositions containing alginate lyase enzymes
JP2023547853A (en) 2020-11-17 2023-11-14 ザ プロクター アンド ギャンブル カンパニー Automatic dishwashing method with alkaline rinse
WO2022108766A1 (en) 2020-11-17 2022-05-27 The Procter & Gamble Company Automatic dishwashing composition comprising amphiphilic graft polymer
EP4001388A1 (en) 2020-11-17 2022-05-25 The Procter & Gamble Company Automatic dishwashing method with amphiphilic graft polymer in the rinse
EP4006131A1 (en) 2020-11-30 2022-06-01 The Procter & Gamble Company Method of laundering fabric
EP4256020A1 (en) 2020-12-07 2023-10-11 Unilever IP Holdings B.V. Detergent compositions
CN116529351A (en) 2020-12-07 2023-08-01 联合利华知识产权控股有限公司 Detergent composition
WO2022136389A1 (en) 2020-12-23 2022-06-30 Basf Se Amphiphilic alkoxylated polyamines and their uses
CA3199985A1 (en) 2021-03-15 2022-09-22 Lars Lehmann Hylling Christensen Cleaning compositions containing polypeptide variants
CN117157382A (en) 2021-05-05 2023-12-01 宝洁公司 Method for preparing cleaning composition and detecting dirt
EP4086330A1 (en) 2021-05-06 2022-11-09 The Procter & Gamble Company Surface treatment
EP4108767A1 (en) 2021-06-22 2022-12-28 The Procter & Gamble Company Cleaning or treatment compositions containing nuclease enzymes
CN117580940A (en) 2021-06-30 2024-02-20 汉高股份有限及两合公司 Cleaning compositions comprising lipolytic enzyme having polyesterase activity
KR20240027619A (en) 2021-06-30 2024-03-04 헨켈 아게 운트 코. 카게아아 Compositions with improved moisture management performance
CN117580939A (en) 2021-06-30 2024-02-20 汉高股份有限及两合公司 Cleaning compositions having improved anti-dusting and/or anti-pilling properties
EP4123007A1 (en) 2021-07-19 2023-01-25 The Procter & Gamble Company Fabric treatment using bacterial spores
EP4123006A1 (en) 2021-07-19 2023-01-25 The Procter & Gamble Company Composition comprising spores and pro-perfume materials
WO2023041694A1 (en) 2021-09-20 2023-03-23 Unilever Ip Holdings B.V. Detergent composition
WO2023064749A1 (en) 2021-10-14 2023-04-20 The Procter & Gamble Company A fabric and home care product comprising cationic soil release polymer and lipase enzyme
EP4194536A1 (en) 2021-12-08 2023-06-14 The Procter & Gamble Company Laundry treatment cartridge
EP4194537A1 (en) 2021-12-08 2023-06-14 The Procter & Gamble Company Laundry treatment cartridge
US20230365897A1 (en) 2021-12-16 2023-11-16 The Procter & Gamble Company Fabric and home care composition including a protease
US20230272310A1 (en) 2021-12-16 2023-08-31 The Procter & Gamble Company Home care composition
US20230265358A1 (en) 2021-12-16 2023-08-24 The Procter & Gamble Company Home care composition comprising an amylase
WO2023114795A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Automatic dishwashing composition comprising a protease
EP4273210A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Detergent compositions containing enzymes
EP4273209A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Machine-cleaning compositions containing enzymes
EP4279571A1 (en) 2022-05-19 2023-11-22 The Procter & Gamble Company Laundry composition comprising spores
WO2023227335A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Liquid composition comprising linear alkyl benzene sulphonate, methyl ester ethoxylate and alkoxylated zwitterionic polyamine polymer
WO2023227421A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer, and a fragrance
WO2023227356A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Composition containing enzyme
WO2023227331A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Composition comprising a specific methyl ester ethoxylate surfactant and a lipase
WO2023227375A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an aminocarboxylate, an organic acid and a fragrance
WO2023227332A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer and a protease
WO2023233025A1 (en) 2022-06-03 2023-12-07 Unilever Ip Holdings B.V. Liquid detergent product
EP4321604A1 (en) 2022-08-08 2024-02-14 The Procter & Gamble Company A fabric and home care composition comprising surfactant and a polyester
WO2024056333A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056331A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056334A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056278A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
EP4349942A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349945A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349946A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Unit dose fabric treatment product
EP4349947A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349943A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349948A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349944A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790482A (en) * 1968-04-12 1974-02-05 Procter & Gamble Enzyme-containing detergent compositions
US3985686A (en) * 1971-12-20 1976-10-12 The Procter & Gamble Company Detergent compositions containing enzymes
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
WO1988001038A1 (en) * 1986-07-31 1988-02-11 Kurt Krieger Device for applying a flowing fluid on webs of material
EP0328229A1 (en) * 1988-02-11 1989-08-16 Genencor International Inc. Novel proteolytic enzymes and their use in detergents
US4990452A (en) * 1986-02-12 1991-02-05 Genex Corporation Combining mutations for stabilization of subtilisin
US5078898A (en) * 1987-11-02 1992-01-07 Novo Nordisk A/S Detergent compositions comprising pseudomonas lipase and a specific protease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790482A (en) * 1968-04-12 1974-02-05 Procter & Gamble Enzyme-containing detergent compositions
US3985686A (en) * 1971-12-20 1976-10-12 The Procter & Gamble Company Detergent compositions containing enzymes
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4990452A (en) * 1986-02-12 1991-02-05 Genex Corporation Combining mutations for stabilization of subtilisin
WO1988001038A1 (en) * 1986-07-31 1988-02-11 Kurt Krieger Device for applying a flowing fluid on webs of material
US5078898A (en) * 1987-11-02 1992-01-07 Novo Nordisk A/S Detergent compositions comprising pseudomonas lipase and a specific protease
EP0328229A1 (en) * 1988-02-11 1989-08-16 Genencor International Inc. Novel proteolytic enzymes and their use in detergents

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
Brot and Weissbach, All Types of Biochemistry and Biophysics (1983) 223:271 281. *
Brot and Weissbach, All Types of Biochemistry and Biophysics (1983) 223:271-281.
Estell, et al., J. Biol. Chem. (1985) 260:6518 6521. *
Estell, et al., J. Biol. Chem. (1985) 260:6518-6521.
Ferrari et al. 1983. J. Bacteriol. 154, 1513 1515. *
Ferrari et al. 1983. J. Bacteriol. 154, 1513-1515.
Hutchinson et al. 1978. J. Biol. Chem. 253, 6551 6550. *
Hutchinson et al. 1978. J. Biol. Chem. 253, 6551-6550.
Kerjan et al. 1979. Eur. J. Biochem 98, 353 362. *
Kerjan et al. 1979. Eur. J. Biochem 98, 353-362.
Nedkov et al. 1983. Hoppe Seyler s Z. Physiol. Chem. 346 (11), 1537 1540 C.A. 100:81934r. *
Nedkov et al. 1983. Hoppe-Seyler's Z. Physiol. Chem. 346 (11), 1537-1540 C.A. 100:81934r.
Patterson et al. 1979. J. Gen. Microbiol. 144, 75 85. *
Patterson et al. 1979. J. Gen. Microbiol. 144, 75-85.
Polgar and Bender, Advances In Enzymology (1970) 33:381 400. *
Polgar and Bender, Advances In Enzymology (1970) 33:381-400.
Polgar et al. 1981. Biochim. Biophys. Acta. 667, 351 354. *
Polgar et al. 1981. Biochim. Biophys. Acta. 667, 351-354.
Rastetter, W. H. 1983. Trends, Biotechnol. 1, 80 84. *
Rastetter, W. H. 1983. Trends, Biotechnol. 1, 80-84.
Robertus, et al. 1972. Biochemistry 11, 2439 2448. *
Robertus, et al. 1972. Biochemistry 11, 2439-2448.
Stahl. et al. 1984. J. Bacteriol. 158, 411 418. *
Stahl. et al. 1984. J. Bacteriol. 158, 411-418.
Stauffer and Etson, J. Biol. Chem. (1969) 244:5333 5338. *
Stauffer and Etson, J. Biol. Chem. (1969) 244:5333-5338.
Svendsen, I. 1976. Carlsberg Res. Commun. 41, 237 291. *
Svendsen, I. 1976. Carlsberg Res. Commun. 41, 237-291.
Uehara et al. 1979. J. Bacteriol. 139(2), 583 590. *
Uehara et al. 1979. J. Bacteriol. 139(2), 583-590.
Wallace et al. 1981. Nucleic Acids Research 9, 3647 3656. *
Wallace et al. 1981. Nucleic Acids Research 9, 3647-3656.
Wells et al. 1983. Nuc. Acids Res. 11, 7911 7923. *
Wells et al. 1983. Nuc. Acids Res. 11, 7911-7923.
Wilkinson, et al., Nature (1984) 307:187 188. *
Wilkinson, et al., Nature (1984) 307:187-188.
Winter, et al., Nature (1982) 299:756 758. *
Winter, et al., Nature (1982) 299:756-758.
Wright et al. 1969. Nature. 221, 235 241. *
Wright et al. 1969. Nature. 221, 235-241.
Zoller and Smith, Methods In Enzymology (1983) 100:468 500. *
Zoller and Smith, Methods In Enzymology (1983) 100:468-500.

Cited By (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955340A (en) 1984-05-29 1999-09-21 Genencor International, Inc. Modified subtilisins having amino acid alterations
US6465235B1 (en) 1984-05-29 2002-10-15 Genenco International, Inc. Non-human carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US5700676A (en) * 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
US5763257A (en) * 1984-05-29 1998-06-09 Genencor International, Inc. Modified subtilisins having amino acid alterations
US5801038A (en) * 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
US6287841B1 (en) 1988-02-11 2001-09-11 Genencor International, Inc. High alkaline serine protease
US6197567B1 (en) * 1989-06-26 2001-03-06 Novo Nordisk A/S Modified subtilisins and detergent compositions containing same
US6632646B1 (en) * 1989-06-26 2003-10-14 Novozymes A/S Modified subtilisins and detergent compositions containing same
US6271012B1 (en) * 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
US5824522A (en) * 1990-12-07 1998-10-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Recombinant decarbamylases for producing D-α-amino acids
US5631217A (en) * 1990-12-21 1997-05-20 Novo Nordisk A/S Detergent compositions comprising a modified subtilisin
US6436690B1 (en) * 1993-09-15 2002-08-20 The Procter & Gamble Company BPN′ variants having decreased adsorption and increased hydrolysis wherein one or more loop regions are substituted
US6440717B1 (en) * 1993-09-15 2002-08-27 The Procter & Gamble Company BPN′ variants having decreased adsorption and increased hydrolysis
US7250281B2 (en) 1993-10-14 2007-07-31 Genencor International, Inc. Subtilisin variants
US6586221B2 (en) 1993-10-14 2003-07-01 Genencor International, Inc. Subtilisin variants multiply-substituted subtilising variants having a substitution at position 76
US6017871A (en) 1993-10-14 2000-01-25 The Procter & Gamble Company Protease-containing cleaning compositions
US5677272A (en) * 1993-10-14 1997-10-14 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US5679630A (en) * 1993-10-14 1997-10-21 The Procter & Gamble Company Protease-containing cleaning compositions
US6599730B1 (en) * 1994-05-02 2003-07-29 Procter & Gamble Company Subtilisin 309 variants having decreased adsorption and increased hydrolysis
WO1996005295A3 (en) * 1994-08-11 1996-03-28 Genencor Int An improved cleaning composition
EP0704167A1 (en) 1994-08-19 1996-04-03 Finnfeeds International Ltd. An enzyme feed additive and animal feed including it
US6066611A (en) 1994-10-13 2000-05-23 The Procter & Gamble Company Bleaching compositions comprising protease enzymes
US6455295B1 (en) * 1995-03-08 2002-09-24 The Procter & Gamble Company Subtilisin Carlsberg variants having decreased adsorption and increased hydrolysis
US6451574B1 (en) * 1995-03-09 2002-09-17 The Procter & Gamble Company Proteinase K variants having decreased adsorption and increased hydrolysis
US6001586A (en) 1996-03-29 1999-12-14 Genencor International, Inc. Compartmentalization method for screening microorganisms
US5958739A (en) 1996-06-06 1999-09-28 Genencor International Inc. Mutant α-amylase
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
US7098017B2 (en) * 1996-11-04 2006-08-29 Novozymes A/S Protease variants and compositions
US20020102702A1 (en) * 1996-11-04 2002-08-01 Novozymes A/S Protease variants and compositions
US6300116B1 (en) * 1996-11-04 2001-10-09 Novozymes A/S Modified protease having improved autoproteolytic stability
EP2278001A1 (en) 1996-11-04 2011-01-26 Novozymes A/S Protease variants and compositions
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
US6558938B1 (en) 1997-08-29 2003-05-06 Novozymes, A/S Protease variants and compositions
US7129076B2 (en) 1997-10-23 2006-10-31 Genencor International, Inc. Multiply-substituted protease variants with altered net charge for use in detergents
US6927055B2 (en) 1997-10-23 2005-08-09 Genencor International, Inc. Multiply-substituted protease variants
EP1612271A2 (en) 1997-10-23 2006-01-04 Genencor International, Inc. Multiply-substituted protease variants with altered net charge for use in detergents
US6312936B1 (en) 1997-10-23 2001-11-06 Genencor International, Inc. Multiply-substituted protease variants
US20080274938A1 (en) * 1997-10-23 2008-11-06 Poulose Ayrookaran J Multiply-substituted protease variants with altered net charge for use in detergents
US6815193B2 (en) 1997-10-23 2004-11-09 Genencor International, Inc. Multiply-substituted protease variants
US7026153B2 (en) 1997-11-21 2006-04-11 Novozymes A/S Protease variants and compositions
US6773907B2 (en) 1997-11-21 2004-08-10 Peter Kamp Hansen Subtilase enzymes
US20030180933A1 (en) * 1997-11-21 2003-09-25 Novozymes A/S Protease variants and compositions
US6605458B1 (en) 1997-11-21 2003-08-12 Novozymes A/S Protease variants and compositions
US6780629B2 (en) 1997-11-21 2004-08-24 Novozymes A/S Subtilase enzymes
US20060024764A1 (en) * 1998-04-15 2006-02-02 Estell David A Proteins producing an altered immunogenic response and methods of making the same
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
EP1997897A1 (en) 1998-04-15 2008-12-03 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20050164257A1 (en) * 1998-04-15 2005-07-28 Estell David A. Proteins producing an altered immunogenic response and methods of making and using the same
US6376450B1 (en) 1998-10-23 2002-04-23 Chanchal Kumar Ghosh Cleaning compositions containing multiply-substituted protease variants
US6831053B1 (en) 1998-10-23 2004-12-14 The Procter & Gamble Company Bleaching compositions comprising multiply-substituted protease variants
EP1803817A1 (en) 1998-12-18 2007-07-04 Novozymes A/S Subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid residue in an active site loop region
WO2000071688A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 126 and 127
WO2000071691A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 125 and 126
WO2000071690A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 128 and 129
WO2000071687A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 129 and 130
WO2000071689A1 (en) 1999-05-20 2000-11-30 Novozymes A/S Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 127 and 128
US6727085B2 (en) 1999-12-15 2004-04-27 Fanoe Tina Sejersgaard Subtilase variants having an improved wash performance on egg stains
US6777218B1 (en) 2000-03-14 2004-08-17 Novozymes A/S Subtilase enzymes having an improved wash performance on egg stains
US6838425B2 (en) 2000-04-20 2005-01-04 The Procter & Gamble Company Cleaning compositions containing multiply-substituted protease variants
US7297354B2 (en) 2000-04-26 2007-11-20 Land O'lakes, Inc. Protein material
WO2002040997A2 (en) 2000-10-02 2002-05-23 Genencor International, Inc. Production and use of proteins producing an altered immunogenic response
US6872696B2 (en) 2000-10-27 2005-03-29 Genencor International, Inc. Particle with substituted polyvinyl alcohol coating
US20040091474A1 (en) * 2001-01-08 2004-05-13 Health Protection Agency Degradation and detection of TSE infectivity
US8110391B2 (en) 2001-01-08 2012-02-07 Health Protection Agency Degradation and detection of TSE infectivity
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
US6929939B2 (en) 2001-03-23 2005-08-16 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US20050202551A1 (en) * 2001-03-23 2005-09-15 Estell David A. Proteins producing an altered immunogenic response and methods of making and using the same
WO2002077187A3 (en) * 2001-03-23 2003-04-24 Genencor Int Proteins producing an altered immunogenic response and methods of making and using the same
US7476528B2 (en) 2001-03-23 2009-01-13 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US7157416B2 (en) 2001-07-20 2007-01-02 Genencor International, Inc. Stabilization of enzymes
US20030216277A1 (en) * 2001-07-20 2003-11-20 Becker Nathaniel T. Stabilization of enzymes
WO2003062380A2 (en) 2002-01-16 2003-07-31 Genencor International, Inc. Multiply-substituted protease variants
US20080124783A1 (en) * 2002-01-16 2008-05-29 Poulose Ayrookaran J Multiply-substituted protease variants
US20110086412A1 (en) * 2002-01-16 2011-04-14 Danisco Us Inc. Multiply-Substituted Protease Variants
EP2287320A1 (en) 2002-01-16 2011-02-23 Genencor International, Inc. Multiply-substituted protease variants
US20080176313A1 (en) * 2002-01-16 2008-07-24 Poulose Ayrookaran J Multiply-substituted protease variants
US20050170488A1 (en) * 2002-01-16 2005-08-04 Poulose Ayrookaran J. Multiply-substituted protease variants
US20110091959A1 (en) * 2002-01-16 2011-04-21 Danisco Us Inc. Multiply-Substituted Protease Variants
EP2287321A1 (en) 2002-01-16 2011-02-23 Genencor International, Inc. Multiply-substituted protease variants
US20040105874A1 (en) * 2002-03-11 2004-06-03 Bott Richard R. Preparations for topical skin use and treatment
US7223386B2 (en) 2002-03-11 2007-05-29 Dow Corning Corporation Preparations for topical skin use and treatment
US20030180281A1 (en) * 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
WO2003101404A2 (en) 2002-03-11 2003-12-11 Dow Corning Corporation Preparations for topical skin use and treatment
EP3023501A1 (en) 2002-03-29 2016-05-25 Danisco US Inc. Enhanced protein expression in bacillus
US8383366B2 (en) 2002-03-29 2013-02-26 Danisco Us Inc. Enhanced protein expression in Bacillus
EP2341070A2 (en) 2002-03-29 2011-07-06 Genencor International, Inc. Ehanced protein expression in bacillus
US9175294B2 (en) 2002-03-29 2015-11-03 Danisco Us Inc. Enhanced protein expression in Bacillus
US8124399B2 (en) 2002-03-29 2012-02-28 Danisco Us Inc. Enhanced protein expression in Bacillus
EP2339016A2 (en) 2002-03-29 2011-06-29 Genencor International, Inc. Enhanced protein expression in bacillus
US20060073559A1 (en) * 2002-03-29 2006-04-06 Eugenio Ferrari Ehanced protein expression in bacillus
EP2339017A2 (en) 2002-03-29 2011-06-29 Genencor International, Inc. Enhanced protein expression in bacillus
WO2004010930A2 (en) 2002-07-30 2004-02-05 Genencor International, Inc. Reduced aerosol generating formulations
US7566448B2 (en) 2002-07-30 2009-07-28 Genencor International, Inc. Reduced aerosol generating formulations
EP2500423A2 (en) 2003-02-26 2012-09-19 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
US8748141B2 (en) 2003-03-10 2014-06-10 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US8497082B2 (en) 2003-03-10 2013-07-30 Poet Research, Inc. Composition comprising corn flour and saccharification enzymes
US20110070618A1 (en) * 2003-03-10 2011-03-24 Poet Research, Inc. Method for producing ethanol using raw starch
US20070196907A1 (en) * 2003-03-10 2007-08-23 Broin & Associates, Inc. Method For Producing Ethanol Using Raw Starch
US20070202214A1 (en) * 2003-03-10 2007-08-30 Broin & Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20040234649A1 (en) * 2003-03-10 2004-11-25 Broin And Associates, Inc. Method for producing ethanol using raw starch
US7919291B2 (en) 2003-03-10 2011-04-05 Poet Research, Inc. Method for producing ethanol using raw starch
US7842484B2 (en) 2003-03-10 2010-11-30 Poet Research, Inc. Method for producing ethanol using raw starch
US8679793B2 (en) 2003-03-10 2014-03-25 Poet Research, Inc. Method for producing ethanol using raw starch
US8409639B2 (en) 2003-03-10 2013-04-02 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20110111085A1 (en) * 2003-03-10 2011-05-12 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20110097446A1 (en) * 2003-03-10 2011-04-28 Poet Research, Inc. Method for producing ethanol using raw starch
US8409640B2 (en) 2003-03-10 2013-04-02 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20100041116A1 (en) * 2003-03-10 2010-02-18 Broin & Associates, Inc. Method for producing ethanol using raw starch
US8470550B2 (en) 2003-03-10 2013-06-25 Poet Research, Inc. Composition comprising raw starch for the production of ethanol
US20050059567A1 (en) * 2003-09-11 2005-03-17 The Procter & Gamble Company Methods of formulating enzyme cocktails, enzyme cocktails for the removal of egg-based and grass-based stains and/or soils, compositions and products comprising same
WO2005040372A1 (en) 2003-10-23 2005-05-06 Novozymes A/S Protease with improved stability in detergents
US20080063774A1 (en) * 2003-11-19 2008-03-13 Wolfgang Aehle Multiple mutation variants of serine protease
US8535927B1 (en) 2003-11-19 2013-09-17 Danisco Us Inc. Micrococcineae serine protease polypeptides and compositions thereof
US8455234B2 (en) 2003-11-19 2013-06-04 Danisco Us Inc. Multiple mutation variants of serine protease
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
US20050233030A1 (en) * 2004-03-10 2005-10-20 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20050239181A1 (en) * 2004-03-10 2005-10-27 Broin And Associates, Inc. Continuous process for producing ethanol using raw starch
US8907026B2 (en) 2004-12-23 2014-12-09 Dow Corning Corporation Crosslinkable saccharide-siloxane compositions, and networks, coatings and articles formed therefrom
US8927250B2 (en) 2005-02-18 2015-01-06 Danisco Us Inc. Polypeptides having alpha-amylase and granular starch hydrolyzing activity
US20070037267A1 (en) * 2005-05-02 2007-02-15 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US20080199417A1 (en) * 2005-05-23 2008-08-21 Dow Corning Corporation Personal Care Composition Comprising Saccharide-Siloxane Copolymers
US20080209645A1 (en) * 2005-05-23 2008-09-04 Dow Corning Corporation Surface Treatment Compositions Comprising Saccharide-Siloxane Copolymers
US8877216B2 (en) 2005-05-23 2014-11-04 Dow Corning Corporation Cosmetic and skin-care compositions comprising saccharide-siloxane copolymers
US7919289B2 (en) 2005-10-10 2011-04-05 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and selecting plant material
US20070178567A1 (en) * 2005-10-10 2007-08-02 Lewis Stephen M Methods and systems for producing ethanol using raw starch and selecting plant material
US8597919B2 (en) 2005-10-10 2013-12-03 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and selecting plant material
US20090258380A1 (en) * 2005-12-06 2009-10-15 Harding Fiona A Perhydrolase Epitopes
US8871722B2 (en) 2005-12-06 2014-10-28 Danisco Us Inc. Perhydrolase epitopes
US20110008866A1 (en) * 2006-03-31 2011-01-13 Dibel Kevin R Tangential Flow Filtration Apparatuses, Systems, and Processes for the Separation of Compounds
EP2583744A1 (en) 2006-03-31 2013-04-24 Genencor International, Inc. Permeate product of tangential flow filtration process
US8968773B2 (en) 2006-05-23 2015-03-03 Dow Corning Corporation Silicone film former for delivery of actives
US20090258058A1 (en) * 2006-05-23 2009-10-15 Dow Corning Corporation Novel silicone film former for delivery of actives
US20110082048A1 (en) * 2006-06-23 2011-04-07 Danisco Us Inc. Systematic Evaluation of Sequence and Activity Relationships Using Site Evaluation Libraries For Engineering Multiple Properties
US20080004186A1 (en) * 2006-06-23 2008-01-03 Estell David A Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US8648015B2 (en) 2006-06-23 2014-02-11 Danisco Us Inc. Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
US20080108126A1 (en) * 2006-08-23 2008-05-08 George England Pullulanase variants with increased productivity
US7968691B2 (en) 2006-08-23 2011-06-28 Danisco Us Inc. Pullulanase variants with increased productivity
US8354101B2 (en) 2006-08-23 2013-01-15 Danisco Us Inc. Pullulanase variants with increased productivity
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
US20110201535A1 (en) * 2006-10-13 2011-08-18 Danisco Us Inc. Expression of Streptomyces Subtilisin Inhibitor (SSI) Proteins In Bacillus and Streptomyces sp.
US20100105598A1 (en) * 2006-10-16 2010-04-29 Pieter Augustinus Non-Phosphate Dish Detergents
US8779112B2 (en) 2007-03-12 2014-07-15 Danisco Us Inc. Modified protease propeptides
US9523088B2 (en) 2007-03-12 2016-12-20 Danisco Us Inc. Modified proteases
US20090075332A1 (en) * 2007-03-12 2009-03-19 Eugenio Ferrari Modified Proteases
WO2008134343A1 (en) 2007-04-30 2008-11-06 Danisco Us Inc., Genencor Division Use of protein hydrolysates to stabilize metalloprotease detergent formulations
US8623630B2 (en) 2007-05-10 2014-01-07 Danisco Us Inc. Modified secretion system to increase expression of polypeptides in bacteria
US8343735B2 (en) 2007-05-10 2013-01-01 Danisco Us Inc. Modified secretion system to increase expression of polypeptides in bacteria
EP2460823A1 (en) 2007-05-10 2012-06-06 Danisco US Inc. A modified secretion system to increase expression of polypeptides in bacteria
US8784662B2 (en) 2007-09-12 2014-07-22 Danisco Us Inc. Filtration with internal fouling control
US20090120873A1 (en) * 2007-09-12 2009-05-14 Becker Nathaniel T Filtration with internal fouling control
US9375683B2 (en) 2007-09-12 2016-06-28 Danisco Us Inc. Filtration with internal fouling control
WO2009058679A1 (en) 2007-10-30 2009-05-07 Danisco Us Inc., Genencor Division Streptomyces protease
US20090111161A1 (en) * 2007-10-30 2009-04-30 Jones Brian E Streptomyces protease
US20100095987A1 (en) * 2007-10-30 2010-04-22 Jones Brian E Streptomyces protease
US20110081711A1 (en) * 2007-10-30 2011-04-07 Jones Brian E Streptomyces Protease
US7618801B2 (en) 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease
US7879788B2 (en) 2007-10-30 2011-02-01 Danisco Us Inc. Methods of cleaning using a streptomyces 1AG3 serine protease
US8597927B2 (en) 2007-12-20 2013-12-03 Danisco Us Inc. Enzymatic prevention and control of biofilm
US20110195059A1 (en) * 2007-12-20 2011-08-11 Danisco Us Inc. Enzymatic Prevention and Control of Biofilm
WO2009094084A1 (en) 2007-12-21 2009-07-30 Danisco Us Inc., Genencor Division Enhanced protein production in bacillus
US20090199877A1 (en) * 2008-02-08 2009-08-13 Piotr Koch Process for making a water-soluble pouch
US8066818B2 (en) 2008-02-08 2011-11-29 The Procter & Gamble Company Water-soluble pouch
US20100192986A1 (en) * 2008-02-08 2010-08-05 Anju Deepali Massey Brooker Water-soluble pouch
WO2009149144A2 (en) 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
EP2578679A1 (en) 2008-06-06 2013-04-10 Danisco US Inc. Compositions and methods comprising variant microbial proteases
EP2578680A1 (en) 2008-06-06 2013-04-10 Danisco US Inc. Compositions and methods comprising variant microbial proteases
EP3095859A1 (en) 2008-06-06 2016-11-23 Danisco US Inc. Compositions and methods comprising variant microbial proteases
US10563189B2 (en) 2008-06-06 2020-02-18 The Procter & Gamble Company Compositions and methods comprising variant microbial proteases
EP2947147A2 (en) 2008-06-06 2015-11-25 Danisco US Inc. Compositions and methods comprising variant microbial proteases
US20100192985A1 (en) * 2008-11-11 2010-08-05 Wolfgang Aehle Compositions and methods comprising serine protease variants
US8753861B2 (en) 2008-11-11 2014-06-17 Danisco Us Inc. Protease comprising one or more combinable mutations
US9434915B2 (en) 2008-11-11 2016-09-06 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
US8183024B2 (en) 2008-11-11 2012-05-22 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
US8530219B2 (en) 2008-11-11 2013-09-10 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
EP3031894A1 (en) 2008-11-11 2016-06-15 Danisco US Inc. Proteases comprising one or more combinable mutations
EP2589651A2 (en) 2008-11-11 2013-05-08 Danisco US Inc. Compositions and methods comprising serine protease variants
US10093887B2 (en) 2008-11-11 2018-10-09 Danisco Us Inc. Compositions and methods comprising serine protease variants
EP2647692A2 (en) 2008-11-11 2013-10-09 Danisco US Inc. Compositions and methods comprising serine protease variants
US20100227369A1 (en) * 2009-03-03 2010-09-09 Narendranath Neelakantam V System for Fermentation of Biomass for the Production of Ethanol
US20100233771A1 (en) * 2009-03-03 2010-09-16 Mcdonald William F System for pre-treatment of biomass for the production of ethanol
US9416376B2 (en) 2009-03-03 2016-08-16 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
US9068206B1 (en) 2009-03-03 2015-06-30 Poet Research, Inc. System for treatment of biomass to facilitate the production of ethanol
US9234167B2 (en) 2009-03-03 2016-01-12 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
US8815552B2 (en) 2009-03-03 2014-08-26 Poet Research, Inc. System for fermentation of biomass for the production of ethanol
US8450094B1 (en) 2009-03-03 2013-05-28 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
WO2010115021A2 (en) 2009-04-01 2010-10-07 Danisco Us Inc. Compositions and methods comprising alpha-amylase variants with altered properties
WO2010115028A2 (en) 2009-04-01 2010-10-07 Danisco Us Inc. Cleaning system comprising an alpha-amylase and a protease
EP2902487A2 (en) 2009-04-01 2015-08-05 Danisco US Inc. Compositions and methods comprising alpha-amylase variants with altered properties
US8852912B2 (en) 2009-04-01 2014-10-07 Danisco Us Inc. Compositions and methods comprising alpha-amylase variants with altered properties
US9593320B2 (en) 2009-04-24 2017-03-14 Danisco Us Inc. Proteases with modified pro regions
US20110045571A1 (en) * 2009-04-24 2011-02-24 Danisco Us Inc. Proteases With Modified Pro Regions
US8530218B2 (en) 2009-04-24 2013-09-10 Danisco Us Inc. Proteases with modified pro regions
US9115351B2 (en) 2009-04-24 2015-08-25 Danisco Us Inc. Proteases with modified pro regions
WO2010144283A1 (en) 2009-06-11 2010-12-16 Danisco Us Inc. Bacillus strain for increased protein production
WO2011072099A2 (en) 2009-12-09 2011-06-16 Danisco Us Inc. Compositions and methods comprising protease variants
EP3599279A1 (en) 2009-12-09 2020-01-29 Danisco US Inc. Compositions and methods comprising protease variants
US9157052B2 (en) 2009-12-09 2015-10-13 Danisco Us Inc. Methods for cleaning using a variant protease derived from subtilisin
US8728790B2 (en) 2009-12-09 2014-05-20 Danisco Us Inc. Compositions and methods comprising protease variants
EP3190183A1 (en) 2009-12-09 2017-07-12 Danisco US Inc. Compositions and methods comprising protease variants
WO2011084412A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing thermobifida fusca lipase and methods of use thereof
US8741609B2 (en) 2009-12-21 2014-06-03 Danisco Us Inc. Detergent compositions containing Geobacillus stearothermophilus lipase and methods of use thereof
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
WO2011130222A2 (en) 2010-04-15 2011-10-20 Danisco Us Inc. Compositions and methods comprising variant proteases
EP3418382A1 (en) 2010-05-06 2018-12-26 Danisco US Inc. Compositions and methods comprising subtilisin variants
EP3868881A2 (en) 2010-05-06 2021-08-25 Danisco US Inc. Compositions and methods comprising subtilisin variants
WO2011140364A1 (en) 2010-05-06 2011-11-10 Danisco Us Inc. Compositions and methods comprising subtilisin variants
US11447762B2 (en) 2010-05-06 2022-09-20 Danisco Us Inc. Bacillus lentus subtilisin protease variants and compositions comprising the same
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
US8853372B2 (en) 2010-08-23 2014-10-07 Dow Corning Corporation Saccharide siloxanes stable in aqueous environments and methods for the preparation and use of such saccharide siloxanes
WO2012149317A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing bacillus agaradhaerens mannanase and methods of use thereof
US8986970B2 (en) 2011-04-29 2015-03-24 Danisco Us Inc. Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof
WO2012149325A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof
US8802388B2 (en) 2011-04-29 2014-08-12 Danisco Us Inc. Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof
WO2012149333A1 (en) 2011-04-29 2012-11-01 Danisco Us Inc. Detergent compositions containing bacillus sp. mannanase and methods of use thereof
WO2012151534A1 (en) 2011-05-05 2012-11-08 Danisco Us Inc. Compositions and methods comprising serine protease variants
EP4230735A1 (en) 2011-05-05 2023-08-23 Danisco US Inc. Compositions and methods comprising serine protease variants
EP3486319A2 (en) 2011-05-05 2019-05-22 Danisco US Inc. Compositions and methods comprising serine protease variants
US9856466B2 (en) 2011-05-05 2018-01-02 Danisco Us Inc. Compositions and methods comprising serine protease variants
WO2012151480A2 (en) 2011-05-05 2012-11-08 The Procter & Gamble Company Compositions and methods comprising serine protease variants
WO2013033318A1 (en) 2011-08-31 2013-03-07 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2013086219A1 (en) 2011-12-09 2013-06-13 Danisco Us Inc. Ribosomal promotors from b. subtilis for protein production in microorganisms
WO2013090053A1 (en) 2011-12-13 2013-06-20 Danisco Us Inc. Enzyme cocktails prepared from mixed cultures
WO2013096653A1 (en) 2011-12-22 2013-06-27 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2013138288A1 (en) 2012-03-16 2013-09-19 Monosol, Llc. Water soluble compositions incorporating enzymes, and method of making same
US10087401B2 (en) 2012-03-16 2018-10-02 Monosol, Llc Water soluble compositions incorporating enzymes, and method of making same
EP3354716A1 (en) 2012-03-16 2018-08-01 Monosol, LLC Water soluble compositions incorporating enzymes, and method of making same
US11753222B2 (en) 2012-04-16 2023-09-12 Monosol, Llc Powdered pouch and method of making same
US9394092B2 (en) 2012-04-16 2016-07-19 Monosol, Llc Powdered pouch and method of making same
WO2013158364A1 (en) 2012-04-16 2013-10-24 Monosol, Llc Powdered pouch and method of making same
US9908675B2 (en) 2012-04-16 2018-03-06 Monosol, Llc Powdered pouch and method of making same
US10696460B2 (en) 2012-04-16 2020-06-30 Monosol, Llc Powdered pouch and method of making same
WO2014059360A1 (en) 2012-10-12 2014-04-17 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2014071410A1 (en) 2012-11-05 2014-05-08 Danisco Us Inc. Compositions and methods comprising thermolysin protease variants
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
WO2014099525A1 (en) 2012-12-21 2014-06-26 Danisco Us Inc. Paenibacillus curdlanolyticus amylase, and methods of use, thereof
WO2014099523A1 (en) 2012-12-21 2014-06-26 Danisco Us Inc. Alpha-amylase variants
WO2014164800A1 (en) 2013-03-11 2014-10-09 Danisco Us Inc. Alpha-amylase combinatorial variants
WO2014164777A1 (en) 2013-03-11 2014-10-09 Danisco Us Inc. Alpha-amylase combinatorial variants
EP3978604A1 (en) 2013-03-11 2022-04-06 Danisco US Inc. Alpha-amylase combinatorial variants
EP3260538A1 (en) 2013-05-29 2017-12-27 Danisco US Inc. Novel metalloproteases
WO2014194054A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194034A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3882346A1 (en) 2013-05-29 2021-09-22 Danisco US Inc. Novel metalloproteases
EP3636662A1 (en) 2013-05-29 2020-04-15 Danisco US Inc. Novel metalloproteases
WO2014194032A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3696264A1 (en) 2013-07-19 2020-08-19 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
EP3653707A1 (en) 2013-09-12 2020-05-20 Danisco US Inc. Compositions and methods comprising lg12-clade protease variants
WO2015038792A1 (en) 2013-09-12 2015-03-19 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
WO2015057619A1 (en) 2013-10-15 2015-04-23 Danisco Us Inc. Clay granule
WO2015073772A1 (en) 2013-11-14 2015-05-21 Danisco Us Inc. Stable enzymes by glycation reduction
EP3553173A1 (en) 2013-12-13 2019-10-16 Danisco US Inc. Serine proteases of the bacillus gibsonii-clade
EP3910057A1 (en) 2013-12-13 2021-11-17 Danisco US Inc. Serine proteases of the bacillus gibsonii-clade
WO2015089447A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of the bacillus gibsonii-clade
WO2015089441A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of bacillus species
EP3514230A1 (en) 2013-12-13 2019-07-24 Danisco US Inc. Serine proteases of bacillus species
EP4163305A1 (en) 2013-12-16 2023-04-12 Nutrition & Biosciences USA 4, Inc. Use of poly alpha-1,3-glucan ethers as viscosity modifiers
EP3789407A1 (en) 2013-12-18 2021-03-10 Nutrition & Biosciences USA 4, Inc. Cationic poly alpha-1,3-glucan ethers
WO2015095358A1 (en) 2013-12-18 2015-06-25 E. I. Du Pont De Nemours And Company Cationic poly alpha-1,3-glucan ethers
WO2015102814A1 (en) 2013-12-31 2015-07-09 Danisco Us Inc. Enhanced protein expression
US10287591B2 (en) 2013-12-31 2019-05-14 Danisco Us Inc Enhanced protein expression
US9725685B2 (en) 2014-01-30 2017-08-08 The Procter & Gamble Company Unit dose article
WO2015123323A1 (en) 2014-02-14 2015-08-20 E. I. Du Pont De Nemours And Company Poly-alpha-1,3-1,6-glucans for viscosity modification
WO2015138283A1 (en) 2014-03-11 2015-09-17 E. I. Du Pont De Nemours And Company Oxidized poly alpha-1,3-glucan as detergent builder
EP4155398A1 (en) 2014-03-21 2023-03-29 Danisco US Inc. Serine proteases of bacillus species
EP3587569A1 (en) 2014-03-21 2020-01-01 Danisco US Inc. Serine proteases of bacillus species
WO2015195777A1 (en) 2014-06-19 2015-12-23 E. I. Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
WO2015195960A1 (en) 2014-06-19 2015-12-23 E. I. Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
EP3919599A1 (en) 2014-06-19 2021-12-08 Nutrition & Biosciences USA 4, Inc. Compositions containing one or more poly alpha-1,3-glucan ether compounds
WO2016061438A1 (en) 2014-10-17 2016-04-21 Danisco Us Inc. Serine proteases of bacillus species
WO2016065238A1 (en) 2014-10-24 2016-04-28 Danisco Us Inc. Method for producing alcohol by use of a tripeptidyl peptidase
WO2016069569A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3550017A1 (en) 2014-10-27 2019-10-09 Danisco US Inc. Serine proteases
WO2016069552A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
WO2016069548A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069544A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
US10683528B2 (en) 2014-12-16 2020-06-16 Danisco Us Inc Enhanced protein expression
WO2016100128A1 (en) 2014-12-19 2016-06-23 Danisco Us Inc Enhanced protein expression
WO2016106011A1 (en) 2014-12-23 2016-06-30 E. I. Du Pont De Nemours And Company Enzymatically produced cellulose
WO2016145428A1 (en) 2015-03-12 2016-09-15 Danisco Us Inc Compositions and methods comprising lg12-clade protease variants
EP3611259A1 (en) 2015-03-12 2020-02-19 Danisco US Inc. Compositions and methods comprising lg12-clade protease variants
EP4219704A2 (en) 2015-05-13 2023-08-02 Danisco US Inc Aprl-clade protease variants and uses thereof
EP3872174A1 (en) 2015-05-13 2021-09-01 Danisco US Inc. Aprl-clade protease variants and uses thereof
WO2016201044A1 (en) 2015-06-09 2016-12-15 Danisco Us Inc Osmotic burst encapsulates
WO2016205755A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2016205710A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
EP4234693A2 (en) 2015-06-17 2023-08-30 Danisco US Inc Bacillus gibsonii-clade serine proteases
WO2017079756A1 (en) 2015-11-05 2017-05-11 Danisco Us Inc Paenibacillus and bacillus spp. mannanases
EP4141113A1 (en) 2015-11-05 2023-03-01 Danisco US Inc Paenibacillus sp. mannanases
WO2017079751A1 (en) 2015-11-05 2017-05-11 Danisco Us Inc Paenibacillus sp. mannanases
WO2017083226A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
WO2017083229A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
US11920170B2 (en) 2015-12-09 2024-03-05 Danisco Us Inc. Alpha-amylase combinatorial variants
EP3901257A1 (en) 2015-12-09 2021-10-27 Danisco US Inc. Alpha-amylase combinatorial variants
WO2017106676A1 (en) 2015-12-18 2017-06-22 Danisco Us Inc Polypeptides with endoglucanase activity and uses thereof
WO2017152169A1 (en) 2016-03-04 2017-09-08 Danisco Us Inc. Engineered ribosomal promoters for protein production in microorganisms
WO2017192692A1 (en) 2016-05-03 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017210295A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
EP4151726A1 (en) 2016-06-17 2023-03-22 Danisco US Inc Protease variants and uses thereof
WO2017219011A1 (en) 2016-06-17 2017-12-21 Danisco Us Inc Protease variants and uses thereof
WO2018085524A2 (en) 2016-11-07 2018-05-11 Danisco Us Inc Laundry detergent composition
WO2018112123A1 (en) 2016-12-15 2018-06-21 Danisco Us Inc. Polypeptides with endoglucanase activity and uses thereof
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2018118917A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
EP4212622A2 (en) 2016-12-21 2023-07-19 Danisco US Inc. Bacillus gibsonii-clade serine proteases
WO2018156705A1 (en) 2017-02-24 2018-08-30 Danisco Us Inc. Compositions and methods for increased protein production in bacillus licheniformis
WO2018169750A1 (en) 2017-03-15 2018-09-20 Danisco Us Inc Trypsin-like serine proteases and uses thereof
WO2018183662A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Delayed release enzyme formulations for bleach-containing detergents
WO2018184004A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Alpha-amylase combinatorial variants
WO2019006077A1 (en) 2017-06-30 2019-01-03 Danisco Us Inc Low-agglomeration, enzyme-containing particles
WO2019036721A2 (en) 2017-08-18 2019-02-21 Danisco Us Inc Alpha-amylase variants
WO2019040412A1 (en) 2017-08-23 2019-02-28 Danisco Us Inc Methods and compositions for efficient genetic modifications of bacillus licheniformis strains
WO2019055261A1 (en) 2017-09-13 2019-03-21 Danisco Us Inc Modified 5'-untranslated region (utr) sequences for increased protein production in bacillus
WO2019089898A1 (en) 2017-11-02 2019-05-09 Danisco Us Inc Freezing point depressed solid matrix compositions for melt granulation of enzymes
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019125683A1 (en) 2017-12-21 2019-06-27 Danisco Us Inc Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant
WO2019135868A1 (en) 2018-01-03 2019-07-11 Danisco Us Inc Mutant and genetically modified bacillus cells and methods thereof for increased protein production
WO2019245705A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
WO2020028443A1 (en) 2018-07-31 2020-02-06 Danisco Us Inc Variant alpha-amylases having amino acid substitutions that lower the pka of the general acid
WO2020047215A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Enzyme-containing granules
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2020068486A1 (en) 2018-09-27 2020-04-02 Danisco Us Inc Compositions for medical instrument cleaning
WO2020077331A2 (en) 2018-10-12 2020-04-16 Danisco Us Inc Alpha-amylases with mutations that improve stability in the presence of chelants
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
WO2020247582A1 (en) 2019-06-06 2020-12-10 Danisco Us Inc Methods and compositions for cleaning
WO2021080948A2 (en) 2019-10-24 2021-04-29 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2021146255A1 (en) 2020-01-13 2021-07-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2021146411A1 (en) 2020-01-15 2021-07-22 Danisco Us Inc Compositions and methods for enhanced protein production in bacillus licheniformis
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
WO2022165107A1 (en) 2021-01-29 2022-08-04 Danisco Us Inc Compositions for cleaning and methods related thereto
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023023644A1 (en) 2021-08-20 2023-02-23 Danisco Us Inc. Polynucleotides encoding novel nucleases, compositions thereof and methods thereof for eliminating dna from protein preparations
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
WO2023039270A2 (en) 2021-09-13 2023-03-16 Danisco Us Inc. Bioactive-containing granules
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2023250301A1 (en) 2022-06-21 2023-12-28 Danisco Us Inc. Methods and compositions for cleaning comprising a polypeptide having thermolysin activity
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024050339A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Mannanase variants and methods of use
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto

Also Published As

Publication number Publication date
US4760025A (en) 1988-07-26
US5441882A (en) 1995-08-15

Similar Documents

Publication Publication Date Title
USRE34606E (en) Modified enzymes and methods for making same
US5264366A (en) Protease deficient bacillus
US5310675A (en) Procaryotic carbonyl hydrolases
EP0246678B1 (en) Bacillus incapable of excreting subtilisin or neutral protease
US5346823A (en) Subtilisin modifications to enhance oxidative stability
EP0328229B2 (en) Novel proteolytic enzymes and their use in detergents
US5411873A (en) Process for producing heterologous polypeptides
EP0396608B1 (en) Mutated subtilisin genes
US6465235B1 (en) Non-human carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors
US6271012B1 (en) Protease muteins and their use in detergents
US5352603A (en) Highly alkaline proteases
US20040014175A1 (en) Efficient production of mutant proteases
CA1339893C (en) Procaryotic carbonyl hydrolases
NZ236052A (en) Bacillus incapable of excreting neutral protease or subtilisin, vector and production of amylase

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENENCOR INTERNATIONAL, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENENCOR, INC.;REEL/FRAME:007153/0966

Effective date: 19940915

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12